FGFR inhibitors and their use

FGFR2-selective compounds address the toxicity and efficacy limitations of pan-FGFR inhibitors by providing targeted cancer therapy with improved response rates and reduced side effects.

JP7948992B2Active Publication Date: 2026-11-11RELAY THERAPEUTICS INC +1
View PDF 14 Cites 0 Cited by

Patent Information

Application Number
JP2024117746
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-04-17
Filing Date
2024-07-23
Publication Date
2026-11-11
Estimated Expiration
2040-05-12

AI Technical Summary

Technical Problem

Current FGFR inhibitors, particularly pan-FGFR inhibitors, face challenges with toxicity issues such as hyperphosphatemia and limited efficacy in cancers with FGFR2 gene fusions, amplifications, or activating mutations, necessitating the development of FGFR2-selective inhibitors to improve treatment outcomes.

Method used

Development of compounds, such as those represented by Formula I and Formula I-1, which are FGFR2-selective inhibitors, designed to target FGFR2 with specificity, reducing off-target effects and enhancing therapeutic efficacy.

Benefits of technology

The FGFR2-selective compounds provide targeted cancer treatment with reduced toxicity, improving response rates and duration in cancers with FGFR2 alterations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007948992000001
    Figure 0007948992000001
  • Figure 0007948992000002
    Figure 0007948992000002
  • Figure 0007948992000003
    Figure 0007948992000003
Patent Text Reader

Abstract

To provide a FGFR inhibitor and a method of use thereof.SOLUTION: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of FGFR enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with FGFR signaling with the compounds and compositions of the disclosure. In some embodiments, the present invention provides a pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or diluent. In some embodiments, the present invention provides a pharmaceutical composition comprising a compound of the disclosure, for example, a compound of formula I-1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or diluent.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] References of related applications This application claims the benefits of U.S. Provisional Application No. 62 / 846,991 (filed May 13, 2019); U.S. Provisional Application No. 62 / 993,957 (filed March 24, 2020); and U.S. Provisional Application No. 63 / 011,469 (filed April 17, 2020). Each of these in whole is incorporated herein by reference. [Background technology]

[0002] background Fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3, and FGFR4) are receptor tyrosine kinases consisting of an extracellular ligand-binding domain and an intracellular tyrosine kinase domain. Binding of FGF ligands leads to receptor dimerization and conformational changes in the intracellular domain, resulting in intracellular phosphate transfer of the kinase domain and intracellular tail. The phosphorylated residues act as docking sites for adapter proteins that facilitate downstream signaling cascades, including proliferation, survival, differentiation, migration, and angiogenesis. Unregulated FGFR signaling can occur through amplification or fusion of the FGFR gene, FGFR missense mutations, receptor overexpression resulting from dysregulation of epigenic and / or transcriptional regulators, or through informational regulation of FGF ligands within the tumor environment. FGFRs are expressed in many cell types. Therefore, abnormal FGFR signaling is considered to be responsible for tumorigenesis, tumor progression, and resistance to treatment across many tumor types (for an overview of FGFR signaling, see N. Turner and R. Grose, Nat. Rev. Cancer 2010, 10:116-129; and the references cited therein). While pan-FGFR1-3 inhibitors have generated clinical responses in numerous FGFR-related cancers, precisely targeted toxicity limits the doses of these inhibitors. One of the most common adverse effects of pan-FGFR inhibition is hyperphosphatemia. The regulation of phosphate reabsorption is mediated by FGFR3 and FGFR1. Therefore, FGFR-selective inhibitors that conserve FGFR1 are needed (J. Gattineni et al., Am. J. Physiol. Renal Physiol. 2014, 306:F351-F358; X. Han et al., PLoS One 2016, 11:e0147845). Cancers possessing FGFR2 gene fusions, as well as those with FGFR2 amplification and / or FGFR2 activating mutations, have shown a response to pan-FGFR inhibition, but the low rate and duration of response suggest that toxicity is limiting. Therefore, there is a need for FGFR2-selective inhibitor compounds and methods for treating cancer and other disorders using these compounds (for an overview of pan-FGFR1-3 inhibitors and clinical responses, see ISBabina and NCTurner, Nat. Rev. Cancer 2017, 17:318-332; M. Katoh, Nat. Rev. Clin. Oncol. 2019, 16:105-122; and the references cited therein). [Prior art documents] [Non-patent literature]

[0003] [Non-Patent Document 1] N.Turner and R.Grose, Nat.Rev.Cancer 2010,10:116-129 [Non-Patent Document 2] J. Gattineni et al.,Am.J.Physiol.Renal Physiol.2014,306:F351-F358 [Non-Patent Document 3] X. Han et al.,PLoS One 2016,11:e0147845 [Non-Patent Document 4] I.S. Babina and N.C. Turner, Nat. Rev. Cancer 2017, 17: 318-332 Non-Patent Document 5 M. Katoh, Nat. Rev. Clin. Oncol. 2019, 16: 105-122 SUMMARY OF THE INVENTION MEANS FOR SOLVING THE PROBLEM

[0004] Abstract In some embodiments, the present disclosure provides Formula I-1: Chemical Formula a compound of or a pharmaceutically acceptable salt thereof, wherein in Formula I-1, Cy A , Cy 6 , L 6 , R 5 , and R W are each as defined in the embodiments and classes and subclasses herein.

[0005] In some embodiments, the present disclosure provides Formula I: Chemical Formula a compound of or a pharmaceutically acceptable salt thereof, wherein in Formula I, Cy 6 , L 6 , R 5 , R 7 , and R W are each as defined in the embodiments and classes and subclasses herein.

[0006] In some embodiments, the present invention provides a pharmaceutical composition containing a compound of formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or diluent. In some embodiments, the present invention provides a pharmaceutical composition containing a compound of the present disclosure, for example, a compound of formula I-1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or diluent.

[0007] In some embodiments, the present invention provides a method for treating FGFR-mediated disorders, the method comprising administering a compound of formula I, or a composition containing the compound, to a patient in need.

[0008] In some embodiments, the present invention provides a process for providing a compound of formula I or a synthetic intermediate thereof. In some embodiments, the present invention provides a process for providing a compound of the present disclosure, for example, a compound of formula I-1 or a synthetic intermediate thereof.

[0009] In some embodiments, the present invention provides a process for providing a pharmaceutical composition containing a compound of formula I. In some embodiments, the present invention provides a process for providing a pharmaceutical composition containing a compound of the present disclosure, for example, a compound of formula I-1. [Modes for carrying out the invention]

[0010] Detailed explanation 1. General Description of Specific Embodiments of the Invention The compounds of the present invention, and their pharmaceutically acceptable compositions, are useful as inhibitors of FGFR2. In some embodiments, the present invention relates to formula I-1: [ka] The compound or a pharmaceutically acceptable salt thereof is provided, in formula I-1: Cy A teeth, [ka] And here [ka] R 5 It represents a connection to, and [ka] Cy 6 Represents a connection to; R 5 is, -R 5A -L 5 -R 5B and; R 5A R B It is a divalent radical, where R 5A is, -L 5 -R 5B In addition, m examples of R 5C It has been replaced with; R 5B is hydrogen or R B And here R 5B This is R for n examples. 5D It has been replaced with; Cy 6 phenylene; a divalent saturated or partially unsaturated 3- to 14-membered carbocyclic ring; a divalent saturated or partially unsaturated 3- to 14-membered heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5- to 14-membered heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where Cy 6 is, -L 6 -R W In addition, the R of p examples 6It has been replaced with; R W Halogen, -CN, [ka] and; R 6 Each example is independent, R A or R B And here R 6 R is the R of q examples. C It is replaced by; or R 6 Two examples of R 6 One example and R L One example is R 6 One example and R WA One example of this is R 6 One example and R 7a One example is that together with the atoms between these, they form a 4- to 8-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where this ring is R in r examples. C It has been replaced with; R 7 is H or R B And here R 7 R for t examples 7A It has been replaced with; R 8 C is replaced as needed with H, -NR2, halogen, -OH, or 1 to 3 halogens. 1~6 It is aliphatic; R 9 C is replaced as needed with H, -NR2, halogen, or 1 to 3 halogens. 1~6 It is aliphatic; R 10 C is replaced as needed with H, or 1 to 3 halogens. 1~6 It is aliphatic; L 5 and L 6 Each of them is independent, covalently bonded, or C 1~4A divalent, saturated or unsaturated, straight or branched hydrocarbon chain, where one or two methylene units in the chain are independently -CH(R L )-,-C(R L )2-, C 3~6 Cycloalkylenes, 3- to 6-membered heterocycloalkylenes, 5- to 6-membered heteroarylenes, -NH-, -N(R) L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-,-NHS(O)2-,-N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)2- as needed; here this C 3~6 Each of the cycloalkylenes, 3- to 6-membered heterocycloalkylenes, and 5- to 6-membered heteroarylenes is one example of R A or C 1~6 It is replaced with aliphatic material as needed; R WA , R WB , and R WC Each of these is independently hydrogen, deuterium, halogen, -CN, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, or a optionally substituted group, the optionally substituted group being C 1~6 Selected from 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or R WA and R WB , R WB and R WC , R WA and R L One example of this is R WC and R LOne example of, together with the atoms therebetween, forms a 4- to 7-membered saturated or partially unsaturated ring having 0 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted with w instances of R C ; R WD is halogen or -OS(O)2R; R 5C , R 5D , R 7A , and each instance of R L is, independently, R A or R B and is substituted with u instances of R C ; or two instances of R 5C , one instance of R 5C and one instance of R 5D , or two instances of R 5D , together with the atoms therebetween, form a 3- to 7-membered saturated, partially unsaturated, or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted with v instances of R C ; each instance of R A is independently oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, or -N(R)S(O)2R; each instance of R B is independently C 1~6Aliphatic; phenyl; 5-6 member monocyclic heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 8-10 member bicyclic heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 3-7 member saturated or partially unsaturated carbocyclic rings; 3-7 member saturated or partially unsaturated monocyclic heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or 7-12 member saturated or partially unsaturated bicyclic heterocyclic rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R C Each example is independently an oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -S(O)2F, -OS(O)2F, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, -N(R)S(O)2R, or a group as optionally substituted, where this optionally substituted group is C 1~6 Selected from 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Each R is independently a hydrogen atom or a optionally substituted group, and this optionally substituted group is C 1~6 Selected from 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: Two R groups on the same nitrogen atom, together with the atom between them, form a 4- to 7-membered saturated, partially unsaturated, or heteroaryl ring having 0 to 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, in addition to this nitrogen; Each of m, n, p, q, r, t, u, v, and w is independently 0, 1, 2, 3, or 4.

[0011] In some embodiments, the present invention relates to formula I: [ka] Provides a compound or a pharmaceutically acceptable salt thereof, in formula I: R 5 is, -R 5A -L 5 -R 5B and; R 5A R B It is a divalent radical, where R 5A is, -L 5 -R 5B In addition, m examples of R 5C It has been replaced with; R 5B is hydrogen or R B And here R 5B This is R for n examples. 5D It has been replaced with; Cy 6 This is phenylene, or a 6-membered heteroarylene having 1 to 3 nitrogen atoms, where Cy 6 is, -L 6 -R W In addition, the R of p examples 6 It has been replaced with; R W Halogen, -CN, [ka] and; R 6 Each example is independent, R A or R B And here R6 R for q examples C It is replaced by; or R 6 Two examples of R 6 One example and R L One example is that together with the atoms between these, they form a 4- to 7-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where this ring is R in r examples. C It has been replaced with; R 7 is H or R B And here R 7 R for t examples 7A It has been replaced with; L 5 and L 6 Each of them is independent, covalently bonded, or C 1~4 A divalent, saturated or unsaturated, straight or branched hydrocarbon chain, where one or two methylene units in the chain are independently -CH(R L )-,-C(R L )2-, C 3~5 Cycloalkylenes, 3- to 5-membered heterocycloalkylenes, 5- to 6-membered heteroarylenes, -NH-, -N(R) L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-,-NHS(O)2-,-N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L It is replaced as needed by -, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)2-; R WA , R WB , and R WC Each of these is independently hydrogen, halogen, -CN, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, or a optionally substituted group, and this optionally substituted group is C 1~6Selected from 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or R WA and R WB , R WB and R WC , R WA and R L One example of this is R WC and R L One example is that together with the atoms between them, they form a 4- to 7-membered saturated or partially unsaturated ring having 0 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R WD is a halogen or -OS(O)2R; R 5C , R 5D , R 7A , and R L Each example is independent, R A or R B And R for u examples C It has been replaced with; R A Each example is independently oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, or -N(R)S(O)2R; R B Each example is independent of C 1~6Aliphatic; phenyl; 5-6 member monocyclic heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 8-10 member bicyclic heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 3-7 member saturated or partially unsaturated carbocyclic rings; 3-7 member saturated or partially unsaturated monocyclic heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or 7-12 member saturated or partially unsaturated bicyclic heterocyclic rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R C Each example is independently an oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -S(O)2F, -OS(O)2F, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, -N(R)S(O)2R, or a group as optionally substituted, where this optionally substituted group is C 1~6 Selected from 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Each R is independently a hydrogen atom or a optionally substituted group, and this optionally substituted group is C 1~6 Selected from 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: Two R groups on the same nitrogen atom, together with the atom between them, form a 4- to 7-membered saturated, partially unsaturated, or heteroaryl ring having 0 to 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, in addition to this nitrogen; Each of m, n, p, q, r, t, and u is independently 0, 1, 2, 3, or 4. 2. Compounds and Definitions

[0012] The compounds of the present invention generally include those described above, and are further illustrated by the classes, subclasses, and species disclosed herein. Where used herein, unless otherwise specified, the following definitions apply. For the purposes of this invention, chemical elements are identified according to the Periodic Table, CAS version, Handbook of Chemistry and Physics, 75th edition. Furthermore, the general principles of organic chemistry are incorporated herein by reference in their entirety in "Organic Chemistry," Thomas Sorrell, University Science. This is described in Books, Sausalito: 1999, and in "March's Advanced Organic Chemistry," 5th edition, edited by Smith, M.B. and March, J., John Wiley & Sons, New York: 2001. Chemical names, common names, and chemical structures may be used interchangeably to describe the same structure. If a compound is described using both a chemical structure and a chemical name, and there is ambiguity between the structure and the name, the structure prevails.

[0013] The terms “aliphatic” or “aliphatic group,” as used herein, mean a linear (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain, which is fully saturated or contains one or more unsaturated units, or a monocyclic or bicyclic hydrocarbon (also referred herein as “carbocyclic” or “alicyclic”) which is fully saturated or contains one or more unsaturated units but is not aromatic, and which has one bond site to the rest of the molecule. Unless otherwise specified, an aliphatic group contains one to six aliphatic carbon atoms. In some embodiments, an aliphatic group contains one to five aliphatic carbon atoms. In other embodiments, an aliphatic group contains one to four aliphatic carbon atoms. In yet another embodiment, an aliphatic group contains one to three aliphatic carbon atoms, and in yet another embodiment, an aliphatic group contains one to two aliphatic carbon atoms. In some embodiments, “alicyclic” (or “carbocyclic”) refers to a monocyclic C3-C6 hydrocarbon that is fully saturated or contains one or more unsaturated units, is not aromatic, and has one bond site to the remainder of the molecule. Suitable aliphatic groups include, but are not limited to, linear or branched, saturated or unsaturated alkyl groups, alkenyl groups, alkynyl groups, and hybrids thereof (e.g., (cycloalkyl)alkyl, (cycloalkenyl)alkyl, or (cycloalkyl)alkenyl).

[0014] The term "alkyl," as used herein unless otherwise indicated, means a monovalent aliphatic hydrocarbon radical having a linear, branched, monocyclic, or polycyclic moiety, or a combination thereof, wherein one or more carbon atoms of the linear, branched, monocyclic, or polycyclic moiety, or a combination thereof, are optionally substituted at each carbon atom with one or more substituents, where these one or more substituents are independently C1-C 10It is an alkyl group. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and norbornyl.

[0015] The term "lower alkyl" refers to C 1~4 This refers to linear or branched alkyl groups. Exemplary lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.

[0016] The term "lower haloalkyl" refers to a C atom that is substituted with one or more halogen atoms. 1~4 This refers to a linear or branched alkyl group.

[0017] The term "heteroatom" refers to oxygen, sulfur, nitrogen, phosphorus, or silicon (any oxidation form of nitrogen, sulfur, phosphorus, or silicon; any quaternary form of basic nitrogen; or a substituteable nitrogen in a heterocyclic ring (e.g., N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or NR) + This means one or more of the following (including, for example, in N-substituted pyrrolidinyls).

[0018] The term "unsaturated," as used herein, means a portion having one or more unsaturated units.

[0019] As used herein, the term "C 1~8 (or C 1~6 , or C 1~4 "Divalent saturated or unsaturated, straight or branched hydrocarbon chains" means straight or branched, divalent alkylene, alkenylene, and alkynylene chains as defined herein.

[0020] The term "alkylene" refers to a divalent alkyl group. An "alkylene chain" is a polymethylene group, i.e., -(CH2) n - where n is a positive integer, preferably 1-6, 1-4, 1-3, 1-2, or 2-3. A substituted alkylene chain is a polymethylene group in which one or more methylene hydrogens are replaced by substituents. Suitable substituents include those listed below for substituted aliphatic groups.

[0021] The term "alkenylene" refers to a divalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond and in which one or more hydrogen atoms are replaced by substituents. Suitable substituents include the substituted aliphatic groups listed below.

[0022] The term "halogen" refers to F, Cl, Br, or I.

[0023] The term “aryl,” used alone or as part of a larger term such as “aralkyl,” “aralkoxy,” or “aryloxyalkyl,” refers to a monocyclic or bicyclic ring system having a total of 5 to 14 ring members, with at least one ring in the system being aromatic, and each ring in the system containing 3 to 7 ring members. The term “aryl” may be used interchangeably with the term “aryl ring.” In certain embodiments of the present invention, “aryl” refers to an aromatic ring system, which includes, but is not limited to, phenyl, biphenyl, naphthyl, and anthracyl, and which may have one or more substituents.

[0024] The terms “heteroaryl” or “heteroaromatic,” as used herein, unless otherwise defined, mean a monocyclic aromatic five- or six-membered ring containing one or more heteroatoms, e.g., one to three heteroatoms such as nitrogen, oxygen, and sulfur, or a polycyclic ring system containing one or more heteroatoms or eight to ten members, wherein at least one ring in the polycyclic ring system is aromatic, and the bonding site in the polycyclic ring system passes through a ring atom on the aromatic ring. Heteroaryl rings may bond to adjacent radicals via carbon or nitrogen. Examples of heteroaryls include, but are not limited to, furan, thiophene, pyrrole, thiazole, oxazole, isothiazole, isoxazole, imidazole, pyrazole, triazole, pyridine, pyrimidine, and indole. For example, unless otherwise defined, 1,2,3,4-tetrahydroquinoline, when its bonding site is via a benzo ring, for example: [ka] In this case, it is a heteroaryl ring.

[0025] The term "heterocyclyl" or "heterocyclic group," unless otherwise defined, refers to a saturated or partially unsaturated monocyclic ring system of 3 to 10 members, or a polycyclic ring system of 7 to 14 members (including bridged or fused rings), in which the ring system contains 1 to 4 heteroatoms, such as nitrogen, oxygen, and sulfur. Heterocyclyl rings can be bonded to adjacent radicals through carbon or nitrogen.

[0026] In the context of rings, the term "partially unsaturated" refers, unless otherwise defined, to a component in a monocyclic or polycyclic (e.g., bicyclic, tricyclic, etc.) ring system whose component ring contains at least one degree of unsaturation in addition to the degree of unsaturation provided by the ring itself, but is not aromatic. Examples of partially unsaturated rings include, but are not limited to, 3,4-dihydro-2H-pyran, 3-pyrroline, and 2-thiazoline. If a partially unsaturated ring is part of a polycyclic ring system, the other component rings in this polycyclic ring system may be saturated, partially unsaturated, or aromatic, but the bonding site of this polycyclic ring system lies on the partially unsaturated component ring. For example, unless otherwise defined, 1,2,3,4-tetrahydroquinoline, when its bonding site is via a piperidino ring, for example: [ka] In this case, it is a partially unsaturated ring.

[0027] In the context of rings, the term "saturated," unless otherwise defined, refers to a monocyclic ring or a polycyclic ring system (e.g., bicyclic, tricyclic, etc.) where the component ring, which is the bonding point to a monocyclic ring system, does not contain any further degree of unsaturation beyond the degree of unsaturation provided by the ring itself. Examples of monocyclic saturated rings include, but are not limited to, azetidine, oxetane, and cyclohexane. If the saturated ring is part of a polycyclic ring system, it may be saturated, partially unsaturated, or aromatic, but the bonding point of this polycyclic ring system lies on a saturated component ring. For example, unless otherwise defined, 2-azaspiro[3.4]octa-6-ene is, for example, when its bonding point is via an azetidino ring: [ka] In this case, it is a saturated ring.

[0028] The terms "alkylene," "arylene," "cycloalkylene," "heteroarylene," "heterocycloalkylene," and other similar terms with the suffix "-ylene" refer, as used herein, to the divalently bonded version of the group modified by this suffix. For example, "alkylene" is a divalent alkyl group bonded to the group to which it is bonded.

[0029] As used herein, the term “bridged bicyclic” means any bicyclic ring system (i.e., carbocyclic or heterocyclic) having at least one bridge, whether saturated or partially unsaturated. As defined by IUPAC, a “bridge” is a multi-atom unbranched chain, or a single atom, or a valence bond connecting two bridgeheads, where “bridgehead” is any skeletal atom of the ring system bonded to three or more skeletal atoms (other than hydrogen). In some embodiments, a bridged bicyclic group has 7 to 12 ring members and 0 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Such bridged bicyclic groups are well known in the art and include the groups described below, where each group is bonded to the remainder of the molecule at any suitable carbon or nitrogen atom. Unless otherwise specified, bridged bicyclic groups are optionally substituted with one or more substituents, as described for aliphatic groups. In addition, or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted. An example of a bridged double-ring type is: [ka] These are some examples.

[0030] As described herein, the compounds of the present invention may include “optionally substituted” moieties. Generally, the term “substituted” means that one or more hydrogens of a designated moiety are replaced with appropriate substituents, whether preceded or not by the term “optionally”. Unless otherwise indicated, an “optionally substituted” group may have appropriate substituents on each of its substituted moieties, and if one or more positions in any given structure can be replaced with one or more substituents selected from a particular group, the substituents may be the same or different at each position. The substituent combinations envisioned by the present invention are preferably combinations that result in the formation of stable compounds or chemically possible compounds. The term “stable,” as used herein, means a compound that remains substantially unchanged when produced, detected, and, in particular embodiments, subjected to conditions that enable their recovery, purification, and use for one or more of the purposes disclosed herein.

[0031] A suitable monovalent substituent on the substitutable carbon atom of the "substituted as needed" group is, independently, a halogen;-(CH2) 0~4 R ○ ;-(CH2) 0~4 Ure ○ ;-O(CH2) 0~4 R ○ -O-(CH2) 0~4 C(O)OR ○ ;-(CH2) 0~4 CH(OR ○ )2;-(CH2) 0~4 SR ○ ;-(CH2) 0~4 Ph (This is R ○ It can be replaced by (CH2) 0~4 O(CH2) 0~1 Ph (This is R ○ It can be substituted with);-CH=CHPh(this is R ○ It can be replaced by (CH2) 0~4 O(CH2) 0~1 -Pyridyl (This is R ○which may be substituted); -NO2; -CN; -N3; -(CH2) 0~4 N(R ○ )2; -(CH2) 0~4 N(R ○ )C(O)R ○ ; -N(R ○ )C(S)R ○ ; -(CH2) 0~4 N(R ○ )C(O)NR ○ 2; -N(R ○ )C(S)NR ○ 2; -(CH2) 0~4 N(R ○ )C(O)OR ○ ; -N(R ○ )N(R ○ )C(O)R ○ ; -N(R ○ )N(R ○ )C(O)NR ○ 2; -N(R ○ )N(R ○ )C(O)OR ○ ; -(CH2) 0~4 C(O)R ○ ; -C(S)R ○ ; -(CH2) 0~4 C(O)OR ○ ; -(CH2) 0~4 C(O)SR ○ ; -(CH2) 0~4 C(O)OSiR ○ 3; -(CH2) 0~4 OC(O)R ○ ; -OC(O)(CH2) 0~4 SR ○ ; -SC(S)SR ○ ; -(CH2) 0~4 SC(O)R ○ ; -(CH2) 0~4 C(O)NR ○ 2; -C(S)NR ○ 2; -C(S)SR ○ ; -SC(S)SR ○ , -(CH2) 0~4 OC(O)NR ○ 2; -C(O)N(OR ○ )R ○ ; -C(O)C(O)R ○;-C(O)CH2C(O)R ○ ;-C(NOR ○ )R ○ ;-(CH2) 0~4 SSR ○ ;-(CH2) 0~4 S(O)2R ○ ;-(CH2) 0~4 S(O)2OR ○ ;-(CH2) 0~4 OS(O)2R ○ ;-S(O)2NR ○ 2;-(CH2) 0~4 S(O)R ○ ;-N(R ○ )S(O)2NR ○ 2;-N(R ○ )S(O)2R ○ ;-N(OR ○ )R ○ ;-C(NH)NR ○ 2;-P(O)(OR ○ )R ○ ;-P(O)R ○ 2;-OP(O)R ○ 2;-OP(O)(OR ○ )2;-SiR ○ 3;-(C 1~4 (Linear or branched alkylene) ON(R ○ )2; or -(C 1~4 (Linear or branched alkylene)C(O)ON(R ○ )2, where each R ○ can be substituted as defined below, and independently, hydrogen, C 1~6 Aliphatic, -CH2Ph, -O(CH2) 0~1 Ph, -CH2- (a 5- to 6-membered heteroaryl ring), or a 5- to 6-membered saturated, partially unsaturated, or aryl ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or notwithstanding the above definition, R ○Two independent entities of these, together with an atom(s) between them, form a 3- to 12-membered saturated, partially unsaturated, or aryl monocyclic or bicyclic ring, each containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which can be substituted as defined below.

[0032] R ○ (R ○ The appropriate monovalent substituents on the ring formed by the two independent entities of these atoms joining together with the atom between them are halogens, -(CH2) 0~2 R ● ,-(HaroR ● ), -(CH2) 0~2 OH, -(CH2) 0~2 Ure ● ,-(CH2) 0~2 CH(OR ● )2;-O(HaroR ● ), -CN, -N3, -(CH2) 0~2 C(O)R ● ,-(CH2) 0~2 C(O)OH, -(CH2) 0~2 C(O)OR ● ,-(CH2) 0~2 SR ● ,-(CH2) 0~2 SH, -(CH2) 0~2 NH2, -(CH2) 0~2 NHR ● ,-(CH2) 0~2 NR ● 2, -NO2, -SiR ● 3. -OSiR ● 3, -C(O)SR ● ,-(C 1~4 (Straight-chain or branched-chain alkylene)C(O)OR ● , or -SSR ● And here each R ● It is either not substituted, or if preceded by "halo", it is substituted by only one or more halogens, and independently, C 1~4 Aliphatic, -CH2Ph, -O(CH2) 0~1Ph, or selected from 5- to 6-membered saturated, partially unsaturated, or aryl rings having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. ○ Suitable divalent substituents on the saturated carbon atom include =O and =S.

[0033] Suitable divalent substituents on the saturated carbon atoms of the "substituted as needed" groups include: =O, =S, =NNR * 2. =NNHC(O)R * ,=NNHC(O)OR * ,=NNHS(O)2R * ,=NR * 、=NOR * , -O(C(R * 2)) 2~3 O-, or -S(C(R * 2)) 2~3 S-. Here's R * Each independent entity is a hydrogen, which can be substituted as defined below. 1~6 Selected from aliphatic, or unsubstituted 5- to 6-membered saturated, partially unsaturated, or aryl rings having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents bonded to the substituteable carbon of the vicinal of the "optionally substituted" group include -O(CR * 2) 2~3 O- is mentioned, and here R * Each independent entity is a hydrogen, which can be substituted as defined below. 1~6 Selected from aliphatic or unsubstituted 5- to 6-membered saturated, partially unsaturated, or aryl rings having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0034] R * Suitable substituents on the aliphatic group include halogens, -R ● ,-(HaroR ● ), -OH, -OR ● ,-O(HaroR ● ), -CN, -C(O)OH, -C(O)OR ● -NH2, -NHR● , -NR ● 2, or -NO2, where each R ● It is either not substituted, or if preceded by "halo", it is substituted by only one or more halogens, and independently, C 1~4 Aliphatic, -CH2Ph, -O(CH2) 0~1 It is a 5- to 6-membered saturated, partially unsaturated, or aryl ring having 0 to 4 heteroatoms, or independently selected from nitrogen, oxygen, or sulfur.

[0035] A suitable substitutionable substituent on the nitrogen of the "substituted as needed" group is -R † , -NR † 2, -C(O)R † , -C(O)OR † ,-C(O)C(O)R † -C(O)CH2C(O)R † -S(O)2R † -S(O)2NR † 2, -C(S)NR † 2. -C(NH)NR † 2, or -N(R † )S(O)2R † These are listed; here each R † C can be substituted independently of hydrogen, as defined below. 1~6 Aliphatic, unsubstituted -OPh, or an unsubstituted 5- to 6-membered saturated, partially unsaturated, or aryl ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or notwithstanding the above definition, R † Two independent entities of these elements, together with an atom(s) between them, form an unsubstituted 3- to 12-membered saturated, partially unsaturated, or aryl monocyclic or bicyclic ring, each containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0036] R † Suitable substituents on the aliphatic group are, independently, halogens, -R ● ,-(HaroR ● ), -OH, -OR● ,-O(HaroR ● ), -CN, -C(O)OH, -C(O)OR ● -NH2, -NHR ● , -NR ● 2, or -NO2, where each R ● It is either not substituted, or if preceded by "halo", it is substituted by only one or more halogens, and independently, C 1~4 Aliphatic, -CH2Ph, -O(CH2) 0~1 It is a 5- to 6-membered saturated, partially unsaturated, or aryl ring having 0 to 4 heteroatoms, or independently selected from nitrogen, oxygen, or sulfur.

[0037] The term "isomer," as used herein, means a compound having the same chemical formula but differing in structure or optical configuration. The term "stereoisomer," as used herein, means an isomer molecule having the same molecular formula but differing in the positions of atoms and / or functional groups in space, and includes these isomer molecules. All stereoisomers of the compound (e.g., those that may exist due to chiral carbons on various substituents), including enantiomer and diastereomer forms, are considered to be within the scope of this disclosure. Accordingly, unless otherwise stated, isomers of a single stereochemistry of the compound, as well as mixtures of enantiomers, diastereomers, and positional (or conformational) isomers, are within the scope of the present invention.

[0038] The term "tautomer," as used herein, refers to one of two or more structural isomers that exist in equilibrium and readily convert from one isomeric form to the other. Tautomers are understood to include valence tautomers and proton tautomers (also known as prototropic tautomers). Valence tautomers include interconversion due to positional isomerism of several bonding electrons. Proton tautomers include interconversion due to proton transfer, such as keto-enol and imine-enamine isomerism. Unless otherwise stated, all tautomers of the compounds of the present invention are within the scope of the invention.

[0039] The term "isotope substitution," as used herein, refers to the replacement of an atom with its isotope. The term "isotope," as used herein, refers to an atom that has the same atomic number as the dominant atom in nature, but has a different mass number (number of neutrons) than the dominant atom in nature. A compound having isotopic substitution is a compound in which at least one atom contained therein is replaced by that isotope. Examples of atoms that can be replaced by this isotope include, but are not limited to, hydrogen, carbon, and oxygen. Examples of hydrogen isotopes include: 2 H (also represented as D) and 3 H is one example. Examples of isotopes of carbon atoms include, 13 C and 14 C is one example. Examples of oxygen atom isotopes include: 18 O is an example. Unless otherwise stated, all isotopic substitutions of the compounds of the present invention are within the scope of the invention. Such compounds are useful, for example, as analytical tools, as probes for biological assays, or as therapeutic agents according to the present invention. In certain embodiments, for example, the warhead portion R of the provided compound. W It contains one or more deuterium atoms.

[0040] As used herein, the term “pharmaceutically acceptable salt” means a salt that, within reasonable medical judgment, is appropriate for use in contact with human and lower animal tissues without excessive toxicity, irritation, and allergic reactions, and that is balanced by a reasonable benefit / risk ratio. Examples of pharmaceutically acceptable salts can be found, for example, in Berge, et al. (J. Pharm. Sci. 1977, 66(1), 1; and Gould, PL, Int. J. Pharmaceutics 1986, 33, 201-217; (each of which is incorporated herein by reference in whole).

[0041] Examples of pharmaceutically acceptable salts of the compounds of the present invention include salts derived from suitable inorganic acids, inorganic bases, organic acids, and organic bases. Examples of pharmaceutically acceptable, non-toxic acid addition salts are salts of amino groups formed with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid) or organic acids (e.g., acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid), or by using other methods used in the art, such as ion exchange. Other pharmaceutically acceptable salts include adipine, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphor sulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptone, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, and 2-hydroxyethanesulfate. Examples include nitrates, lactobionates, lactates, laurates, lauryl sulfates, malates, maleates, malons, methanesulfons, 2-naphthalenesulfons, nicotinates, nitrates, oleates, oxalates, palmitates, pamoates, pectins, persulfates, 3-phenylpropionates, phosphates, pivalates, propions, stearates, succinates, sulfates, tartrates, thiocyans, p-toluenesulfons, undecanoates, and valersates.

[0042] Examples of salts derived from suitable bases include alkali metal salts, alkaline earth metal salts, ammonium salts, and N + (C 1~4Examples include alkyl)4 salts. Typical alkali metal salts or alkaline earth metal salts include sodium, lithium, potassium, calcium, and magnesium. Further pharmaceutically acceptable salts, where appropriate, include non-toxic ammonium, quaternary ammonium, and amine cations formed with counterions such as halide ions, hydroxide ions, carbonate ions, sulfate ions, phosphate ions, nitrate ions, lower alkyl sulfonate ions, and aryl sulfonate ions.

[0043] Pharmaceutically acceptable salts are also intended to include hemisalts, where the compound:acid ratio is 2:1, respectively. Exemplary hemisalts are salts derived from acids containing two carboxylic acid groups, such as malic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, glutaric acid, oxalic acid, adipic acid, and citric acid. Other exemplary hemisalts are salts derived from diprotic mineral acids such as sulfuric acid. Exemplary preferred hemisalts include, but are not limited to, hemimaleate, hemifumarate, and hemisuccinate.

[0044] As used herein, the term “about” means approximately, roughly, about, or within a range. When the term “about” is used in relation to a numerical range, it modifies this range by extending the upper and lower boundaries of the numerical value being described. Generally, the term “about” is used herein to modify a numerical value being described by a variation of 20 percent above or below (higher or lower).

[0045] Where used herein, “effective dose,” “sufficient dose,” or “therapeutic effective dose” means a quantity of a compound sufficient to produce a favorable or desired outcome, including clinical outcomes. Thus, an effective dose may be sufficient, for example, to reduce or alleviate the severity and / or duration of distress or one or more symptoms associated with FGFR2 signaling, to prevent the progression of a condition or symptom associated with distress related to FGFR2 signaling, or to enhance or otherwise improve the preventive or therapeutic effect (one or more) of another treatment. An effective dose also includes a quantity of the compound that avoids or substantially reduces an undesirable side effect.

[0046] Where used herein, “treatment” means, as will be fully understood in the art, an approach to obtain a favorable or desired outcome, including a clinical outcome. Favorable or desired clinical outcomes may include, but are not limited to, the alleviation or reduction of one or more symptoms or conditions, whether detectable or undetectable; a reduction in the severity of the disease or distress; a stabilized (i.e., non-exacerbating) state of the disease or distress; prevention of the spread of the disease or distress; delay or slowing the progression of the disease or distress; reduction or temporary relief of the state of the disease or distress; and a remission (whether partial or whole). “Treatment” may also mean an extension of survival compared to the survival expected without treatment. In some embodiments, treatment may be administered after the onset of one or more symptoms. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to a susceptible individual before the onset of symptoms (e.g., taking into account the history of the symptoms and / or genetic or other susceptibility factors). Treatment may also be continued after the symptoms have subsided, for example, to prevent or delay the recurrence of those symptoms.

[0047] The phrase "the need for such relief" means the need for symptomatic or asymptomatic relief from a condition related to FGFR2 signaling activity, or a condition that can otherwise be relieved by the compounds and / or compositions of the present disclosure. 3. Description of Exemplary Embodiments

[0048] As described above, in some embodiments, the present invention relates to formula I-1: [ka] Provides a compound or a pharmaceutically acceptable salt thereof, in formula I-1: Cy A teeth, [ka] And here [ka] R 5 It represents a connection to, and [ka] Cy 6 Represents a connection to; R 5 is, -R 5A -L 5 -R 5B and; R 5A R B It is a divalent radical, where R 5A is, -L 5 -R 5B In addition, m examples of R 5C It has been replaced with; R 5B is hydrogen or R B And here R 5B This is R for n examples. 5D It has been replaced with; Cy 6phenylene; a divalent saturated or partially unsaturated 3- to 14-membered carbocyclic ring; a divalent saturated or partially unsaturated 3- to 14-membered heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5- to 14-membered heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where Cy 6 is, -L 6 -R W In addition, the R of p examples 6 It has been replaced with; R W Halogen, -CN, [ka] and; R 6 Each example is independent, R A or R B And here R 6 R is the R of q examples. C It is replaced by; or R 6 Two examples of R 6 One example and R L One example is R 6 One example and R WA One example of this is R 6 One example and R 7a One example is that together with the atoms between these, they form a 4- to 8-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where this ring is R in r examples. C It has been replaced with; R 7 is H or R B And here R 7 R for t examples 7A It has been replaced with; R 8 C is replaced as needed with H, -NR2, halogen, -OH, or 1 to 3 halogens. 1~6 It is aliphatic; R 9C is replaced as needed with H, -NR2, halogen, or 1 to 3 halogens. 1~6 It is aliphatic; R 10 C is replaced as needed with H, or 1 to 3 halogens. 1~6 It is aliphatic; L 5 and L 6 Each of them is independent, covalently bonded, or C 1~4 A divalent, saturated or unsaturated, straight or branched hydrocarbon chain, where one or two methylene units in the chain are independently -CH(R L )-,-C(R L )2-, C 3~6 Cycloalkylenes, 3- to 6-membered heterocycloalkylenes, 5- to 6-membered heteroarylenes, -NH-, -N(R) L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-,-NHS(O)2-,-N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)2- as needed; here this C 3~6 Each of the cycloalkylenes, 3- to 6-membered heterocycloalkylenes, and 5- to 6-membered heteroarylenes is one example of R A or C 1~6 It is replaced with aliphatic material as needed; R WA , R WB , and R WC Each of these is independently hydrogen, deuterium, halogen, -CN, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, or a optionally substituted group, the optionally substituted group being C 1~6Selected from 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or R WA and R WB , R WB and R WC , R WA and R L One example of this is R WC and R L One example is that together with the atoms between these, they form a 4- to 7-membered saturated or partially unsaturated ring having 0 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where this ring is w examples of R C It has been replaced with; R WD is a halogen or -OS(O)2R; R 5C , R 5D , R 7A , and R L Each example is independent, R A or R B And R for u examples C It is replaced by; or R 5C Two examples of R 5C One example and R 5D One example of, or R 5D The two examples, together with the atoms between them, form a 3- to 7-membered saturated, partially unsaturated, or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where this ring is the R of the v examples C It has been replaced with; R AEach example is independently oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, or -N(R)S(O)2R; R B Each example is independent of C 1~6 Aliphatic; phenyl; 5-6 member monocyclic heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 8-10 member bicyclic heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 3-7 member saturated or partially unsaturated carbocyclic rings; 3-7 member saturated or partially unsaturated monocyclic heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or 7-12 member saturated or partially unsaturated bicyclic heterocyclic rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R C Each example is independently an oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -S(O)2F, -OS(O)2F, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, -N(R)S(O)2R, or a group as optionally substituted, where this optionally substituted group is C 1~6 Selected from 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Each R is independently a hydrogen atom or a optionally substituted group, and this optionally substituted group is C 1~6 Selected from 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: Two R groups on the same nitrogen atom, together with the atom between them, form a 4- to 7-membered saturated, partially unsaturated, or heteroaryl ring having 0 to 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, in addition to this nitrogen; Each of m, n, p, q, r, t, u, v, and w is independently 0, 1, 2, 3, or 4.

[0049] As generally defined above, Cy A teeth, [ka] And here [ka] R 5 It represents a connection to, and [ka] Cy 6 Represents a coupling to Cy A teeth, [ka] In some embodiments, Cy A teeth, [ka] In some embodiments, CyA teeth, [ka] In some embodiments, Cy A teeth, [ka] In some embodiments, Cy A teeth, [ka] In some embodiments, Cy A teeth, [ka] In some embodiments, Cy A teeth, [ka] In some embodiments, Cy A teeth, [ka] That is the case.

[0050] In some embodiments, Cy A teeth, [ka] In some embodiments, Cy A teeth, [ka] In some embodiments, Cy A teeth, [ka] In some embodiments, Cy A The group is selected from the groups illustrated in the compounds in Table 1.

[0051] As generally defined above, Cy 6 phenylene; a divalent saturated or partially unsaturated 3- to 14-membered carbocyclic ring; a divalent saturated or partially unsaturated 3- to 14-membered heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5- to 14-membered heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where Cy 6 is, -L 6 -R W In addition, the R of p examples 6 It has been replaced with.

[0052] In some embodiments, Cy 6 phenylene; divalent saturated or partially unsaturated 3- to 7-membered monocyclic carbocyclic ring; divalent saturated or partially unsaturated 8- to 14-membered bicyclic carbocyclic ring; divalent saturated or partially unsaturated 3- to 7-membered monocyclic heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or divalent saturated or partially unsaturated 8- to 14-membered bicyclic heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 5- to 6-membered monocyclic heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or 9- to 10-membered bicyclic heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where Cy 6 is, -L 6 -R W In addition, the R of p examples 6 It has been replaced with.

[0053] In some embodiments, Cy 6This is a divalent saturated or partially unsaturated 3- to 14-membered carbocyclic ring; where Cy 6 is, -L 6 -R W In addition, the R of p examples 6 It is replaced by Cy 6 Here, is a divalent saturated or partially unsaturated 3- to 7-member monocyclic carbocyclic ring, or a divalent saturated or partially unsaturated 8- to 14-member bicyclic carbocyclic ring; where Cy 6 is, -L 6 -R W In addition, the R of p examples 6 It is replaced by Cy 6 This is a divalent saturated or partially unsaturated 3- to 7-membered monocyclic carbocyclic ring; where Cy 6 is, -L 6 -R W In addition, the R of p examples 6 It is replaced by Cy 6 This is a divalent saturated or partially unsaturated 8- to 14-membered bicyclic carbocyclic ring; where Cy 6 is, -L 6 -R W In addition, the R of p examples 6 It has been replaced with.

[0054] In some embodiments, Cy 6 A is a divalent, saturated or partially unsaturated, 3- to 14-membered heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where Cy 6 is, -L 6 -R W In addition, the R of p examples 6 It is replaced by Cy 6 is a divalent saturated or partially unsaturated 3- to 7-membered monocyclic or heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a divalent saturated or partially unsaturated 8- to 14-membered bicyclic or heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where Cy 6is, -L 6 -R W In addition, the R of p examples 6 It has been replaced with.

[0055] In some embodiments, Cy 6 A is a divalent, saturated or partially unsaturated, 3- to 7-membered monocyclic or heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where Cy 6 is, -L 6 -R W In addition, the R of p examples 6 It is replaced by Cy 6 A is a divalent, saturated or partially unsaturated, 5- to 6-membered monocyclic or heterocyclic ring having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur; where Cy 6 is, -L 6 -R W In addition, the R of p examples 6 It is replaced by Cy 6 is a divalent pyrrolidine ring or dihydropyrrolidine ring; where Cy 6 is, -L 6 -R W In addition, the R of p examples 6 It has been replaced with.

[0056] In some embodiments, Cy 6 This is a 5- to 14-membered heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where Cy 6 is, -L 6 -R W In addition, the R of p examples 6 It is replaced by Cy 6 is a 5- to 6-membered monocyclic heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 9- to 10-membered bicyclic heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where Cy 6 is, -L6 -R W In addition, the R of p examples 6 It has been replaced with.

[0057] In some embodiments, Cy 6 This is a 5- to 6-membered monocyclic heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where Cy 6 is, -L 6 -R W In addition, the R of p examples 6 It is replaced by Cy 6 This is a 5-6 member monocyclic heteroarylene having 1-2 nitrogen atoms; where Cy 6 is, -L 6 -R W In addition, the R of p examples 6 It is replaced by Cy 6 This is a 5-membered monocyclic heteroarylene having 1 to 2 nitrogen atoms; where Cy 6 is, -L 6 -R W In addition, the R of p examples 6 It has been replaced with.

[0058] In some embodiments, Cy 6 This is a 9- to 10-membered bicyclic heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where Cy 6 is, -L 6 -R W In addition, the R of p examples 6 It is replaced by Cy 6 This is a 9- to 10-membered bicyclic heteroarylene having 1 to 3 nitrogen atoms; where Cy 6 is, -L 6 -R W In addition, the R of p examples 6 It has been replaced with.

[0059] In some embodiments, Cy 6The group is selected from the groups illustrated in the compounds in Table 1.

[0060] In some embodiments, -Cy 6 -L 6 -R W Things that come together: [ka] [ka] And, Here L 6 , R 6 , R W Each of , and p is as defined in the embodiments and classes and subclasses herein. In some embodiments, -Cy 6 -L 6 -R W Things that come together: [ka] And, Here L 6 , R 6 , R W Each of , and p is as defined in the embodiments and classes and subclasses herein. In some embodiments, -Cy 6 -L 6 -R W Things that come together: [ka] And, Here L 6 , R 6 , R W Each of , and p is as defined in the embodiments and classes and subclasses herein. In some embodiments, -Cy 6 -L 6 -R W Things that come together: [ka] [ka] And, Here L 6 , R 6 , R W Each of , and p is as defined in the embodiments and classes and subclasses herein.

[0061] As generally defined above, R 6 Each example is independent, R A or R B And here R 6 R is the R of q examples. C It is replaced by; or R 6 Two examples of R 6 One example and R L One example is R 6 One example and R WA One example of this is R 6 One example and R 7a One example is that together with the atoms between these, they form a 4- to 8-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where this ring is R in r examples. C It has been replaced with.

[0062] In some embodiments, R 6 Two examples of R 6 One example and R L One example is R 6 One example and R WA One example of this is R 6 One example and R 7a One example is that together with the atoms between these, they form a 4- to 8-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where this ring is R in r examples. C It has been replaced with.

[0063] In some embodiments, R 6 One example and R WA One example is that together with the atoms between these, they form a 4- to 8-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where this ring is R in r examples. C It is replaced by R 6 One example and R 7a One example is that together with the atoms between these, they form a 4- to 8-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where this ring is R in r examples. C It has been replaced with.

[0064] In some embodiments, R 6 One example and R 7a One example is that together with the atoms between these, they form a 4- to 8-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where this ring is R in r examples. C It is replaced by R 6 One example and R 7a One example is when these atoms combine to form a 4- to 8-membered partial unsaturated ring with one nitrogen atom; where this ring is a halogen, -CN, -O-(C 1~4 Alkyl), and -(C 1~4 It is optionally substituted with one, two, or three substituents independently selected from the alkyl group; where each C 1~4 The alkyl group is optionally substituted with one, two, or three fluoropolymers. In some embodiments, R 6 One example and R 7a One example is that together with the atoms between them, they form a 4- to 8-membered partial unsaturated ring. In some embodiments, R 6 One example and R 7aOne example is when these atoms combine to form a 4- to 8-membered partial unsaturated ring with one nitrogen atom.

[0065] In some embodiments, each R 6 The group is selected from the groups illustrated in the compounds in Table 1.

[0066] As generally defined above, R 8 C is replaced as needed with H, -NR2, halogen, -OH, or 1 to 3 halogens. 1~6 It is aliphatic. In some embodiments, R 8 is H. In some embodiments, R 8 is -NR2. In some embodiments, R 8 is a halogen. In some embodiments, R 8 is -OH. In some embodiments, R 8 C is replaced as needed with 1 to 3 halogens. 1~6 It is an aliphatic.

[0067] In some embodiments, R 8 is -NH2. In some embodiments, R 8 is C 1~4 It is alkyl. In some embodiments, R 8 is methyl. In some embodiments, R 8 is -NH2 or methyl. In some embodiments, R 8 The group is selected from the groups illustrated in the compounds in Table 1.

[0068] As generally defined above, R 9 C is replaced as needed with H, -NR2, halogen, or 1 to 3 halogens. 1~6 It is aliphatic. In some embodiments, R 9 is H. In some embodiments, R 9 is -NR2. In some embodiments, R 9 is -NH2. In some embodiments, R9 is a halogen. In some embodiments, R 9 C is replaced as needed with 1 to 3 halogens. 1~6 It is aliphatic. In some embodiments, R 9 is C 1~4 It is alkyl. In some embodiments, R 9 The group is selected from the groups illustrated in the compounds in Table 1.

[0069] As generally defined above, R 10 C is replaced as needed with H, or 1 to 3 halogens. 1~6 It is aliphatic. In some embodiments, R 10 is H. In some embodiments, R 10 C is replaced as needed with 1 to 3 halogens. 1~6 It is aliphatic. In some embodiments, R 10 is C 1~4 It is alkyl. In some embodiments, R 10 is methyl. In some embodiments, R 10 is H or methyl. In some embodiments, R 10 The group is selected from the groups illustrated in the compounds in Table 1.

[0070] As generally defined above, L 6 is a covalent bond, or C 1~4 A divalent, saturated or unsaturated, straight or branched hydrocarbon chain, where one or two methylene units in the chain are independently -CH(R L )-,-C(R L )2-, C 3~6 Cycloalkylenes, 3- to 6-membered heterocycloalkylenes, 5- to 6-membered heteroarylenes, -NH-, -N(R) L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-,-NHS(O)2-,-N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(RL )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)2- as needed; here this C 3~6 Each of the cycloalkylenes, 3- to 6-membered heterocycloalkylenes, and 5- to 6-membered heteroarylenes is one example of R A or C 1~6 It is replaced with an aliphatic as needed.

[0071] In some embodiments, L 6 C 3~6 These are cycloalkylenes, 3- to 6-membered heterocycloalkylenes, or 5- to 6-membered heteroarylenes, each of which is one example of R A or C 1~6 It is replaced with an aliphatic as needed. In some embodiments, L 6 C 3~6 These are cycloalkylenes, 3- to 6-membered heterocycloalkylenes, or 5- to 6-membered heteroarylenes.

[0072] In some embodiments, L 6 The group is selected from the groups illustrated in the compounds in Table 1.

[0073] As generally defined above, R 5C Examples and R 5D R is independent of A or R B And R for u examples C It is replaced with; or R 5C Two examples of R 5C One example and R 5D One example of, or R 5D The two examples, together with the atoms between them, form a 3- to 7-membered saturated, partially unsaturated, or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where this ring is the R of the v examples C It has been replaced with.

[0074] In some embodiments, R5C The two examples, together with the atoms between them, form a 3- to 7-membered saturated, partially unsaturated, or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where this ring is the R of the v examples C It has been replaced with.

[0075] In some embodiments, R 5C One example and R 5D One example of these, together with the atoms between them, forms a 3- to 7-membered saturated, partially unsaturated, or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where this ring is R of v examples C It is replaced by R 5C One example and R 5D One example of this is the R of v examples, together with the atoms between them. C It forms a 3- to 7-membered saturated or partially unsaturated carbocyclic ring by substitution.

[0076] In some embodiments, R 5D The two examples, together with the atoms between them, form a 3- to 7-membered saturated, partially unsaturated, or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where this ring is the R of the v examples C It is replaced by R 5D The two examples, together with the atoms between them, make up the R of v examples. C It forms a 3- to 7-membered saturated or partially unsaturated carbocyclic ring by substitution.

[0077] In some embodiments, R 5C Examples and R 5D The group is selected from the groups illustrated in the compounds in Table 1.

[0078] As generally defined above, v is 0, 1, 2, 3, or 4. In some embodiments, v is 0. In some embodiments, v is 1. In some embodiments, v is 2. In some embodiments, v is 3. In some embodiments, v is 4. In some embodiments, v is 0 or 1. In some embodiments, v is 0, 1, or 2. In some embodiments, v is 0, 1, 2, or 3. In some embodiments, v is 1 or 2. In some embodiments, v is 1, 2, or 3. In some embodiments, v is 1, 2, 3, or 4. In some embodiments, v is 2 or 3. In some embodiments, v is 2, 3, or 4. In some embodiments, v is 3 or 4. In some embodiments, v is selected from the values ​​shown in the compounds in Table 1.

[0079] As generally defined above, w is 0, 1, 2, 3, or 4. In some embodiments, w is 0. In some embodiments, w is 1. In some embodiments, w is 2. In some embodiments, w is 3. In some embodiments, w is 4. In some embodiments, w is 0 or 1. In some embodiments, w is 0, 1, or 2. In some embodiments, w is 0, 1, 2, or 3. In some embodiments, w is 1 or 2. In some embodiments, w is 1, 2, or 3. In some embodiments, w is 1, 2, 3, or 4. In some embodiments, w is 2 or 3. In some embodiments, w is 2, 3, or 4. In some embodiments, w is 3 or 4. In some embodiments, w is selected from the values ​​shown in the compounds in Table 1.

[0080] In some embodiments, the present invention provides compounds of formula I-1, where each of its variants, both alone and in combination, is defined by the following description of formula I or formula I-2, and as described in the embodiments herein.

[0081] As described above, in some embodiments, the present invention relates to formula I-2: [ka] Provides a compound or a pharmaceutically acceptable salt thereof, in formula I-2: R 5 is, -R 5A -L 5 -R 5B and; R 5A R B It is a divalent radical, where R 5A is, -L 5 -R 5B In addition, m examples of R 5C It has been replaced with; R 5B is hydrogen or R B And here R 5B This is R for n examples. 5D It has been replaced with; Cy 6 This is phenylene, or a 6-membered heteroarylene having 1 to 3 nitrogen atoms, where Cy 6 is, -L 6 -R W In addition, the R of p examples 6 It has been replaced with; R W Halogen, -CN, [ka] and; R 6 Each example is independent, R A or R B And here R 6 R is the R of q examples. CIt is replaced by; or R 6 Two examples of R 6 One example and R L One example is that together with the atoms between these, they form a 4- to 7-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where this ring is R in r examples. C It has been replaced with; R 7 is H or R B And here R 7 R for t examples 7A It has been replaced with; L 5 and L 6 Each of them is independent, covalently bonded, or C 1~4 A divalent, saturated or unsaturated, straight or branched hydrocarbon chain, where one or two methylene units in the chain are independently -CH(R L )-,-C(R L )2-, C 3~5 Cycloalkylenes, 3- to 5-membered heterocycloalkylenes, 5- to 6-membered heteroarylenes, -NH-, -N(R) L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-,-NHS(O)2-,-N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L It is replaced as needed by -, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)2-; R WA , R WB , and R WC Each of these is independently hydrogen, deuterium, halogen, -CN, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, or a optionally substituted group, the optionally substituted group being C 1~6Selected from 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or R WA and R WB , R WB and R WC , R WA and R L One example of this is R WC and R L One example is that together with the atoms between them, they form a 4- to 7-membered saturated or partially unsaturated ring having 0 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R WD is a halogen or -OS(O)2R; R 5C , R 5D , R 7A , and R L Each example is independent, R A or R B And R for u examples C It has been replaced with; R A Each example is independently oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, or -N(R)S(O)2R; R B Each example is independent of C 1~6Aliphatic; phenyl; 5-6 member monocyclic heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 8-10 member bicyclic heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 3-7 member saturated or partially unsaturated carbocyclic rings; 3-7 member saturated or partially unsaturated monocyclic heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or 7-12 member saturated or partially unsaturated bicyclic heterocyclic rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R C Each example is independently an oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -S(O)2F, -OS(O)2F, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, -N(R)S(O)2R, or a group as optionally substituted, where this optionally substituted group is C 1~6 Selected from 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Each R is independently a hydrogen atom or a optionally substituted group, and this optionally substituted group is C 1~6 Selected from 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: Two R groups on the same nitrogen atom, together with the atom between them, form a 4- to 7-membered saturated, partially unsaturated, or heteroaryl ring having 0 to 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, in addition to this nitrogen; and Each of m, n, p, q, r, t, and u is independently 0, 1, 2, 3, or 4.

[0082] As generally defined above, R WA , R WB , and R WC Each of these is independently hydrogen, deuterium, halogen, -CN, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, or a optionally substituted group, the optionally substituted group being C 1~6 Selected from 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or R WA and R WB , R WB and R WC , R WA and R L One example of this is R WC and R L One example is that these atoms, together with the atoms in between, form a 4- to 7-membered saturated or partially unsaturated ring having 0 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0083] In some embodiments, R WA , R WB , and R WC Each of these is independently hydrogen, deuterium, halogen, -CN, -C(O)R, -C(O)OR, -C(O)NR2, or -C(O)N(R)OR. In some embodiments, R WA , R WB , and R WC Each of these can independently be hydrogen, deuterium, or a substituted C as needed.1~6 It is aliphatic. In some embodiments, R WA , R WB , and R WC Each of them independently consists of hydrogen, deutherium, and -C. 1~4 Alkyl, -(C 1~4 Alkyl)-O-(C 1~4 Alkyl), or -(C 1~4 Alkyl)-N(C 1~4 Alkyl)2; where each C 1~4 The alkyl group is optionally substituted with one, two, or three fluoropolymers. In some embodiments, R WA , R WB , and R WC Each of these is independently substituted as needed with hydrogen, deutherium, or one, two, or three fluorocarbons -C 1~4 It is alkyl. In some embodiments, R WA , R WB , and R WC Each of these can independently be hydrogen, deuterium, or -C 1~4 It is alkyl. In some embodiments, R WA , R WB , and R WC Each of them is independently hydrogen, deutherium, or -CH3. In some embodiments, R WA , R WB , and R WC Each of them is independently hydrogen or deutherium. In some embodiments, R WA , R WB , and R WC Each of them is a Deuterium.

[0084] In some embodiments, the present invention provides compounds of formula I-2, in which each of its variable products is defined both alone and in combination by the following description of formula I, and as described in the embodiments herein.

[0085] As described above, in some embodiments, the present invention relates to formula I: [ka] Provides a compound or a pharmaceutically acceptable salt thereof, in formula I: R 5 is, -R 5A -L 5 -R 5B and; R 5A R B It is a divalent radical, where R 5A is, -L 5 -R 5B In addition, m examples of R 5C It has been replaced with; R 5B is hydrogen or R B And here R 5B This is R for n examples. 5D It has been replaced with; Cy 6 This is phenylene, or a 6-membered heteroarylene having 1 to 3 nitrogen atoms, where Cy 6 is, -L 6 -R W In addition, the R of p examples 6 It has been replaced with; R W Halogen, -CN, [ka] and; R 6 Each example is independent, R A or R B And here R 6 R is the R of q examples. C It is replaced by; or R 6 Two examples of R 6 One example and R L One example is that together with the atoms between these, they form a 4- to 7-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where this ring is R in r examples. C It has been replaced with; R 7 is H or R B And here R 7 R for t examples 7A It has been replaced with; L 5 and L 6 Each of them is independent, covalently bonded, or C 1~4 A divalent, saturated or unsaturated, straight or branched hydrocarbon chain, where one or two methylene units in the chain are independently -CH(R L )-,-C(R L )2-, C 3~5 Cycloalkylenes, 3- to 5-membered heterocycloalkylenes, 5- to 6-membered heteroarylenes, -NH-, -N(R) L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-,-NHS(O)2-,-N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L It is replaced as needed by -, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)2-; R WA , R WB , and R WC Each of these is independently hydrogen, halogen, -CN, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, or a optionally substituted group, and this optionally substituted group is C 1~6 Selected from 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or R WA and R WB , R WB and R WC , R WA and R L One example of this is R WC and R Lone example of which, together with the atoms therebetween, forms a 4- to 7-membered saturated or partially unsaturated ring having 0 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R WD is halogen or -OS(O)2R; R 5C , R 5D , R 7A , and R L are each independently R A or R B and are substituted with u instances of R C ; R A are each independently oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, or -N(R)S(O)2R; R B are each independently C 1~6 aliphatic; phenyl; a 5- to 6-membered monocyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8- to 10-membered bicyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3- to 7-membered saturated or partially unsaturated carbocyclic ring; a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7- to 12-membered saturated or partially unsaturated bicyclic heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R CEach instance of is independently oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -S(O)2F, -OS(O)2F, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, -N(R)S(O)2R, or an optionally substituted group, and this optionally substituted group is C 1~6 aliphatic, phenyl, a 3- to 7-membered saturated or partially unsaturated heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, as well as a 5- to 6-membered heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Each R is independently hydrogen, or an optionally substituted group, and this optionally substituted group is C 1~6 aliphatic, phenyl, a 3- to 7-membered saturated or partially unsaturated heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, as well as a 5- to 6-membered heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or alternatively: Two R groups on the same nitrogen, together with the atoms therebetween, form a 4- to 7-membered saturated, partially unsaturated, or heteroaryl ring having 0 to 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, in addition to this nitrogen; and Each of m, n, p, q, r, t, and u is independently 0, 1, 2, 3, or 4.

[0086] As generally defined above, R 5A is R B is a divalent radical, where R 5A is -L 5 -R 5B is substituted with m instances of R 5C . In some embodiments, R 5A is -L5 -R 5B In addition, m examples of R 5C Divalent C substituted with 1~6 It is aliphatic. In some embodiments, R 5A is, -L 5 -R 5B In addition, m examples of R 5C It is phenylene substituted with R. In some embodiments, 5A It is a 5- to 6-membered monocyclic heteroarylene ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;-L 5 -R 5B In addition, m examples of R 5C It is replaced by R 5A It is an 8- to 10-membered bicyclic heteroarylene ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;-L 5 -R 5B In addition, m examples of R 5C It is replaced by R 5A is, -L 5 -R 5B In addition, m examples of R 5C It is a divalent 3- to 7-membered saturated or partially unsaturated carbocyclic ring substituted with R. In some embodiments, 5A A divalent 3- to 7-membered saturated or partially unsaturated monocyclic or heterocyclic ring having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur; -L 5 -R 5B In addition, m examples of R 5C It is replaced by R 5A A divalent 7- to 12-membered saturated or partially unsaturated bicyclic heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; -L 5 -R 5B In addition, m examples of R 5C It is replaced by R 5A The group is selected from the groups illustrated in the compounds in Table 1.

[0087] As generally defined above, L 5 is a covalent bond, or C 1~4 A divalent, saturated or unsaturated, straight or branched hydrocarbon chain, where one or two methylene units in the chain are independently -CH(R L )-,-C(R L )2-, C 3~5 Cycloalkylenes, 3- to 5-membered heterocycloalkylenes, 5- to 6-membered heteroarylenes, -NH-, -N(R) L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-,-NHS(O)2-,-N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L It is replaced as needed with -, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)2-. In some embodiments, L 5 L is a covalent bond. In some embodiments, L 5 C 1~4 A divalent, saturated or unsaturated, straight or branched hydrocarbon chain, where one or two methylene units in the chain are independently -CH(R L )-,-C(R L )2-, C 3~5 Cycloalkylenes, 3- to 5-membered heterocycloalkylenes, 5- to 6-membered heteroarylenes, -NH-, -N(R) L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-,-NHS(O)2-,-N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L It is replaced as needed by -, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)2-.

[0088] In some embodiments, L 5is a C 1~2 divalent saturated or unsaturated, linear or branched hydrocarbon chain, wherein 1 or 2 methylene units of this chain are each independently optionally replaced by -CH(R L )-, -C(R L )2-, C 3~5 cycloalkylene, 3- to 5-membered heterocycloalkylene, 5- to 6-membered heteroarylene, -NH-, -N(R L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-, -NHS(O)2-, -N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)2-. In some embodiments, L 5 is a C 1~2 divalent saturated or unsaturated, linear or branched hydrocarbon chain, wherein 1 or 2 methylene units of this chain are each independently optionally replaced by -O-, -C(O)-, -C(O)NH-, or -C(O)N(R L )-.

[0089] In some embodiments, L 5 is -O-, -C(O)-, -C(O)NH-, or -C(O)N(R L )-. In some embodiments, L 5 is -O-. In some embodiments, L 5 is -C(O)-. In some embodiments, L 5 is -C(O)NH-. In some embodiments, L 5 is -C(O)N(R L )-. In some embodiments, L 5 is selected from the groups illustrated in the compounds of Table 1.

[0090] As generally defined above, R 5B is hydrogen or RB And here R 5B This is R for n examples. 5D It is replaced by R 5B is hydrogen. In some embodiments, R 5B This is R for n examples. 5D R replaced by B In some embodiments, R 5B This is R for n examples. 5D C replaced by 1~6 It is aliphatic. In some embodiments, R 5B This is R for n examples. 5D It is a phenyl substituted with R. In some embodiments, 5B R is a 5- to 6-membered monocyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; n examples of R 5D It is replaced by R 5B R is an 8- to 10-membered bicyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; n examples of R 5D It is replaced by R 5B This is R for n examples. 5D It is a 3- to 7-membered saturated or partially unsaturated carbocyclic ring substituted with R. In some embodiments, R 5B R is a 3- to 7-membered saturated or partially unsaturated monocyclic or heterocyclic ring having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur; n examples of R 5D It is replaced by R 5B R is a 7- to 12-membered saturated or partially unsaturated bicyclic or heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; n examples of R 5D It has been replaced with.

[0091] In some embodiments, R 5BR is a 4- to 6-membered saturated or partially unsaturated monocyclic or heterocyclic ring having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur; n examples of R 5D It is replaced by R 5B R is a 5-membered monocyclic heteroaryl ring having 1 to 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; n examples of R 5D It is replaced by R 5B R is a six-membered monocyclic heteroaryl ring having one to two heteroatoms independently selected from nitrogen, oxygen, and sulfur; n examples of R 5D It is replaced by R 5B The group is selected from the groups illustrated in the compounds in Table 1.

[0092] As generally defined above, R 5C Each example is independent, R A or R B And R for u examples C It is replaced by R 5C Each example is R A In some embodiments, R 5C Each example is independently selected from halogen, -CN, -OR, -S(O)2NR2, -C(O)R, -C(O)OR, -C(O)NR2, -OC(O)R, and -N(R)C(O)R. In some embodiments, R 5C Each example is independently selected from halogen, -CN, -OR, and -C(O)NR2. In some embodiments, R 5C Each example is independent of halogen, -CN, -O-(C 1~4 alkyl), and -C(O)N(C 1~4 Selected from alkyl)2; where each C 1~4 The alkyl group is optionally substituted with one, two, or three halogens. In some embodiments, R 5C Each example is independent of halogen, -CN, -O-(C 1~4 alkyl), and -C(O)N(C1~4 Selected from alkyl)2.

[0093] In some embodiments, R 5C Each example is R B And here R 5C R for u examples C It is replaced by R 5C Each example is R B And here R 5C This is one example of R C It is replaced by R 5C Each example is independent of C 1~6 Selected from aliphatic; phenyl; 5-6 membered monocyclic heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 3-7 membered saturated or partially unsaturated carbocyclic rings; 3-7 membered saturated or partially unsaturated monocyclic or heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of these is R for u examples. C It is replaced as needed.

[0094] In some embodiments, R 5C Each example is independent of C 1~6 Selected from aliphatic; 3- to 7-membered saturated or partially unsaturated carbocyclic rings; and 3- to 7-membered saturated or partially unsaturated monocyclic or heterocyclic rings having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of these is u examples of R C It is replaced as needed by R 5C Each example is independent of the R example. C C replaced as needed 1~4 Selected from aliphatic; 3- to 5-membered saturated carbocyclic rings; and 3- to 5-membered saturated monocyclic and heterocyclic rings having one heteroatom independently selected from nitrogen, oxygen, and sulfur; each of these is optionally substituted with one, two, or three halogens. In some embodiments, R 5C Each example is independent of -OH, -O-(C1~4 Alkyl), or -N(C 1~4 C as needed, as an example of alkyl)2 1~4 Selected from alkyl groups; 3- to 5-membered saturated carbocyclic rings; and 3- to 5-membered saturated monocyclic or heterocyclic rings having one oxygen atom; each of these is optionally substituted with one, two, or three fluoro or chloro atoms.

[0095] In some embodiments, R 5C Each example is independent of halogen, -CN, -OR, -C(O)NR2, and each of the u examples of R C The following bases are replaced as needed by: C 1~6 Selected from aliphatic; 3- to 7-membered saturated or partially unsaturated carbocyclic rings; and 3- to 7-membered saturated or partially unsaturated monocyclic or heterocyclic rings having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 5C Each example independently includes the following groups, each substituted as needed with one, two, or three halogens: -O-(C 1~4 Alkyl), -C(O)N(C 1~4 Alkyl) 2, 1 example R C C replaced as needed 1~4 Selected from aliphatic; 3- to 5-membered saturated carbocyclic rings; and 3- to 5-membered saturated monocyclic or heterocyclic rings having one heteroatom independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 5C Each example is independent of halogen, -CN, -O-(C 1~4 Alkyl), -C(O)N(C 1~4 Alkyl)2, and the following groups, each optionally substituted with one, two, or three fluoro or chloro groups: -OH, -O-(C 1~4 Alkyl), or -N(C 1~4 C as needed, as an example of alkyl)2 1~4Selected from alkyl groups; 3- to 5-membered saturated carbocyclic rings; and 3- to 5-membered saturated monocyclic or heterocyclic rings having one oxygen atom. In some embodiments, R 5C The group is selected from the groups illustrated in the compounds in Table 1.

[0096] As generally defined above, R 5D Each example is independent, R A or R B And R for u examples C It is replaced by R 5D Each example is R A In some embodiments, R 5D Each example is independently selected from halogen, -CN, -OR, -S(O)2NR2, -C(O)R, -C(O)OR, -C(O)NR2, -OC(O)R, and -N(R)C(O)R. In some embodiments, R 5D Each example is independently selected from halogen, -CN, -OR, and -C(O)NR2. In some embodiments, R 5D Each example is independent of halogen, -CN, -O-(C 1~4 alkyl), and -C(O)N(C 1~4 Selected from alkyl)2; where each C 1~4 The alkyl group is optionally substituted with one, two, or three halogens. In some embodiments, R 5D Each example is independent of halogen, -CN, -O-(C 1~4 alkyl), and -C(O)N(C 1~4 Selected from alkyl)2.

[0097] In some embodiments, R 5D Each example is R B And here R 5D R for u examples C It is replaced by R 5D Each example is R B And here R 5D This is one example of R CIt is replaced by R 5D Each example is independent of C 1~6 Selected from aliphatic; phenyl; 5-6 membered monocyclic heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 3-7 membered saturated or partially unsaturated carbocyclic rings; 3-7 membered saturated or partially unsaturated monocyclic or heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of these is R for u examples. C It is replaced as needed.

[0098] In some embodiments, R 5D Each example is independent of C 1~6 Selected from aliphatic; 3- to 7-membered saturated or partially unsaturated carbocyclic rings; and 3- to 7-membered saturated or partially unsaturated monocyclic or heterocyclic rings having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of these is u examples of R C It is replaced as needed by R 5D Each example is independent of the R example. C C replaced as needed 1~4 Selected from aliphatic; 3- to 5-membered saturated carbocyclic rings; and 3- to 5-membered saturated monocyclic and heterocyclic rings having one heteroatom independently selected from nitrogen, oxygen, and sulfur; each of these is optionally substituted with one, two, or three halogens. In some embodiments, R 5D Each example is independent of -OH, -O-(C 1~4 Alkyl), or -N(C 1~4 C as needed, as an example of alkyl)2 1~4 Selected from alkyl groups; 3- to 5-membered saturated carbocyclic rings; and 3- to 5-membered saturated monocyclic or heterocyclic rings having one oxygen atom; each of these is optionally substituted with one, two, or three fluoro or chloro atoms.

[0099] In some embodiments, R 5DEach example is independent of halogen, -CN, -OR, -C(O)NR2, and each of the u examples of R C The following bases are replaced as needed by: C 1~6 Selected from aliphatic; 3- to 7-membered saturated or partially unsaturated carbocyclic rings; and 3- to 7-membered saturated or partially unsaturated monocyclic or heterocyclic rings having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 5D Each example independently includes the following groups, each substituted as needed with one, two, or three halogens: -O-(C 1~4 Alkyl), -C(O)N(C 1~4 Alkyl) 2, 1 example R C C replaced as needed 1~4 Selected from aliphatic; 3- to 5-membered saturated carbocyclic rings; and 3- to 5-membered saturated monocyclic or heterocyclic rings having one heteroatom independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 5D Each example is independent of halogen, -CN, -O-(C 1~4 Alkyl), -C(O)N(C 1~4 Alkyl)2, and the following groups, each optionally substituted with one, two, or three fluoro or chloro groups: -OH, -O-(C 1~4 Alkyl), or -N(C 1~4 C as needed, as an example of alkyl)2 1~4 Selected from alkyl groups; 3- to 5-membered saturated carbocyclic rings; and 3- to 5-membered saturated monocyclic or heterocyclic rings having one oxygen atom. In some embodiments, R 5D The group is selected from the groups illustrated in the compounds in Table 1.

[0100] As generally defined above, in some embodiments, the present invention provides compounds of formula I, wherein in formula I, R 5 is, -R 5A -L 5 -R 5B In some embodiments, R 5 (i.e., -R5A -L 5 -R 5B (A combination of these) is: [ka] And here L 5 , R 5B , R 5C Each of , and m is as defined in the embodiments, classes and subclasses herein.

[0101] In some embodiments, R 5 (i.e., -R 5A -L 5 -R 5B (A combination of these) is: [ka] And here R 5B , R 5C Each of , and m is as defined in the embodiments, classes and subclasses herein.

[0102] In some embodiments, R 5 (i.e., -R 5A -L 5 -R 5B (A combination of these) is: [ka] And here R 5B , R 5C Each of , and m is as defined in the embodiments, classes and subclasses herein.

[0103] In some embodiments, R 5 (i.e., -R 5A -L 5 -R 5B (A combination of these) is: [ka] And here R 5B , R 5C Each of , and m is as defined in the embodiments, classes and subclasses herein.

[0104] In some embodiments, R 5 (i.e., -R 5A -L 5 -R 5B (A combination of these) is: [ka] And here R 5B , R 5C Each of , and m is as defined in the embodiments, classes and subclasses herein.

[0105] In some embodiments, R 5 (i.e., -R 5A -L 5 -R 5B (A combination of these) is: [ka] And here R 5B and R 5C Each of these is defined in the embodiments, classes, and subclasses herein.

[0106] In some embodiments, R 5 (i.e., -R 5A -L 5 -R 5B (A combination of these) is: [ka] And here R 5B and R 5C Each of these is defined in the embodiments, classes, and subclasses herein.

[0107] In some embodiments, R 5 (i.e., -R 5A -L 5 -R 5B The group(s) that are combined are selected from the groups illustrated in the compounds in Table 1.

[0108] As generally defined above, Cy 6 This is phenylene, or a 6-membered heteroarylene having 1 to 3 nitrogen atoms, where Cy 6 is, -L 6 -R W In addition, the R of p examples 6 It is replaced by Cy 6 is, -L 6 -R W In addition, R for p examples 6 It is phenylene substituted with Cy. In some embodiments, Cy 6 This is a 6-membered heteroarylene having 1 to 3 nitrogen atoms, where Cy 6 is, -L 6 -R W In addition, the R of p examples 6 It is replaced by Cy 6 It has 1 to 2 nitrogen atoms, -L 6 -R W In addition, R for p examples 6 It is a 6-membered heteroarylene substituted with Cy. In some embodiments, Cy 6 It has one nitrogen atom, -L 6 -R W In addition, R for p examples 6 It is a 6-membered heteroarylene substituted with Cy. In some embodiments, Cy 6 It has two nitrogen atoms, -L 6 -R W In addition, R for p examples 6 It is a 6-membered heteroarylene substituted with Cy. In some embodiments, Cy 6 It has two nitrogen atoms, -L 6 -R WIt is a 6-membered heteroarylene substituted only with Cy. In some embodiments, 6 It has 1 to 2 nitrogen atoms, -L 6 -R W In addition, R for p examples 6 It is a 6-membered heteroarylene substituted with, where L 6 It is a covalent bond, and -R W -CN or [ka] In some embodiments, Cy 6 The group is selected from the groups illustrated in the compounds in Table 1.

[0109] As generally defined above, R 6 Each example is independent, R A or R B And here R 6 R is the R of q examples. C It is replaced by; or R 6 Two examples of R 6 One example and R L One example is that together with the atoms between these, they form a 4- to 7-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where this ring is R in r examples. C It is replaced by R 6 Each example is independent, R A or R B And here R 6 R is the R of q examples. C It has been replaced by [this].

[0110] In some embodiments, R 6 Two examples of R 6 One example and R LOne example is that together with the atoms between these, they form a 4- to 7-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where this ring is R in r examples. C It is replaced by R 6 The two examples, together with the atoms between them, form a 4- to 7-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where this ring is R of the r examples C It has been replaced with.

[0111] In some embodiments, R 6 One example and R L One example is that together with the atoms between these, they form a 4- to 7-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where this ring is R in r examples. C It is replaced by R 6 One example and R L One example is when these atoms combine to form a 4- to 7-membered partial unsaturated ring with one nitrogen atom; where this ring is a halogen, -CN, -O-(C 1~4 Alkyl), and -(C 1~4 It is optionally substituted with one, two, or three substituents independently selected from the alkyl group; where each C 1~4 The alkyl group is optionally substituted with one, two, or three fluoropolymers. In some embodiments, R 6 One example and R L One example is when these atoms combine to form a 4- to 7-membered partial unsaturated ring with one nitrogen atom.

[0112] In some embodiments, R 6 Each example is R A In some embodiments, R 6Each example is independently selected from halogen, -CN, -OR, -S(O)2NR2, -C(O)R, -C(O)OR, -C(O)NR2, -OC(O)R, and -N(R)C(O)R. In some embodiments, R 6 Each example is independently selected from halogen, -CN, -OR, and -C(O)NR2. In some embodiments, R 6 Each example is independent of halogen, -CN, -O-(C 1~4 alkyl), and -C(O)N(C 1~4 Selected from alkyl)2; where each C 1~4 The alkyl group is optionally substituted with one, two, or three halogens. In some embodiments, R 6 Each example is independent of halogen, -CN, -O-(C 1~4 alkyl), and -C(O)N(C 1~4 Selected from alkyl)2.

[0113] In some embodiments, R 6 Each example is R B And here R 6 R is the R of q examples. C It is replaced by R 6 Each example is R B And here R 6 This is one example of R C It is replaced by R 6 Each example is independent of C 1~6 Selected from aliphatic; phenyl; 5-6 membered monocyclic heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 3-7 membered saturated or partially unsaturated carbocyclic rings; 3-7 membered saturated or partially unsaturated monocyclic or heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of these is q examples of R C It is replaced as needed.

[0114] In some embodiments, R 6 Each example is independent of C1~6 Selected from aliphatic; 3- to 7-membered saturated or partially unsaturated carbocyclic rings; and 3- to 7-membered saturated or partially unsaturated monocyclic or heterocyclic rings having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of these is q examples of R C It is replaced as needed by R 6 Each example is independent of the R example. C C replaced as needed 1~4 Selected from aliphatic; 3- to 5-membered saturated carbocyclic rings; and 3- to 5-membered saturated monocyclic and heterocyclic rings having one heteroatom independently selected from nitrogen, oxygen, and sulfur; each of these is optionally substituted with one, two, or three halogens. In some embodiments, R 6 Each example is independent of -OH, -O-(C 1~4 Alkyl), or -N(C 1~4 C as needed, as an example of alkyl)2 1~4 The elements are selected from alkyl groups; 3- to 5-membered saturated carbocyclic rings; and 3- to 5-membered saturated monocyclic or heterocyclic rings having one oxygen atom, each of which is optionally substituted with one, two, or three fluoro or chloro groups.

[0115] In some embodiments, R 6 Each example is independent of halogen, -CN, -OR, -C(O)NR2, and each of the q examples of R C The following bases are replaced as needed by: C 1~6 Selected from aliphatic; 3- to 7-membered saturated or partially unsaturated carbocyclic rings; and 3- to 7-membered saturated or partially unsaturated monocyclic or heterocyclic rings having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 6 Each example independently includes the following groups, each substituted as needed with one, two, or three halogens: -O-(C 1~4 Alkyl), -C(O)N(C 1~4 Alkyl) 2, 1 example RC C replaced as needed 1~4 Selected from aliphatic; 3- to 5-membered saturated carbocyclic rings; and 3- to 5-membered saturated monocyclic or heterocyclic rings having one heteroatom independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 6 Each example is independent of halogen, -CN, -O-(C 1~4 Alkyl), -C(O)N(C 1~4 Alkyl)2, and the following groups, each optionally substituted with one, two, or three fluoro or chloro groups: -OH, -O-(C 1~4 Alkyl), or -N(C 1~4 C as needed, as an example of alkyl)2 1~4 Selected from alkyl groups; 3- to 5-membered saturated carbocyclic rings; and 3- to 5-membered saturated monocyclic or heterocyclic rings having one oxygen atom. In some embodiments, R 6 The group is selected from the groups illustrated in the compounds in Table 1.

[0116] As generally defined above, L 6 is a covalent bond, or C 1~4 A divalent, saturated or unsaturated, straight or branched hydrocarbon chain, where one or two methylene units in the chain are independently -CH(R L )-,-C(R L )2-, C 3~5 Cycloalkylenes, 3- to 5-membered heterocycloalkylenes, 5- to 6-membered heteroarylenes, -NH-, -N(R) L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-,-NHS(O)2-,-N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L It is replaced as needed with -, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)2-. In some embodiments, L 6 L is a covalent bond. In some embodiments, L6 C 1~4 A divalent, saturated or unsaturated, straight or branched hydrocarbon chain, where one or two methylene units in the chain are independently -CH(R L )-,-C(R L )2-, C 3~5 Cycloalkylenes, 3- to 5-membered heterocycloalkylenes, 5- to 6-membered heteroarylenes, -NH-, -N(R) L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-,-NHS(O)2-,-N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L It is replaced as needed by -, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)2-.

[0117] In some embodiments, L 6 C 1~2 A divalent, saturated or unsaturated, straight or branched hydrocarbon chain, where one or two methylene units in the chain are independently -CH(R L )-,-C(R L )2-, C 3~5 Cycloalkylenes, 3- to 5-membered heterocycloalkylenes, 5- to 6-membered heteroarylenes, -NH-, -N(R) L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-,-NHS(O)2-,-N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L It is replaced as needed with -, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)2-. In some embodiments, L 6 C 1~2 A divalent, saturated or unsaturated, straight or branched hydrocarbon chain, where each methylene unit in the chain is -NH- or -N(RL )- is replaced as needed.

[0118] In some embodiments, L 6 is -NH- or -N(R L )-. In some embodiments, L 6 is -NH-. In some embodiments, L 6 is -N(R L )-. In some embodiments, L 6 is -NH- or -N(CH3)-. In some embodiments, L 6 is -N(CH3)-. In some embodiments, L 6 The group is selected from the groups illustrated in the compounds in Table 1.

[0119] As generally defined above, R W Halogen, -CN, [ka] In some embodiments, R W Halogen, -CN, [ka] That is the case.

[0120] In some embodiments, R W is a halogen. In some embodiments, R W is -CN. In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] That is the case.

[0121] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] That is the case.

[0122] In some embodiments, R W -CN, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] That is the case.

[0123] In some embodiments, R W teeth, [ka] And R WA and R WB , R WB and R WC , R WA and R L One example of this is R WC and R L One example is that these atoms, together with the atoms in between, form a 4- to 7-membered saturated or partially unsaturated ring having 0 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0124] In some embodiments, R W teeth, [ka] And R WA and R WB , or R WB and R WCThese atoms, together with the atoms between them, form a 4- to 7-membered partial unsaturated ring having 0 to 1 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R W teeth, [ka] And R WA and R L One example is that together with the atoms between them, they form a 4- to 7-membered saturated or partially unsaturated ring having 0 to 1 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R W teeth, [ka] And R WC and R L One example is that together with the atoms between these, they form a 4- to 7-membered partial unsaturated ring having 0 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R W The group is selected from the groups illustrated in the compounds in Table 1.

[0125] I do not wish to be bound by any particular theory, but R W R is a warhead group and is considered particularly suitable for covalent bonding to the sulfhydryl side chain portion of protein kinases, such as Cys491 of FGFR2. Therefore, in some embodiments, W It is characterized by its ability to covalently bind to a cysteine ​​residue, thereby irreversibly inhibiting the protein kinase. In some embodiments, the protein kinase is FGFR. In certain embodiments, the protein kinase is FGFR2. In certain embodiments, the protein kinase is FGFR2, and the cysteine ​​residue is Cys491.

[0126] As generally defined above, RWA , R WB , and R WC Each of these is independently hydrogen, halogen, -CN, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, or a optionally substituted group, and this optionally substituted group is C 1~6 Selected from 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or R WA and R WB , R WB and R WC , R WA and R L One example of this is R WC and R L One example is that these atoms, together with the atoms in between, form a 4- to 7-membered saturated or partially unsaturated ring having 0 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0127] In some embodiments, R WA , R WB , and R WC Each of these is independently hydrogen, halogen, -CN, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, or a optionally substituted group, and this optionally substituted group is C 1~6 The selection includes 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R WA and R WB , R WB and R WC , R WA and R L One example of this is R WC and R LOne example is that these atoms, together with the atoms in between, form a 4- to 7-membered saturated or partially unsaturated ring having 0 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0128] In some embodiments, R WA , R WB , and R WC Each of these is independently hydrogen, halogen, -CN, -C(O)R, -C(O)OR, -C(O)NR2, or -C(O)N(R)OR. In some embodiments, R WA , R WB , and R WC Each of them is independent, C 1~6 The group is optionally substituted, selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur-independently saturated or partially unsaturated heterocyclic rings with 3 to 7 members having 1 to 2 heteroatoms, and 5 to 6 members having 1 to 4 heteroatoms, unilaterally selected from nitrogen, oxygen, and sulfur.

[0129] In some embodiments, R WA , R WB , and R WC Each of them is independently a hydrogen atom, or a C atom substituted as needed. 1~6 It is aliphatic. In some embodiments, R WA , R WB , and R WC Each of them is independently a hydrogen atom, or a C atom substituted as needed. 1~6 It is aliphatic. In some embodiments, R WA , R WB , and R WC Each of them independently consists of hydrogen and -C 1~4 Alkyl, -(C 1~4 Alkyl)-O-(C 1~4 Alkyl), or -(C 1~4 Alkyl)-N(C 1~4 Alkyl)2; where each C 1~4 The alkyl group is optionally substituted with one, two, or three fluoropolymers. In some embodiments, RWA , R WB , and R WC Each of these is independently substituted with hydrogen, or one, two, or three fluorocarbons as needed, -C 1~4 It is alkyl. In some embodiments, R WA , R WB , and R WC Each of them independently is either hydrogen or -C 1~4 It is alkyl. In some embodiments, R WA , R WB , and R WC Each of them is independently hydrogen or -CH3.

[0130] In some embodiments, R WA and R WB , or R WB and R WC These atoms, together with the atoms between them, form a 4- to 7-membered partial unsaturated ring having 0 to 1 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R WA and R WB , or R WB and R WC These atoms, together with the atoms between them, form a 4- to 7-membered partially unsaturated carbocyclic ring. In some embodiments, R WA and R L One example is that together with the atoms between them, they form a 4- to 7-membered saturated or partially unsaturated ring having 0 to 1 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R WC and R L One example is that together with the atoms between these, they form a 4- to 7-membered partial unsaturated ring having 0 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R WC and R L One example is that together with the atoms between these, they form a 5- to 6-membered partial unsaturated ring having 0 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R WA , RWB , and R WC Each of these is selected from the groups illustrated in the compounds in Table 1.

[0131] As generally defined above, R WD is a halogen or -OS(O)2R. In some embodiments, R WD is a halogen. In some embodiments, R WD In some embodiments, R is chloro or bromo. WD is chloro. In some embodiments, R WD is -OS(O)2R. In some embodiments, R WD is -OS(O)2-(C substituted as needed) 1~3 It is alkyl. In some embodiments, R WD is -OS(O)2CH3 or -OS(O)2CF3. In some embodiments, R WD is -OS(O)2- (phenyl substituted as needed). In some embodiments, R WD The group is selected from the groups illustrated in the compounds in Table 1.

[0132] In some embodiments, -Cy 6 -L 6 -R W Things that come together: [ka] And here L 6 , R 6 , R W Each of , and p is as defined in the embodiments and classes and subclasses herein. In some embodiments, -Cy 6 -L 6 -R W Things that come together: [ka] And here L 6, R 6 , and R W Each of these is defined in the embodiments, classes, and subclasses herein. In some embodiments, -Cy 6 -L 6 -R W Things that come together: [ka] And here L 6 , R 6 , and R W Each of these is defined in the embodiments, classes, and subclasses herein. In some embodiments, -Cy 6 -L 6 -R W Things that come together: [ka] And here L 6 and R W Each of these is defined in the embodiments, classes, and subclasses herein.

[0133] In some embodiments, -Cy 6 -L 6 -R W Things that come together: [ka] And here L 6 , R 6 , R W Each of , and p is as defined in the embodiments and classes and subclasses herein. In some embodiments, -Cy 6 -L 6 -R W Things that come together: [ka] And here L6 , R 6 , R W Each of , and p is as defined in the embodiments and classes and subclasses herein. In some embodiments, -Cy 6 -L 6 -R W Things that come together: [ka] And here L 6 , R 6 , R W Each of , and p is as defined in the embodiments and classes and subclasses herein. In some embodiments, -Cy 6 -L 6 -R W Things that come together: [ka] And here L 6 , R 6 , R W Each of , and p is as defined in the embodiments and classes and subclasses herein.

[0134] In some embodiments, -Cy 6 -L 6 -R W Things that come together: [ka] And here L 6 , R 6 , and R W Each of these is defined in the embodiments, classes, and subclasses herein. In some embodiments, -Cy 6 -L 6 -R W Things that come together: [ka] And here L 6 , R 6 , and R W Each of these is defined in the embodiments, classes, and subclasses herein. In some embodiments, -Cy 6 -L 6 -R W Things that come together: [ka] And here L 6 and R W Each of these is defined in the embodiments, classes, and subclasses herein.

[0135] In some embodiments, -Cy 6 -L 6 -R W Things that come together: [ka] And here L 6 , R 6 , R W Each of , and p is as defined in the embodiments and classes and subclasses herein. In some embodiments, -Cy 6 -L 6 -R W Things that come together: [ka] And here L 6 , R 6 , and R W Each of these is defined in the embodiments, classes, and subclasses herein. In some embodiments, -Cy 6 -L 6 -R W Things that come together: [ka] And here L 6 , R 6 , and R W Each of these is defined in the embodiments, classes, and subclasses herein. In some embodiments, -Cy 6 -L 6 -R W Things that come together: [ka] And here L 6 and R W Each of these is defined in the embodiments, classes, and subclasses herein.

[0136] In some embodiments, -Cy 6 -L 6 -R W Things that come together: [ka] And here L 6 , R 6 , R W Each of , and p is as defined in the embodiments and classes and subclasses herein. In some embodiments, -Cy 6 -L 6 -R W Things that come together: [ka] And here L 6 , R 6 , R W Each of , and p is as defined in the embodiments and classes and subclasses herein. In some embodiments, -Cy 6 -L 6 -R W Things that come together: [ka] And here L 6 , R 6 , R W Each of , and p is as defined in the embodiments and classes and subclasses herein. In some embodiments, -Cy 6 -L 6 -R W Things that come together: [ka] And here L 6 , R 6 , R W Each of , and p is as defined in the embodiments and classes and subclasses herein.

[0137] In some embodiments, -Cy 6 -L 6 -R W Things that come together: [ka] And here L 6 , R 6 , and R W Each of these is defined in the embodiments, classes, and subclasses herein. In some embodiments, -Cy 6 -L 6 -R W Things that come together: [ka] And here L 6 , R 6 , and R W Each of these is defined in the embodiments, classes, and subclasses herein. In some embodiments, -Cy 6 -L6 -R W Things that come together: [ka] And here L 6 and R W Each of these is defined in the embodiments, classes, and subclasses herein.

[0138] In some embodiments, -Cy 6 -L 6 -R W The group is selected from the groups illustrated in the compounds in Table 1.

[0139] As generally defined above, R 7 is H or R B And here R 7 R for t examples 7A It is replaced by R 7 is H. In some embodiments, R 7 is R B And here R 7 R for t examples 7A It is replaced by R 7 C 1~6 Aliphatic; phenyl; 5-6 member monocyclic heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 3-7 member saturated or partially unsaturated carbocyclic rings; or 3-7 member saturated or partially unsaturated monocyclic or heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of these is t examples of R 7A It is replaced by R 7 C 1~6 Aliphatic; 3- to 7-membered saturated or partially unsaturated carbocyclic rings; or 3- to 7-membered saturated or partially unsaturated monocyclic or heterocyclic rings having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of these is t examples of R 7AIt has been replaced with.

[0140] In some embodiments, R 7 C 1~6 Alkyl; a 3- to 7-membered saturated carbocyclic ring; or a 3- to 7-membered saturated monocyclic or heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen and oxygen; each of these having 0 to 1 example R 7A and are substituted with 0 to 3 halogens. In some embodiments, R 7 R has 0 to 1 example. 7A and C substituted with 0 to 3 halogens 1~6 It is alkyl. In some embodiments, R 7 is -C 1~4 Alkyl, -(C 1~4 alkyl)-OH, -(C 1~4 Alkyl)-O-(C 1~4 Alkyl), or -(C 1~4 Alkyl)-N(C 1~4 Alkyl)2; where each C 1~4 The alkyl group is optionally substituted with one, two, or three fluoropolymers. In some embodiments, R 7 is -C 1~4 It is alkyl and optionally substituted with one, two, or three fluoropolymers. In some embodiments, R 7 is -CH3. In some embodiments, R 7 R has 0 to 1 example. B and C substituted with 0 to 3 halogens 1~6 It is alkyl.

[0141] In some embodiments, R 7 R has 0 to 1 example. 7A and a 3- to 7-membered saturated carbocyclic ring substituted with 0 to 3 halogens. In some embodiments, R 7 R is a 3- to 7-membered saturated monocyclic or heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen and oxygen; this is an example of R with 0 to 1 heteroatoms. 7Aand are substituted with 0 to 3 halogens. In some embodiments, R 7 R is a 5- to 6-membered saturated monocyclic heterocyclic ring having one oxygen atom; this is an example of R with 0 to 1 atoms. 7A and are substituted with 0 to 3 halogens. In some embodiments, R 7 It is a 5- to 6-membered saturated monocyclic heterocyclic ring having one oxygen atom; it has 0 to 3 halogens, and -C 1~4 Alkyl, -OH, -O-(C 1~4 Alkyl), or N(C 1~4 Substituted with 0 to 1 group selected from alkyl)2; where each C 1~4 The alkyl group is optionally substituted with one, two, or three fluoropolymers. In some embodiments, R 7 R is a saturated monocyclic or heterocyclic ring with 5 to 6 members having one oxygen atom. In some embodiments, R 7 The group is selected from the groups illustrated in the compounds in Table 1.

[0142] As generally defined above, m is 0, 1, 2, 3, or 4. In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4. In some embodiments, m is 0 or 1. In some embodiments, m is 0, 1, or 2. In some embodiments, m is 0, 1, 2, or 3. In some embodiments, m is 1 or 2. In some embodiments, m is 1, 2, or 3. In some embodiments, m is 1, 2, 3, or 4. In some embodiments, m is 2 or 3. In some embodiments, m is 2, 3, or 4. In some embodiments, m is 3 or 4. In some embodiments, m is selected from the values ​​shown in the compounds in Table 1.

[0143] As generally defined above, n is 0, 1, 2, 3, or 4. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 0 or 1. In some embodiments, n is 0, 1, or 2. In some embodiments, n is 0, 1, 2, or 3. In some embodiments, n is 1 or 2. In some embodiments, n is 1, 2, or 3. In some embodiments, n is 1, 2, 3, or 4. In some embodiments, n is 2 or 3. In some embodiments, n is 2, 3, or 4. In some embodiments, n is 3 or 4. In some embodiments, n is selected from the values ​​shown in the compounds in Table 1.

[0144] As generally defined above, p is 0, 1, 2, 3, or 4. In some embodiments, p is 0. In some embodiments, p is 1. In some embodiments, p is 2. In some embodiments, p is 3. In some embodiments, p is 4. In some embodiments, p is 0 or 1. In some embodiments, p is 0, 1, or 2. In some embodiments, p is 0, 1, 2, or 3. In some embodiments, p is 1 or 2. In some embodiments, p is 1, 2, or 3. In some embodiments, p is 1, 2, 3, or 4. In some embodiments, p is 2 or 3. In some embodiments, p is 2, 3, or 4. In some embodiments, p is 3 or 4. In some embodiments, p is selected from the values ​​shown in the compounds in Table 1.

[0145] As generally defined above, q is 0, 1, 2, 3, or 4. In some embodiments, q is 0. In some embodiments, q is 1. In some embodiments, q is 2. In some embodiments, q is 3. In some embodiments, q is 4. In some embodiments, q is 0 or 1. In some embodiments, q is 0, 1, or 2. In some embodiments, q is 0, 1, 2, or 3. In some embodiments, q is 1 or 2. In some embodiments, q is 1, 2, or 3. In some embodiments, q is 1, 2, 3, or 4. In some embodiments, q is 2 or 3. In some embodiments, q is 2, 3, or 4. In some embodiments, q is 3 or 4. In some embodiments, q is selected from the values ​​shown in the compounds in Table 1.

[0146] As generally defined above, r is 0, 1, 2, 3, or 4. In some embodiments, r is 0. In some embodiments, r is 1. In some embodiments, r is 2. In some embodiments, r is 3. In some embodiments, r is 4. In some embodiments, r is 0 or 1. In some embodiments, r is 0, 1, or 2. In some embodiments, r is 0, 1, 2, or 3. In some embodiments, r is 1 or 2. In some embodiments, r is 1, 2, or 3. In some embodiments, r is 1, 2, 3, or 4. In some embodiments, r is 2 or 3. In some embodiments, r is 2, 3, or 4. In some embodiments, r is 3 or 4. In some embodiments, r is selected from the values ​​shown in the compounds in Table 1.

[0147] As generally defined above, t is 0, 1, 2, 3, or 4. In some embodiments, t is 0. In some embodiments, t is 1. In some embodiments, t is 2. In some embodiments, t is 3. In some embodiments, t is 4. In some embodiments, t is 0 or 1. In some embodiments, t is 0, 1, or 2. In some embodiments, t is 0, 1, 2, or 3. In some embodiments, t is 1 or 2. In some embodiments, t is 1, 2, or 3. In some embodiments, t is 1, 2, 3, or 4. In some embodiments, t is 2 or 3. In some embodiments, t is 2, 3, or 4. In some embodiments, t is 3 or 4. In some embodiments, t is selected from the values ​​shown in the compounds in Table 1.

[0148] As generally defined above, u is 0, 1, 2, 3, or 4. In some embodiments, u is 0. In some embodiments, u is 1. In some embodiments, u is 2. In some embodiments, u is 3. In some embodiments, u is 4. In some embodiments, u is 0 or 1. In some embodiments, u is 0, 1, or 2. In some embodiments, u is 0, 1, 2, or 3. In some embodiments, u is 1 or 2. In some embodiments, u is 1, 2, or 3. In some embodiments, u is 1, 2, 3, or 4. In some embodiments, u is 2 or 3. In some embodiments, u is 2, 3, or 4. In some embodiments, u is 3 or 4. In some embodiments, u is selected from the values ​​shown in the compounds in Table 1.

[0149] In some embodiments, the present invention comprises pyrrolopyrimidine, pyrrolotriadin, pyrazolopyrazine, pyrrolopyridine, phlopyrimidine, thienopyrimidine, or pyrrolopyridazinon, thereby comprising formulas Ia, Ib, Ic, Id, Ie, If, Ig, or Ih: [ka] We provide compounds of formula I-1 that form a compound of or a pharmaceutically acceptable salt thereof, wherein in formulas Ia, Ib, Ic, Id, Ie, If, Ig, and Ih, Cy 6 , L 6 , R W , R 5 , R 7 , R 8 , R 9 , and R 10 Each of these is defined in the embodiments, classes, and subclasses herein.

[0150] In some embodiments, the present invention is R 5A However, these are phenylene, pyridinylene, or cyclohexynylene, thereby forming formulas II-1, III-1, IV-1, or V-1: [ka] [ka] We provide a compound of formula I-1 that forms a compound of or a pharmaceutically acceptable salt thereof, and in formulas II-1, III-1, IV-1, and V-1, Cy A Cy 6 , L 5 , L 6 , R 5B , R 5C , R W Each of , and m is as defined in the embodiments, classes and subclasses herein.

[0151] In some embodiments, the present invention is Cy 6 However, these are phenylene, pyridinylene, or pyrimidinylene, and thus formulas VI-1, VII-1, VIII-1, or IX-1: [ka] The present invention provides a compound of formula I-1 that forms a compound of or a pharmaceutically acceptable salt thereof, and in formulas VI-1, VII-1, VIII-1, and IX-1, Cy A , L 6 , R 5 , R W , R 6 Each of , and p is as defined in the embodiments and classes and subclasses herein.

[0152] In some embodiments, the present invention is Cy 6 This is phenylene, and thus, equations X-1, XI-1, XII-1, or XIII-1 respectively: [ka] We provide compounds of formula II-1, III-1, IV-1, or V-1 that form a compound of or a pharmaceutically acceptable salt thereof, wherein in formulas X-1, XI-1, XII-1, and XIII-1, Cy A , L 5 , L 6 , R 5B , R 5C , R W , R 6 Each of , m, and p is as defined in the embodiments, classes, and subclasses herein.

[0153] For example, in some embodiments, the present invention relates to formulas X-1, XI-1, XII-1, or XIII-1: [ka] [ka] We provide compounds of or pharmaceutically acceptable salts thereof, in formulas X-1, XI-1, XII-1, and XIII-1: Cy A teeth, [ka] And here Cy A of [ka] teeth, [ka] It represents a connection to Cy A of [ka] teeth, [ka] Represents a connection to; R 5B is hydrogen or R B And here R 5B This is R for n examples. 5D It has been replaced with; R W Halogen, -CN, [ka] and; R 6 Each example is independent, R A or R B And here R 6 R is the R of q examples. C It is replaced by; or R 6 Two examples of R 6One example and R L One example is that together with the atoms between these, they form a 4- to 7-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where this ring is R in r examples. C It has been replaced with; R 7 is H or R B And here R 7 R for t examples 7A It has been replaced with; R 8 C is replaced as needed with H, -NR2, halogen, -OH, or 1 to 3 halogens. 1~6 It is aliphatic; R 9 C is replaced as needed with H, -NR2, halogen, or 1 to 3 halogens. 1~6 It is aliphatic; R 10 C is replaced as needed with H, or 1 to 3 halogens. 1~6 It is aliphatic; L 5 and L 6 Each of them is independent, covalently bonded, or C 1~4 A divalent, saturated or unsaturated, straight or branched hydrocarbon chain, where one or two methylene units in the chain are independently -CH(R L )-,-C(R L )2-, C 3~5 Cycloalkylenes, 3- to 5-membered heterocycloalkylenes, 5- to 6-membered heteroarylenes, -NH-, -N(R) L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-,-NHS(O)2-,-N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L It is replaced as needed by -, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)2-; R WA , R WB, and R WC Each of these is independently hydrogen, halogen, -CN, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, or a optionally substituted group, and this optionally substituted group is C 1~6 Selected from 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or R WA and R WB , R WB and R WC , R WA and R L One example of this is R WC and R L One example is that together with the atoms between them, they form a 4- to 7-membered saturated or partially unsaturated ring having 0 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R WD is a halogen or -OS(O)2R; R 5C , R 5D , R 7A , and R L Each example is independent, R A or R B And R for u examples C It has been replaced with; R A Each example is independently oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, or -N(R)S(O)2R; R B Each example is independent of C 1~6Aliphatic; phenyl; 5-6 member monocyclic heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 8-10 member bicyclic heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 3-7 member saturated or partially unsaturated carbocyclic rings; 3-7 member saturated or partially unsaturated monocyclic heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or 7-12 member saturated or partially unsaturated bicyclic heterocyclic rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R C Each example is independently an oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -S(O)2F, -OS(O)2F, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, -N(R)S(O)2R, or a group as optionally substituted, where this optionally substituted group is C 1~6 Selected from 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Each R is independently a hydrogen atom or a optionally substituted group, and this optionally substituted group is C 1~6 Selected from 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: Two R groups on the same nitrogen atom, together with the atom between them, form a 4- to 7-membered saturated, partially unsaturated, or heteroaryl ring having 0 to 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, in addition to this nitrogen; and Each of m, n, p, q, r, t, and u is independently 0, 1, 2, 3, or 4.

[0154] In some embodiments, the present invention relates to formulas X-1, XI-1, XII-1, or XIII-1: [ka] We provide compounds of or pharmaceutically acceptable salts thereof, in formulas X-1, XI-1, XII-1, and XIII-1: Cy A teeth, [ka] [ka] And here Cy A of [ka] teeth, [ka] It represents a connection to Cy A of [ka] teeth, [ka] Represents a connection to; R 5B is hydrogen or R BAnd here R 5B This is R for n examples. 5D It has been replaced with; R W Halogen, -CN, [ka] and; R 6 Each example is independent, R A or R B And here R 6 R is the R of q examples. C It is replaced by; or R 6 Two examples of R 6 One example and R L One example is that together with the atoms between these, they form a 4- to 7-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where this ring is R in r examples. C It has been replaced with; R 7 is H or R B And here R 7 R for t examples 7A It has been replaced with; R 8 C is replaced as needed with H, -NR2, halogen, -OH, or 1 to 3 halogens. 1~6 It is aliphatic; R 9 C is replaced as needed with H, -NR2, halogen, or 1 to 3 halogens. 1~6 It is aliphatic; R 10 C is replaced as needed with H, or 1 to 3 halogens. 1~6 It is aliphatic; L 5 and L 6 Each of them is independent, covalently bonded, or C 1~4 A divalent, saturated or unsaturated, straight or branched hydrocarbon chain, where one or two methylene units in the chain are independently -CH(R L)-,-C(R L )2-, C 3~5 Cycloalkylenes, 3- to 5-membered heterocycloalkylenes, 5- to 6-membered heteroarylenes, -NH-, -N(R) L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-,-NHS(O)2-,-N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L It is replaced as needed by -, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)2-; R WA , R WB , and R WC Each of these is independently hydrogen, deuterium, halogen, -CN, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, or a optionally substituted group, the optionally substituted group being C 1~6 Selected from 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or R WA and R WB , R WB and R WC , R WA and R L One example of this is R WC and R L One example is that together with the atoms between them, they form a 4- to 7-membered saturated or partially unsaturated ring having 0 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R WD is a halogen or -OS(O)2R; R 5C , R 5D , R 7A , and R L Each example is independent, R A or RB And R for u examples C It has been replaced with; R A Each example is independently oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, or -N(R)S(O)2R; R B Each example is independent of C 1~6 Aliphatic; phenyl; 5-6 member monocyclic heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 8-10 member bicyclic heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 3-7 member saturated or partially unsaturated carbocyclic rings; 3-7 member saturated or partially unsaturated monocyclic heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or 7-12 member saturated or partially unsaturated bicyclic heterocyclic rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R C Each example is independently an oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -S(O)2F, -OS(O)2F, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, -N(R)S(O)2R, or a group as optionally substituted, where this optionally substituted group is C 1~6Selected from 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Each R is independently a hydrogen atom or a optionally substituted group, and this optionally substituted group is C 1~6 Selected from 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: Two R groups on the same nitrogen atom, together with the atom between them, form a 4- to 7-membered saturated, partially unsaturated, or heteroaryl ring having 0 to 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, in addition to this nitrogen; and Each of m, n, p, q, r, t, and u is independently 0, 1, 2, 3, or 4.

[0155] In some embodiments, the present invention is Cy 6 This is pyridinylene, and thus formulas XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, or XXI-1: [ka] [ka] We provide compounds of formula II-1, III-1, IV-1, or V-1 that form a compound of or a pharmaceutically acceptable salt thereof, and in formulas XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, and XXI-1, Cy A , L 5 , L 6 , R 5B , R5C , R W , R 6 Each of , m, and p is as defined in the embodiments, classes, and subclasses herein.

[0156] In some embodiments, the present invention is Cy 6 This is pyrimidinylene, and thus formulas XXII-1, XXIII-1, XXIV-1, or XXV-1 respectively: [ka] We provide compounds of formula II-1, III-1, IV-1, or V-1 that form a compound of or a pharmaceutically acceptable salt thereof, wherein in formulas XXII-1, XXIII-1, XXIV-1, and XXV-1, Cy A , L 5 , L 6 , R 5B , R 5C , R W , R 6 Each of , m, and p is as defined in the embodiments, classes, and subclasses herein.

[0157] In some embodiments, the present invention is Cy A but, [ka] We provide compounds of formulas I-1, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1, and here [ka] R 5 It represents a connection to, and [ka] Cy 6 This represents a connection to something.

[0158] In some embodiments, the present invention is Cy A but, [ka] We provide compounds of formulas I-1, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1, and here [ka] R 5 It represents a connection to, and [ka] Cy 6 This represents a connection to something.

[0159] In some embodiments, the present invention is L 5 However, -O-, -C(O)-, -C(O)NH-, or -C(O)N(R L The present invention provides compounds of formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1. In some embodiments, the present invention provides compounds of formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, VIII-1, XV-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1. 5The present invention provides compounds of formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1, where -O-. In some embodiments, the present invention provides compounds of formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V 5 The present invention provides compounds of formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1, where -C(O)-. In some embodiments, the present invention provides compounds of formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, V-1, VII-1, VIII-1, VIII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1, wherein L 5 The present invention provides compounds of formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1, where -C(O)NH-. In some embodiments, the present invention provides compounds of formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, V-1, V-1, VII-1, VIII-1, VIII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1, wherein L 5 -C(O)N(R L )-, the formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, X A compound of III-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1 is provided.

[0160] In some embodiments, the present invention is L 6 However, -NH- or -N(R LThe present invention provides compounds of formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1. In some embodiments, the present invention provides compounds of formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, VIII-1, XV-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1. 6 is -NH-, formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, A compound of XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1 is provided.

[0161] In some embodiments, the present invention provides compounds of formulas I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1, where m is 0 or 1. In some embodiments, the present invention provides compounds of formulas I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1, where m is 0. In some embodiments, the present invention provides compounds of formulas I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1, where m is 1.

[0162] In some embodiments, the present invention provides compounds of formulas I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1, where p is 0 or 1. In some embodiments, the present invention provides compounds of formulas I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1, where p is 0. In some embodiments, the present invention provides compounds of formulas I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1, where p is 1.

[0163] In some embodiments, the present invention is R W but, [ka] The present invention provides compounds of formulas I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1. In some embodiments, the present invention provides compounds of formulas RW but, [ka] The present invention provides compounds of formulas I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1. In some embodiments, the present invention provides compounds of formulas R W but, [ka] , formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XI A compound of II-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1 is provided.

[0164] In some embodiments, the present invention is R 5A However, these are phenylene, pyridinylene, or cyclohexynylene, thereby forming formulas II, III, IV, or V: [ka] We provide a compound of formula I that forms a compound of or a pharmaceutically acceptable salt thereof, and in formulas II, III, IV, and V, Cy 6 , L 5 , L 6 , R 5B , R 5C , R W , R 7Each of , and m is as defined in the embodiments and classes and subclasses herein.

[0165] In some embodiments, the present invention is Cy 6 However, these are phenylene, pyridinylene, or pyrimidinylene, and thus formulas VI, VII, VIII, or IX: [ka] We provide a compound of formula I that forms a compound of or a pharmaceutically acceptable salt thereof, and in formulas VI, VII, VIII, and IX, L 6 , R 5 , R W , R 6 , R 7 Each of , and p is as defined in the embodiments and classes and subclasses herein.

[0166] In some embodiments, the present invention is Cy 6 This is phenylene, and thus equations X, XI, XII, or XIII respectively: [ka] We provide compounds of formula II, III, IV, or V that form a compound of or a pharmaceutically acceptable salt thereof, and in formulas X, XI, XII, and XIII, L 5 , L 6 , R 5B , R 5C , R W , R 6 , R 7 Each of , m, and p is as defined in the embodiments, classes, and subclasses herein.

[0167] In some embodiments, the present invention is Cy 6 This is pyridinylene, and thus formulas XIV, XV, XVI, XVII, XVIII, XIX, XX, or XXI are derived respectively: [ka] [ka] We provide compounds of formula II, III, IV, or V that form a compound of or a pharmaceutically acceptable salt thereof, wherein in formulas XIV, XV, XVI, XVII, XVIII, XIX, XX, and XXI, Cy A , L 5 , L 6 , R 5B , R 5C , R W , R 6 Each of , m, and p is as defined in the embodiments, classes, and subclasses herein.

[0168] In some embodiments, the present invention is Cy 6 This is pyrimidinylene, and as a result, formulas XXII, XXIII, XXIV, or XXV respectively: [ka] We provide compounds of formula II, III, IV, or V that form a compound of or a pharmaceutically acceptable salt thereof, wherein in formulas XXII, XXIII, XXIV, and XXV, Cy A , L 5 , L 6 , R 5B , R 5C , R W , R 6 Each of m and p is as defined in the embodiments, classes, and subclasses herein.

[0169] In some embodiments, the present invention is L 5 However, -O-, -C(O)-, -C(O)NH-, or -C(O)N(R LThe present invention provides compounds of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII, which are )-. In some embodiments, the present invention provides L 5 The present invention provides compounds of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII, wherein -O-. In some embodiments, the present invention provides L 5 The present invention provides compounds of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII, wherein -C(O)-. In some embodiments, the present invention provides L 5 The present invention provides compounds of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII, wherein -C(O)NH-. In some embodiments, the present invention provides L 5 -C(O)N(R L The present invention provides compounds of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII, which are )-.

[0170] In some embodiments, the present invention is L 6 However, -NH- or -N(R L The present invention provides compounds of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII, which are )-. In some embodiments, the present invention provides L 6 The present invention provides compounds of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII, wherein the integral is -NH-.

[0171] In some embodiments, the present invention provides compounds of formulas I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII, where m is 0 or 1. In some embodiments, the present invention provides compounds of formulas I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII, where m is 0. In some embodiments, the present invention provides compounds of formulas I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII, where m is 1.

[0172] In some embodiments, the present invention provides compounds of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII, where p is 0 or 1. In some embodiments, the present invention provides compounds of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII, where p is 0. In some embodiments, the present invention provides compounds of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII, where p is 1.

[0173] In some embodiments, the present invention is R W but, [ka] The present invention provides compounds of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII. In some embodiments, the present invention provides R W but, [ka] The present invention provides compounds of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII. In some embodiments, the present invention provides R W but, [ka] The present invention provides compounds of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII.

[0174] In some embodiments, the present invention is L 5 However, -O-, -C(O)-, -C(O)NH-, or -C(O)N(R L The present invention provides compounds of XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV, which are )-. In some embodiments, the present invention provides L 5 The present invention provides compounds of formulas XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV, wherein -O-. In some embodiments, the present invention provides L 5 The present invention provides compounds of formulas XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV, wherein the compound is -C(O)-. In some embodiments, the present invention provides L 5 The present invention provides compounds of formula XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV, wherein -C(O)NH-. In some embodiments, the present invention provides L 5 -C(O)N(R L The present invention provides compounds of type XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV.

[0175] In some embodiments, the present invention is L 6 However, -NH- or -N(R L The present invention provides compounds of formula XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV, which are )-. In some embodiments, the present invention provides L 6The present invention provides compounds of formula XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV, wherein -NH- is provided.

[0176] In some embodiments, the present invention provides compounds of formula XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV, where m is 0 or 1. In some embodiments, the present invention provides compounds of formula XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV, where m is 0. In some embodiments, the present invention provides compounds of formula XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV, where m is 1.

[0177] In some embodiments, the present invention provides compounds of formula XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV, where p is 0 or 1. In some embodiments, the present invention provides compounds of formula XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV, where p is 0. In some embodiments, the present invention provides compounds of formula XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV, where p is 1.

[0178] In some embodiments, the present invention is R W but, [ka] The present invention provides compounds of formulas XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV. In some embodiments, the present invention provides R W but, [ka] The present invention provides compounds of formulas XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV. In some embodiments, the present invention provides R W but, [ka] The present invention provides compounds of formulas XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV.

[0179] Examples of compounds of the present invention include those listed in the tables and examples herein, or their pharmaceutically acceptable salts, stereoisomers, or mixtures of stereoisomers. In some embodiments, the present invention encompasses compounds selected from those illustrated in Table 1 below, or their pharmaceutically acceptable salts, stereoisomers, or mixtures of stereoisomers. In some embodiments, the present invention provides the compounds listed in Table 1 below, or their pharmaceutically acceptable salts. In some embodiments, the present invention provides the compounds listed in Table 1 below. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] Table 1-8 Table 1-9 Table 1-10 Table 1-11 Table 1-12 Table 1-13 Table 1-14 Table 1-15 Table 1-16 Table 1-17 Table 1-18 Table 1-19 Table 1-20 Table 1-21 Table 1-22 Table 1-23 Table 1-24 Table 1-25 Table 1-26 Table 1-27 Table 1-28 Table 1-29 Table 1-30 Table 1-31 Table 1-32 Table 1-33 Table 1-34 Table 1-35 Table 1-36 Table 1-37 Table 1-38 Table 1-39 Table 1-40 Table 1-41 Table 1-42 Table 1-43 Table 1-44 Table 1-45 Table 1-46 Table 1-47 Table 1-48 Table 1-49 Table 1-50 Table 1-51 Table 1-52 Table 1-53 Table 1-54 Table 1-55 Table 1-56 Table 1-57 Table 1-58 Table 1-59 Table 1-60 Table 1-61 Table 1-62 Table 1-63 Table 1-64 Table 1-65 Table 1-66 Table 1-67 Table 1-68 Table 1-69 Table 1-70 Table 1-71 Table 1-72 Table 1-73 Table 1-74 Table 1-75 Table 1-76 Table 1-77 Table 1-78 Table 1-79 Table 1-80 Table 1-81 Table 1-82 Table 1-83 Table 1-84 Table 1-85 Table 1-86 Table 1-87 Table 1-88 Table 1-89

Table 1-90

Table 1-100

Table 1-110

Table 1-120

Table 1-150

Table 1-202

Table 1-204

Table 1-206

Table 1-210

Table 1-220

Table 1-234

Table 1-240

Table 1-285

Table 1-289

Table 1-290

Table 1-300

Table 1-301

Table 1-302

Table 1-319

[0180] In the chemical structures shown in Table 1 above, if the stereocenter is indicated by a dashed line or wedge bond and labeled (or unlabeled) "abs", the compound is essentially a single isomer at this stereocenter (rather than an equimolar mixture), and its absolute stereochemistry is shown in the chemical structure (see, for example, the structure of Example 146). If the stereocenter is indicated by a dashed line or wedge bond and labeled "or 1", the compound is a single isomer at this stereocenter, but its absolute stereochemistry at this stereocenter has not been determined (see, for example, the structures of Examples 397 and 398). If the stereocenter is indicated by a dashed line or wedge bond and labeled "and 1" or "& 1", the compound is a mixture of two isomers at this stereocenter, i.e., the shown structure and an isomer whose stereogenic center has the opposite configuration (see, for example, the structure of Example 581).

[0181] The specific compounds illustrated in Table 1 above exist as liquid atropisomers that do not interconvert via biaryl bonds at room temperature. If one of the atoms in the biaryl bond is labeled "or 1", this indicates that the compound exists as a liquid atropisomer at room temperature and is essentially a single atropisomer (rather than an equimolar mixture) (see, for example, the structures in Examples 516 and 517).

[0182] In some embodiments, the present invention relates to a Biochemical FGFR2 Caliper IC in which the compound is "A". 50 The present invention provides the compounds listed in Table 1 above, which are described as having "A" or "B" in the Biochemical FGFR2 Caliper IC. 50 The present invention provides the compounds of Table 1 described as having "A", "B", or "C" in Biochemical FGFR2 Caliper IC. In some embodiments, the present invention provides the compounds of Biochemical FGFR2 Caliper IC 50The above provides the compounds listed in Table 1, which are described as having the following properties.

[0183] In some embodiments, the present invention relates to the cell SNU-16 IC2, in which the compound "A" 50 The present invention provides the compounds listed in Table 1 above, which are described as having the following properties. In some embodiments, the present invention provides the compounds in the cells SNU-16 IC2 of "A" or "B". 50 The present invention provides the compounds listed in Table 1 above, which are described as having the following properties. In some embodiments, the present invention provides the compounds in the cells SNU-16 IC2 of "A", "B", or "C". 50 The above provides the compounds listed in Table 1, which are described as having the following properties. 4. General method for providing the compound

[0184] The compounds of the present invention can generally be prepared or isolated by synthetic and / or semi-synthetic methods known to those skilled in the art with respect to similar compounds, as well as by methods described in detail in the examples herein. 5. Use, prescription, and administration Pharmaceutically acceptable compositions

[0185] In another embodiment, the present invention provides compositions containing the compound of the present invention, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle. In some embodiments, the present invention provides pharmaceutical compositions containing the compound of the present invention and a pharmaceutically acceptable carrier. The amount of the compound in the composition of the present invention is an amount effective to measurably inhibit FGFR2 protein kinase or its variants in a biological sample or in a patient. In certain embodiments, the amount of the compound in the composition of the present invention is an amount effective to measurably inhibit FGFR2 protein kinase or its variants in a biological sample or in a patient. In certain embodiments, the composition of the present invention is formulated for administration to a patient requiring such a composition. In some embodiments, the composition of the present invention is formulated for oral administration to a patient.

[0186] The terms “subject” and “patient,” as used herein, mean an animal (i.e., a member of the animal kingdom), preferably a mammal, and most preferably a human. In some embodiments, the subject is a human, mouse, rat, cat, monkey, dog, horse, or pig. In some embodiments, the subject is a human. In some embodiments, the subject is a mouse, rat, cat, monkey, dog, horse, or pig.

[0187] The term "pharmaceutically acceptable carrier, adjuvant, or vehicle" refers to a non-toxic carrier, adjuvant, or vehicle that does not impair the pharmacological activity of the compound formulated with it. Examples of pharmaceutically acceptable carriers, adjuvants, or vehicles that can be used in the compositions of this invention include ion exchangers, alumina, aluminum stearate, serum proteins such as lecithin and human serum albumin, buffering substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, electrolytes such as water, salts, or protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulosic substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol, and lanolin.

[0188] "Pharmacologically acceptable derivative" means any non-toxic salt, ester, ester salt or other derivative of the compound of the present invention that can directly or indirectly provide the compound of the present invention or its inhibitory metabolite or residue when administered to a recipient.

[0189] As used herein, the term “its inhibitory metabolite or residue” means that the metabolite or residue is also an inhibitor of FGFR2 protein kinase or its variants.

[0190] The compositions of the present invention can be administered orally, parenterally, by inhalation spray, topically, rectally, intranasally, oralally, vaginally, or by implantable reservoir. The term "parenteral," as used herein, includes subcutaneous, intravenous, intramuscular, intra-articular, intrabursal, intrasternal, intramedullary, intrahepatic, intrafocal, and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally, or intravenously.

[0191] The sterile injectable forms of the compositions of this invention may be aqueous or oily suspensions. These suspensions may be formulated according to techniques known in the art using suitable dispersants or wetting agents and suspending agents. The sterile injectable preparations may also be sterile injectable solutions or suspensions in non-toxic, parenterally acceptable diluents or solvents, such as a solution in 1,3-butanediol. Acceptable vehicles and solvents that can be used include water, Ringer's solution, and isotonic sodium chloride solution. Furthermore, sterile fixing oils have conventionally been used as solvents or suspension media.

[0192] For this purpose, any non-irritating fixed oil containing synthetic monoglycerides or diglycerides can be used. Fatty acids, such as oleic acid and its glyceride derivatives, are useful in the preparation of injectable substances, particularly in their polyoxyethylated forms, as they are naturally pharmaceutically acceptable oils such as olive oil or castor oil. Solutions or suspensions of these oils may also contain long-chain alcohol diluents or dispersants, such as carboxymethylcellulose or similar dispersants, which are commonly used in the formulation of pharmaceutically acceptable dosage forms, including emulsions or suspensions. Other commonly used surfactants, such as Tween, Span, and other emulsifiers or bioavailability enhancers, which are commonly used in the manufacture of pharmaceutically acceptable solids, liquids, or other dosage forms, can also be used for formulation purposes.

[0193] The pharmaceutically acceptable compositions of this invention can be administered orally in any orally acceptable dosage form, including but not limited to capsules, tablets, aqueous suspensions, or liquids. For tablets for oral use, commonly used carriers include lactose and corn starch. Lubricants such as magnesium stearate are also typically added. For oral administration in capsule form, lactose and dried corn starch are useful diluents. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifiers and suspending agents. Certain sweeteners, flavoring agents, or colorants may also be added, if desired.

[0194] Alternatively, the pharmaceutically acceptable compositions of this invention may be administered in the form of suppositories for rectal or vaginal administration. These can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal or vaginal temperature and therefore dissolves in the rectum or vagina to release the drug. Examples of such materials include cocoa butter, beeswax, and polyethylene glycol.

[0195] The pharmaceutically acceptable compositions of this invention can also be administered topically, particularly when the target of treatment includes areas or organs that are easily accessible by topical application, such as diseases of the eyes, skin, or lower intestines. Suitable topical formulations can be readily prepared for each of these areas or organs.

[0196] Topical application to the lower intestinal tract may be performed with rectal suppositories (see above) or suitable enema formulations. Topical transdermal patches may also be used.

[0197] For topical application, the pharmaceutically acceptable compositions provided may be formulated into suitable ointments containing the active ingredient suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid paraffin, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying wax, and water. Alternatively, the pharmaceutically acceptable compositions provided may be formulated into suitable lotions or creams containing the active ingredient suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol, and water.

[0198] For ophthalmic use, the pharmaceutically acceptable compositions provided may be formulated as a finely powdered suspension in isotonic pH-adjusted sterile saline, or preferably as a liquid in isotonic pH-adjusted sterile saline with or without a preservative such as benzylalkonium chloride. Alternatively, the pharmaceutically acceptable compositions for ophthalmic use may be formulated as an ointment such as petrolatum.

[0199] The pharmaceutically acceptable compositions of this invention can also be administered by nasal aerosol or inhalation. Such compositions may be prepared according to techniques well known in the art of pharmaceutical formulations and prepared as liquids in saline using benzyl alcohol or other suitable preservatives, absorption enhancers to enhance bioavailability, carbon fluoride, and / or other conventional solubilizers or dispersants.

[0200] Preferably, the pharmaceutically acceptable compositions of this invention are formulated for oral administration. Such formulations may be administered with or without food. In some embodiments, the pharmaceutically acceptable compositions of this invention are administered without food. In other embodiments, the pharmaceutically acceptable compositions of this invention are administered with food.

[0201] The amount of the compounds of the present invention, which may be combined with carrier materials to produce a single dosage form, will vary depending on the patient being treated and the specific administration method. Preferably, the provided compositions should be formulated so that a dosage of inhibitor between 0.01 and 100 mg per kg of body weight per day can be administered to a patient receiving these compositions.

[0202] It should be understood that the specific dosage and treatment regimen for any particular patient will vary depending on various factors, including the activity of the specific compound used, age, weight, overall health, sex, diet, administration time, elimination rate, drug combination, and the judgment of the treating physician and the severity of the specific disease being treated. The amount of the compound of the present invention in a composition will also vary depending on the specific compound in the composition.

[0203] The precise dose to be used in the composition also depends on the route of administration and should be determined according to the practitioner's judgment and the condition of each subject. In specific embodiments of this disclosure, the appropriate oral dose of the compounds of this disclosure is generally about 1 mg / day to about 1000 mg / day. In some embodiments, this oral dose is about 1 mg / day to about 800 mg / day. In some embodiments, this oral dose is about 1 mg / day to about 500 mg / day. In some embodiments, this oral dose is about 1 mg / day to about 250 mg / day. In some embodiments, this oral dose is about 1 mg / day to about 100 mg / day. In some embodiments, this oral dose is about 5 mg / day to about 50 mg / day. In some embodiments, this oral dose is about 5 mg / day. In some embodiments, this oral dose is about 10 mg / day. In some embodiments, this oral dose is about 20 mg / day. In some embodiments, this oral dose is about 30 mg / day. In some embodiments, this oral dose is about 40 mg / day. In some embodiments, this oral dose is about 50 mg / day. In some embodiments, this oral dose is about 60 mg / day. In some embodiments, this oral dose is about 70 mg / day. In some embodiments, this oral dose is about 100 mg / day. It is recognized that any of the dosages listed herein may constitute a higher or lower dosage range, and may be combined with any other dosage to constitute a dosage range including upper and lower limits.

[0204] In some embodiments, a pharmaceutically acceptable composition contains the compound and / or a pharmaceutically acceptable salt thereof in concentrations ranging from about 0.01 to about 90 wt%, about 0.01 to about 80 wt%, about 0.01 to about 70 wt%, about 0.01 to about 60 wt%, about 0.01 to about 50 wt%, about 0.01 to about 40 wt%, about 0.01 to about 30 wt%, about 0.01 to about 20 wt%, about 0.01 to about 2.0 wt%, about 0.01 to about 1 wt%, about 0.05 to about 0.5 wt%, about 1 to about 30 wt%, or about 1 to about 20 wt%. The composition can be formulated as a liquid, suspension, ointment, or capsule, etc. This pharmaceutical composition may be prepared as an aqueous solution and may contain further components such as preservatives, buffering agents, isotonic agents, antioxidants, stabilizers, and viscosity modifiers.

[0205] Pharmaceutically acceptable carriers are well known to those skilled in the art and include, for example, adjuvants, diluents, excipients, fillers, lubricants, and vehicles. In some embodiments, the carrier is a diluent, adjuvant, excipient, or vehicle. In some embodiments, the carrier is a diluent, adjuvant, or excipient. In some embodiments, the carrier is a diluent or adjuvant. In some embodiments, the carrier is an excipient.

[0206] Examples of pharmaceutically acceptable carriers include, for example, water or saline solution, polymers such as polyethylene glycol, carbohydrates and their derivatives, oils, fatty acids, or alcohols. Non-limiting examples of oils as pharmaceutically acceptable carriers include oils of petroleum, animal, plant, or synthetic origin, such as peanut oil, soybean oil, mineral oil, and sesame oil. Pharmaceutical carriers may also include saline solution, acacia gum, gelatin, starch paste, talc, keratin, colloidal silica, and urea. Furthermore, auxiliaries, stabilizers, thickeners, lubricants, and colorants may be used. Other examples of suitable pharmaceutically acceptable carriers are, for example, Remington's: The Science and Practice of Pharmacy, 22nd Ed. (Allen, Loyd V., Jr ed., Pharmaceutical Press (2012)); Modern Pharmaceutics, 5 th Ed.(Alexander T.Florence,Juergen Siepmann,CRC Press(2009));Handbook of Pharmaceutical Excipients,7 th Ed. (Rowe, Raymond C.; Sheskey, Paul J.; Cook, Walter G.; Fenton, Marian E. eds., Pharmaceutical Press (2012)) (each of these is incorporated herein by reference in whole).

[0207] The pharmaceutically acceptable carriers used herein may be selected from a variety of organic or inorganic materials used as materials for pharmaceutical formulations and incorporated as analgesics, buffers, binders, disintegrants, diluents, emulsifiers, excipients, fillers, glidants, solubilizers, stabilizers, suspending agents, isotonic agents, vehicles, and thickeners. Pharmaceutical additives such as antioxidants, fragrances, colorants, flavor enhancers, preservatives, and sweeteners may also be added. Examples of acceptable pharmaceutically acceptable carriers include, among others, carboxymethylcellulose, crystalline cellulose, glycerin, gum arabic, lactose, magnesium stearate, methylcellulose, powders, saline, sodium alginate, sucrose, starch, talc, and water. In some embodiments, the term “pharmaceutically acceptable” means that its use in animals, and more specifically in humans, is approved by a federal or national governmental agency or is listed in the United States Pharmacopeia or other generally recognized pharmacopoeias.

[0208] Surfactants such as detergents are also suitable for use in formulations. Specific examples of surfactants include polyvinylpyrrolidone, polyvinyl alcohol, copolymers of vinyl acetate and vinylpyrrolidone, polyethylene glycol, benzyl alcohol, mannitol, glycerol, sorbitol, or polyoxyethylene esters of sorbitan; lecithin or sodium carboxymethylcellulose; or acrylic acid derivatives such as methacrylate; anionic surfactants, such as alkaline stearates, especially sodium stearate, potassium stearate, or ammonium stearate; calcium stearate or triethanolamine stearate; alkyl sulfates, especially sodium lauryl sulfate and sodium cetyl sulfate; sodium dodecylbenzenesulfonate or sodium dioctyl sulfosuccinate; or fatty acids, especially those derived from coconut oil; cationic surfactants, such as those of formula N + R'R''R'''R''''Y -The water-soluble quaternary ammonium salt (where R radical is the same or different substituted hydroxylated hydrocarbon radical as needed, and Y - (These are strong acid anions, such as halide anions, sulfate anions, and sulfonic acid anions); cetyltrimethylammonium bromide is one of the cationic surfactants that can be used, formula N + Amine salts of R'R''R''' (where R radical is the same or different substituted hydroxylated hydrocarbon radical as needed); octadecylamine hydrochloride is one of the cationic surfactants that can be used; nonionic surfactants, e.g., polyoxyethylenelated esters of sorbitan as needed, particularly polysorbate 80, or polyoxyethylenelated alkyl ethers; polyethylene glycol stearate, polyoxyethylenelated derivatives of castor oil, polyglycerol esters, polyoxyethylenelated fatty alcohols, polyoxyethylenelated fatty acids, or copolymers of ethylene oxide and propylene oxide; amphoteric surfactants, e.g., substituted lauryl compounds of betaine.

[0209] Suitable pharmaceutical carriers may also contain excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, wheat flour, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, polyethylene glycol 300, water, ethanol, and polysorbate 20. The composition may also contain, if desired, a wetting agent or emulsifier, or a pH buffering agent.

[0210] Tablet and capsule formulations may contain one or more adjuvants, binders, diluents, disintegrants, excipients, fillers, or lubricants, each of which is known in the art. Examples of such include carbohydrates, e.g., lactose or sucrose; anhydrous calcium hydrogen phosphate; corn starch; mannitol; xylitol; cellulose or its derivatives; microcrystalline cellulose; gelatin; stearate; silicon dioxide; talc; sodium starch glycolate; acacia; flavoring agents; preservatives; buffering agents; disintegrants; and colorants. Compositions administered orally may contain one or more as needed agents, e.g., sweeteners, e.g., fructose, aspartame, or saccharin; flavoring agents, e.g., peppermint, snowberry oil, or cherry; colorants; and preservatives, etc., to provide pharmaceutically good-tasting preparations. Use of compounds and pharmaceutically acceptable compositions

[0211] The compounds and compositions described herein are generally useful for inhibiting kinases or their variants. In some embodiments, the kinase inhibited by the compounds and compositions described herein is a fibroblast growth factor receptor (FGFR). In some embodiments, the kinase inhibited by the compounds and compositions described herein is one or more of FGFR1, FGFR2, FGFR3, and FGFR4. In some embodiments, the kinase inhibited by the compounds and compositions described herein is FGFR2.

[0212] The compounds or compositions of this disclosure may be useful in applications that benefit from the inhibition of FGFR2 enzymes. For example, the FGFR2 inhibitors of the present invention are generally useful for treating proliferative disorders.

[0213] Activation of FGFR2 gene fusions has been detected in numerous cancers, including intrahepatic cholangiocarcinoma, hepatocellular carcinoma, breast cancer, prostate cancer, squamous cell carcinoma of the lung, thyroid cancer, gastric cancer, and ovarian cancer (ISBabina and NCTurner, Nat. Rev. Cancer 2017, 17:318-332; YM Wu, et al. Cancer Discov. 3:636-647; and references cited herein).

[0214] FGFR2 amplification has been described in gastric cancer, breast cancer, triple-negative breast cancer, and colorectal cancer (ISBabina and NCTurner, Nat. Rev. Cancer 2017, 17:318-332; M. Katoh, Nat. Rev. Clin. Oncol. 2019, 16:105-122; and references cited herein).

[0215] Activation of FGFR2 variants has been detected in endometrial cancer, non-small cell lung cancer, squamous cell carcinoma of the lung, gastric cancer, breast cancer, and urothelial carcinoma. The most common mutations are those in the intracellular kinase domain (e.g., N549K and K659N / M) and those in the extracellular domain (S252W and P253R). Resistance mutations in FGFR2 resulting from treatment with pan-FGFR1-3 inhibitors can also be targeted with FGFR2 inhibitors. These include V564F, E565A, N549K / H / T, and L617V (ISBabina and NCTurner, Nat. Rev. Cancer 2017, 17:318-332; M. Katoh, Nat. Rev. Clin. Oncol. 2019, 16:105-122; R. Porta, et al. Crit. Rev. Oncol. Hematol. 2017, 113:256-267; and the references cited therein).

[0216] Inhibition of FGFR2 also exhibits antitumor activity in tumors with increased expression of FGFR2 ligands (FGF1-4, 7, 8, 10, 21-23) (N. Turner and R. Grose, Nat. Rev. Cancer 2010, 10:116-129; and references cited herein).

[0217] Inhibition of FGFR2 also exhibits antitumor activity in tumors with amplification or overexpression of the FGFR adapter protein FRS2 (ISBabina and NCTurner, Nat. Rev. Cancer 2017, 17:318-332; and references cited herein).

[0218] Selective inhibition of FGFR2 may be effective in indications where pan-FGFR1-3 inhibitors are generally effective. Such indications are described in ISBabina and NCTurner, Nat. Rev. Cancer 2017, 17:318-332; M. Katoh, Nat. Rev. Clin. Oncol. 2019, 16:105-122; R. Porta, et al. Crit. Rev. Oncol. Hematol. 2017, 113:256-267; and the references cited therein.

[0219] Activation of mutations in FGFR2 has also been detected in craniosynostotic syndromes, including Crouzon, Apert, Pfeiffer, Antley Bixler, Bea Stevenson cutis gyrate, Jackson-Weiss, curved dysplasia, and Seathre-Chotzen-like syndromes, which result in premature fusion of cranial sutures (SCAzoury, et al. Int. J. Biol. Sci. 2017, 13:1479-1488; and references cited therein). Inhibition of FGFR2 is also effective in such craniosynostotic syndromes.

[0220] In this specification, the activity of compounds used as degradation agents and / or inhibitors of FGFR kinases, e.g., FGFR2, or its variants, can be assayed in vitro, in vivo, or in cell lines. In vitro assays include those that determine the inhibition of either the phosphorylation activity and / or subsequent functional consequences, or ATPase activity, of activated FGFR2 or its variants. Alternative in vitro assays quantify the ability of inhibitors to bind to FGFR2. Inhibitor binding can be measured by radiolabeling the inhibitor before binding, isolating the inhibitor / FGFR2 complex, and determining the amount of radiolabeled material bound. Alternatively, inhibitor binding can be determined by performing competitive experiments in which a novel inhibitor is incubated with FGFR2 bound to a known radioligand. Representative in vitro and in vivo assays useful for assaying FGFR2 inhibitors are described and disclosed in the patents and scientific publications cited herein. Detailed conditions for assaying compounds used as inhibitors of FGFR2 or its variants in the present invention are described in the following examples. Disability treatment

[0221] The compounds provided are inhibitors of FGFR2 and are therefore useful for treating one or more disorders related to the activity of FGFR2 or its variants. Accordingly, in certain embodiments, the present invention provides a method for treating FGFR2-mediated disorders in a subject, the method comprising administering a therapeutically effective amount of the compounds of the present invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof, to a subject in need. In certain embodiments, the present invention provides a method for treating FGFR2-mediated disorders in a subject, the method comprising administering a therapeutically effective amount of the compounds of the present invention, or a pharmaceutically acceptable composition thereof, to a subject in need.

[0222] As used herein, the terms “FGFR2-mediated” disorder, disease, and / or condition mean any disease or other adverse condition in which FGFR2 or its variants are known to play a role. Accordingly, another embodiment of the present invention relates to treating or reducing the severity of one or more diseases in which FGFR2 or its variants are known to play a role. Such FGFR2-mediated disorders include, but are not limited to, proliferative disorders (e.g., cancer) and craniosynostosis syndrome.

[0223] In some embodiments, the present invention provides a method for treating one or more disorders, where these disorders are selected from proliferative disorders and craniosynostosis syndrome, and the method comprises the step of administering to a patient in need a therapeutically effective amount of the compound of the present invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

[0224] In some embodiments, the present invention provides a method for treating a disorder in a subject, comprising the step of administering a therapeutically effective amount of the compound of the present invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof, to a subject in need, wherein the disorder is cholangiocarcinoma, liver cancer, breast cancer, prostate cancer, lung cancer, thyroid cancer, gastric cancer, ovarian cancer, rectal cancer, endometrial cancer, or urothelial cancer. In some embodiments, the disorder is intrahepatic cholangiocarcinoma. In some embodiments, the disorder is hepatocellular carcinoma. In some embodiments, the disorder is squamous cell carcinoma of the lung or non-small cell lung cancer.

[0225] In some embodiments, this disorder is cholangiocarcinoma. In some embodiments, this cholangiocarcinoma is intrahepatic cholangiocarcinoma. In some embodiments, this disorder is liver cancer. In some embodiments, this liver cancer is hepatocellular carcinoma. In some embodiments, this disorder is lung cancer. In some embodiments, this lung cancer is squamous cell carcinoma or non-small cell lung cancer.

[0226] In some embodiments, the present invention provides a method for treating intrahepatic cholangiocarcinoma in a subject, the method comprising administering a therapeutically effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to a subject in need. In some embodiments, the present invention provides a method for treating hepatocellular carcinoma in a subject, the method comprising administering a therapeutically effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to a subject in need. In some embodiments, the present invention provides a method for treating squamous cell carcinoma of the lung or non-small cell lung cancer in a subject, the method comprising administering a therapeutically effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to a subject in need.

[0227] In some embodiments, this impairment is related to FGFR2 signaling. FGFR2 and other receptor tyrosine kinases (RTKs) are known to have multiple upstream and downstream signaling pathways (see Turner and Grose, Nat. Rev. Cancer (2010) 10, 116), and inhibition of FGFR2 can be used to address impairments associated with abnormal signaling within these pathways. In some embodiments, this impairment is related to FGF signaling, JAK-STAT signaling, PI3K-Akt signaling, PLC-γ signaling, or MAPK signaling.

[0228] In some embodiments, the treatment method comprises the steps of: i) identifying a subject requiring such treatment; (ii) providing a disclosed compound or a pharmaceutically acceptable salt thereof; and (iii) administering the provided compound in a therapeutically effective dose to treat, suppress and / or prevent a disease state or condition in a subject requiring such treatment.

[0229] In some embodiments, the treatment method comprises the steps of: i) identifying a subject requiring such treatment; (ii) providing a composition containing the disclosed compound or a pharmaceutically acceptable salt thereof; and (iii) administering the composition in a therapeutically effective dose to treat, suppress and / or prevent a disease state or condition in a subject requiring such treatment.

[0230] Another aspect of the present invention provides compounds according to the definitions herein, or pharmaceutically acceptable salts thereof, or any pharmaceutical composition thereof, for use in the treatment of disorders described herein. Another aspect of the present invention provides specifications of compounds according to the definitions herein, or pharmaceutically acceptable salts thereof, or any pharmaceutical composition thereof, for the treatment of disorders described herein. Similarly, the present invention provides the use of compounds according to the definitions herein, or pharmaceutically acceptable salts thereof, for the preparation of pharmaceuticals for the treatment of disorders described herein. Proliferative disorder

[0231] In some embodiments, this disorder is a proliferative disorder. In some embodiments, this proliferative disorder is cancer. In some embodiments, this proliferative disorder is leukemia, breast cancer, lung cancer, colorectal cancer, or a combination thereof. In some embodiments, this proliferative disorder is leukemia. In some embodiments, this proliferative disorder is breast cancer. In some embodiments, this proliferative disorder is lung cancer. In some embodiments, this proliferative disorder is colorectal cancer.

[0232] In some embodiments, this proliferative disorder is intrahepatic cholangiocarcinoma, hepatocellular carcinoma, breast cancer, prostate cancer, squamous cell carcinoma of the lung, thyroid cancer, gastric cancer, ovarian cancer, rectal cancer, endometrial cancer, non-small cell lung cancer, or urothelial carcinoma. In some embodiments, this proliferative disorder is intrahepatic cholangiocarcinoma, hepatocellular carcinoma, breast cancer, prostate cancer, squamous cell carcinoma of the lung, thyroid cancer, gastric cancer, or ovarian cancer. In some embodiments, this proliferative disorder is gastric cancer, breast cancer, triple-negative breast cancer, or rectal cancer. In some embodiments, this proliferative disorder is endometrial cancer, non-small cell lung cancer, squamous cell carcinoma of the lung, gastric cancer, breast cancer, or urothelial carcinoma.

[0233] In some embodiments, this proliferative disorder is associated with one or more activating mutations in FGFR2. In some embodiments, the activating mutation in FGFR2 is a mutation in one or more of the intracellular kinase domain and / or extracellular domain. In some embodiments, the activating mutation in FGFR2 is a mutation in the intracellular kinase domain. In some embodiments, the activating mutation in FGFR2 is a mutation in the extracellular domain. In some embodiments, the activating mutation in FGFR2 is selected from N549K, K659N / M, S252W, P253R, and combinations thereof. In some embodiments, the activating mutation in FGFR2 is N549K or K659N / M. In some embodiments, the activating mutation in FGFR2 is N549K. In some embodiments, the activating mutation in FGFR2 is K659N / M. In some embodiments, the activating mutation in FGFR2 is S252W or P253R. In some embodiments, the activating mutation in FGFR2 is S252W. In some embodiments, the activating mutation in FGFR2 is P253R.

[0234] In some embodiments, this proliferative disorder is associated with one or more resistance mutations in FGFR2. In some embodiments, the resistance mutations in FGFR2 are selected from V564F, E565A, N549K / H / T, and L617V, as well as combinations thereof. In some embodiments, the resistance mutation in FGFR2 is V564F. In some embodiments, the resistance mutation in FGFR2 is E565A. In some embodiments, the resistance mutation in FGFR2 is N549K / H / T. In some embodiments, the resistance mutation in FGFR2 is L617V. Route of administration and dosage form

[0235] The compounds and compositions can be administered in any amount and via any route of administration that is effective in treating or reducing the severity of a disorder (e.g., proliferative disorder or craniosynostosis syndrome) according to the methods of the present invention. The exact amount required will vary from subject to subject, depending on the subject's species, age and general condition, the severity of the infection, the specific drug, and the method of administration. The compounds of the present invention are preferably formulated into unit dosage forms to facilitate administration and ensure uniformity of dosage. When used herein, the term "unit dosage form" refers to a physically distinct unit of the drug appropriate for the patient being treated. However, it is understood that the total daily dose of the compounds and compositions of the present invention will be determined by the attending physician within the bounds of sound medical judgment. The effective dose level specific to any particular patient or organism depends on a variety of factors, including the disorder being treated and its severity; the activity of the specific compound used; the specific composition used; the patient's age, weight, overall health, sex, and diet; the timing of administration, route of administration, and elimination rate of the specific compound used; the duration of treatment; drugs used in combination with or concurrently with the specific compound used; and similar factors well known in the medical field.

[0236] The pharmaceutically acceptable compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisionally, intravaginally, intraperitoneally, topically (as powders, ointments, or drops), orally, as oral sprays or nasal sprays, etc. In certain embodiments, the compounds of the present invention can be administered orally or parenterally once or multiple times a day at a dosage level of about 0.01 mg to about 50 mg, preferably about 1 mg to about 25 mg, per kg of body weight of the subject per day, to obtain the desired therapeutic effect.

[0237] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compound, the liquid dosage form may contain, for example, water or other solvents, inert diluents, solubilizers, and emulsifiers commonly used in the art, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol, and fatty acid esters of sorbitan, as well as mixtures thereof. In addition to inert diluents, the oral composition may also contain adjuvants such as humectants, emulsifiers, and suspending agents, as well as sweeteners, flavoring agents, and fragrances.

[0238] Preparations for injection, such as aqueous or oily sterile suspensions for injection, may be formulated by known techniques using suitable dispersants or wetting agents and suspending agents. Sterile preparations for injection may be sterile solutions, suspensions, or emulsions for injection in non-toxic, parenterally acceptable diluents or solvents, such as solutions in 1,3-butanediol. Acceptable vehicles and solvents that can be used include water, Ringer's solution, USP, and isotonic sodium chloride solutions. Furthermore, sterile fixatives have conventionally been used as solvents or suspension media. For this purpose, any non-irritating fixative, including synthetic monoglycerides or diglycerides, can be used. Additionally, fatty acids such as oleic acid are used in the preparation of injectable substances.

[0239] Injectable formulations can be sterilized before use, for example, by filtration through a bacterial-retaining filter, or by incorporating a sterilizing agent in the form of a sterile solid composition that can be dissolved or dispersed in sterile water or other sterile media for injection.

[0240] To extend the effects of the compounds of the present invention, it is often desirable to slow down the absorption of the compounds from subcutaneous or intramuscular injection. This can be achieved by using liquid suspensions of crystalline or amorphous materials with poor water solubility. The absorption rate of the compound then depends on its dissolution rate, which may depend on the crystal size and crystalline form. Alternatively, delayed absorption of parenterally administered compound forms is achieved by dissolving or suspending the compound in an oil vehicle. Depot formulations for injection are prepared by forming a microcapsule matrix of the compound within a biodegradable polymer such as polylactide-polyglycolide. The compound release rate can be controlled depending on the ratio of the compound to the polymer and the properties of the specific polymer used. Other examples of biodegradable polymers include poly(orthoester) and poly(anhydrous). Depot injection formulations can also be prepared by capturing the compound within liposomes or microemulsions that conform to body tissues.

[0241] A composition for rectal or vaginal administration is preferably a suppository that can be prepared by mixing the compound of this invention with a suitable non-irritating excipient or carrier, such as cocoa butter, polyethylene glycol, or suppository wax, which is solid at ambient temperature but liquid at body temperature and therefore melts in the rectum or vaginal cavity to release the active compound.

[0242] Examples of solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier, such as sodium citrate or dicalcium phosphate, and / or a) fillers or bulking agents such as starch, lactose, sucrose, glucose, mannitol, and silicic acid; b) binders such as carboxymethylcellulose, alginate, gelatin, polyvinylpyrrolidinone, sucrose, and acacia; c) humectants such as glycerol; d) disintegrants such as agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain silicates, and sodium carbonate; e) dissolution retarders such as paraffin; f) absorption enhancers such as quaternary ammonium compounds; g) wetting agents such as cetyl alcohol and glycerol monostearate; h) absorbents such as kaolin and bentonite clay; and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may include a buffering agent.

[0243] Similar types of solid compositions may be used as fillers for flexible and rigid gelatin capsules using excipients such as lactose or lactose and high molecular weight polyethylene glycol. Solid dosage forms of tablets, sugar-coated tablets, capsules, pills, and granules can be prepared using coatings and shells, such as enteric coatings and other coatings well known in the art of pharmaceutical formulation. These may optionally contain opacifying agents and may optionally be compositions that release the active ingredient(s) to only or preferentially to a specific portion of the intestinal tract in a delayed manner. Examples of embedding compositions that can be used include polymer materials and waxes. Similar types of solid compositions may be used as fillers for flexible and rigid gelatin capsules using excipients such as lactose or lactose and high molecular weight polyethylene glycol.

[0244] The active compound may be in a microencapsulated form having one or more of the excipients described above. Solid dosage forms of tablets, sugar-coated tablets, capsules, pills, and granules can be prepared using coatings and shells, such as enteric coatings, controlled-release coatings, and other coatings well known in the art of pharmaceutical formulation. In such solid dosage forms, the active compound may be mixed with at least one inert diluent, such as sucrose, lactose, or starch. Such dosage forms may also contain additional substances other than the inert diluent, such as tableting lubricants and other tableting aids, such as magnesium stearate and microcrystalline cellulose, as is common practice. In the case of capsules, tablets, and pills, the dosage form may also contain buffers. These may optionally contain opacifying agents and may be compositions that release the active ingredient(s) to only or preferentially to a specific portion of the intestinal tract, either in a delayed manner or otherwise. Examples of embedding compositions that can be used include polymeric substances and waxes.

[0245] Topical or transdermal dosage forms of the compounds of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, or patches. The active ingredient is mixed, as needed, with a pharmaceutically acceptable carrier and any necessary preservatives or buffers under sterile conditions. Ophthalmic formulations, ear drops, and eye drops are also intended to be within the scope of this invention. Furthermore, the invention intends to utilize transdermal patches, which have the additional advantage of providing controlled delivery of the compound to the body. Such dosage forms can be prepared by dissolving or dispersing the compound in a suitable medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. This rate can be controlled by providing a rate-controlling membrane or by dispersing the compound in a polymer matrix or gel. Dosage and regimen

[0246] According to one embodiment, the present invention relates to a method for inhibiting protein kinase activity in a biological sample, the method comprising the step of contacting the biological sample with a compound of the present invention or a composition containing the compound.

[0247] In some embodiments, these methods involve administering a therapeutically effective dose of the compound of this disclosure. In some embodiments, this therapeutically effective dose is at least about 0.0001 mg / kg body weight, at least about 0.001 mg / kg body weight, at least about 0.01 mg / kg body weight, at least about 0.05 mg / kg body weight, at least about 0.1 mg / kg body weight, at least about 0.25 mg / kg body weight, at least about 0.3 mg / kg body weight, at least about 0.5 mg / kg body weight, at least about 0.75 mg / kg body weight, at least about 1 mg / kg body weight, at least about 2 mg / kg body weight, at least about 3 mg / kg body weight, at least about 4 mg / kg body weight, at least about 5 mg / kg body weight, at least about 6 mg / kg body weight, at least about 7 mg / kg body weight, at least about 8 mg / kg body weight, at least about 9 mg / kg body weight, at least about 10 mg / kg body weight, at least about 15 mg / kg body weight, and at least about 20 mg / kg of body weight, at least about 25mg / kg of body weight, at least about 30mg / kg of body weight, at least about 40mg / kg of body weight, at least about 50mg / kg of body weight, at least about 75mg / kg of body weight, at least about 100mg / kg of body weight, at least about 200mg / kg of body weight, at least about 250mg / kg of body weight, at least about 300mg / kg of body weight, at least about 350mg / kg of body weight, at least about 400mg / kg of body weight, at least about 450mg / kg of body weight, at least about 500mg / kg of body weight, at least about 550mg / kg of body weight, at least about 600mg / kg of body weight, at least about 650mg / kg of body weight, at least about 700mg / kg of body weight, at least about 750mg / kg of body weight, at least about 800mg / kg of body weight, at least about 900mg / kg of body weight, or at least about 1000mg / kg of body weight. It is recognized that any of the dosages listed herein may constitute a higher or lower dosage range, and that any other dosage may be combined with other dosages to constitute a dosage range including a higher upper limit and a lower lower limit.

[0248] In some embodiments, the therapeutically effective dose is in the range of approximately 0.1 mg to approximately 10 mg / kg body weight, approximately 0.1 mg to approximately 6 mg / kg body weight, approximately 0.1 mg to approximately 4 mg / kg body weight, or approximately 0.1 mg to approximately 2 mg / kg body weight.

[0249] In some embodiments, this therapeutically effective dosage is within the range of approximately 1-500 mg, approximately 2-150 mg, approximately 2-120 mg, approximately 2-80 mg, approximately 2-40 mg, approximately 5-150 mg, approximately 5-120 mg, approximately 5-80 mg, approximately 10-150 mg, approximately 10-120 mg, approximately 10-80 mg, approximately 10-40 mg, approximately 20-150 mg, approximately 20-120 mg, approximately 20-80 mg, approximately 20-40 mg, approximately 40-150 mg, approximately 40-120 mg, or approximately 40-80 mg.

[0250] In some embodiments, these methods involve a single dose or administration (e.g., as a single injection or deposition). Alternatively, in some embodiments, these methods involve administering once, twice, three, or four times daily to a subject in need for a period of about two days to about 28 days, or about seven days to about ten days, or about seven days to about fifteen days, or for a longer period. In some embodiments, these methods involve chronic administration. In other embodiments, these methods involve administration over a period of several weeks, months, years, or decades. In yet another embodiment, these methods involve administration over a period of several weeks. In yet another embodiment, these methods involve administration over a period of several months. In yet another embodiment, these methods involve administration over a period of several years. In yet another embodiment, these methods involve administration over a period of several decades.

[0251] The dosage administered may vary depending on known factors such as the pharmacokinetic properties of the active ingredient and the mode and route of administration; the timing of administration of the active ingredient; the recipient's age, sex, health, and weight; the nature and severity of symptoms; the type, frequency, and desired effect of concurrent treatments; and the rate of elimination. All of these can be easily determined and used by those skilled in the art to adjust or titrate the dosage and / or drug regimen. Protein kinase inhibition

[0252] According to one embodiment, the present invention relates to a method for inhibiting protein kinase activity in a biological sample, the method comprising the step of contacting the biological sample with a compound of the present invention or a composition containing the compound.

[0253] According to another embodiment, the present invention relates to a method for inhibiting the activity of FGFR2 or a variant thereof in a biological sample, comprising the step of contacting the biological sample with a compound of the present invention or a composition comprising the compound thereof. According to a particular embodiment, the present invention relates to a method for reversibly inhibiting the activity of FGFR2 or a variant thereof in a biological sample, comprising the step of contacting the biological sample with a compound of the present invention or a composition comprising the compound thereof. According to a particular embodiment, the present invention relates to a method for irreversibly inhibiting the activity of FGFR2 or a variant thereof in a biological sample, comprising the step of contacting the biological sample with a compound of the present invention or a composition comprising the compound thereof.

[0254] In some embodiments, the present invention relates to a method for irreversibly inhibiting FGFR2 or its variants, in which the compound of the present invention forms a covalent bond with FGFR2 or its variants. In some embodiments, the present invention relates to a method for irreversibly inhibiting FGFR2 or its variants, in which the compound of the present invention forms a covalent bond with the compound R WThis forms a covalent bond with the cysteine ​​of FGFR2 or its variants. In some embodiments, the present invention relates to a method for irreversibly inhibiting FGFR2 or its variants, wherein the compound of the present invention is the R of the compound. W It forms a covalent bond with FGFR2 or its variant Cys491.

[0255] In another embodiment, the present invention relates to FGFR2, or a variant thereof, which is irreversibly inhibited by the compound of the present invention. In some embodiments, the present invention relates to FGFR2, or a variant thereof, which is covalently bonded to the compound of the present invention. In some embodiments, the present invention relates to FGFR2, or a variant thereof, which is covalently bonded to the compound of the present invention, wherein this covalent bond is R of the compound W and between FGFR2 or its variant cysteine. In some embodiments, the present invention relates to FGFR2 or its variant covalently bonded to the compound of the present invention, wherein this covalent bond is R of the compound. W The relationship lies between FGFR2 or its variant Cys491.

[0256] In another embodiment, the present invention provides a method for selectively inhibiting FGFR2 more than one or more of FGFR1, FGFR3, and FGFR4. In some embodiments, the compounds of the present invention are more than 5 times more selective than FGFR1, FGFR3, and FGFR4. In some embodiments, the compounds of the present invention are more than 10 times more selective than FGFR1, FGFR3, and FGFR4. In some embodiments, the compounds of the present invention are more than 50 times more selective than FGFR1, FGFR3, and FGFR4. In some embodiments, the compounds of the present invention are more than 100 times more selective than FGFR1, FGFR3, and FGFR4. In some embodiments, the compounds of the present invention are more than 200 times more selective than FGFR1, FGFR3, and FGFR4.

[0257] The term “biological sample” as used herein includes, but is not limited to, cell cultures or extracts thereof; biopsy material obtained from mammals or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other bodily fluids or extracts thereof.

[0258] Inhibition of the activity of FGFR2 or its variants in biological samples is useful for a variety of purposes known to those skilled in the art. Examples of such purposes, but not limited to, include blood transfusion, organ transplantation, preservation of biological specimens, and biological assays.

[0259] Another embodiment of the present invention relates to a method for inhibiting protein kinase activity in a patient, comprising the step of administering to the patient a compound of the present invention or a composition containing the compound.

[0260] In another embodiment, the present invention relates to a method for inhibiting the activity of FGFR2 or its variants in a patient, the method comprising administering the patient a compound of the present invention or a composition containing the compound. In a particular embodiment, the present invention relates to a method for reversibly or irreversibly inhibiting the activity of one or more of the FGFR2 or its variants in a patient, the method comprising administering the patient a compound of the present invention or a composition containing the compound. In some embodiments, the present invention relates to a method for reversibly inhibiting the activity of one or more of the FGFR2 or its variants in a patient, the method comprising administering the patient a compound of the present invention or a composition containing the compound. In some embodiments, the present invention relates to a method for irreversibly inhibiting the activity of one or more of the FGFR2 or its variants in a patient, the method comprising administering the patient a compound of the present invention or a composition containing the compound.

[0261] In some embodiments, the present invention relates to a method for irreversibly inhibiting the activity of one or more of the FGFR2 or its variants in a patient, the method comprising the step of administering to the patient a compound of the present invention or a composition containing the compound, wherein the compound forms a covalent bond with FGFR2 or its variants. In some embodiments, the present invention relates to a method for irreversibly inhibiting the activity of one or more of the FGFR2 or its variants in a patient, the method comprising the step of administering to the patient a compound of the present invention or a composition containing the compound, wherein the compound forms a covalent bond with the compound. W This forms a covalent bond with the cysteine ​​of FGFR2 or its variants. In some embodiments, the present invention relates to a method for irreversibly inhibiting the activity of one or more of the FGFR2 or its variants in a patient, the method comprising the step of administering to the patient a compound of the present invention or a composition containing the compound, wherein the compound is the R of the compound W It forms a covalent bond with FGFR2 or its variant Cys491.

[0262] In another embodiment, the present invention provides a method for treating a disorder mediated by FGFR2 or its variants in a patient who requires treatment for such a disorder, the method comprising administering to the patient a compound according to the present invention or a pharmaceutically acceptable composition thereof. Such disorders are described in detail herein. In some embodiments, the present invention provides a method for treating a disorder mediated by FGFR2 or its variants in a patient who requires treatment for such a disorder, the method comprising administering to the patient a compound according to the present invention or a pharmaceutically acceptable composition thereof, the compound reversibly inhibits FGFR2 or its variants.

[0263] In some embodiments, the present invention provides a method for treating FGFR2 or variant-mediated disorders in patients who require treatment of such disorders, the method comprising administering to the patient a compound according to the present invention or a pharmaceutically acceptable composition thereof, which irreversibly inhibits FGFR2 or its variants. In some embodiments, the present invention provides a method for treating FGFR2 or variant-mediated disorders in patients who require treatment of such disorders, the method comprising administering to the patient a compound according to the present invention or a pharmaceutically acceptable composition thereof, where the compound forms a covalent bond with FGFR2 or its variants. In some embodiments, the present invention provides a method for treating FGFR2 or variant-mediated disorders in patients who require treatment of such disorders, the method comprising administering to the patient a compound according to the present invention or a pharmaceutically acceptable composition thereof, where the compound forms a covalent bond with FGFR2 or its variants. W This forms a covalent bond with the cysteine ​​of FGFR2 or its variants. In some embodiments, the present invention provides a method for treating a disorder mediated by FGFR2 or its variants in a patient who needs treatment for such disorder, the method comprising administering to the patient a compound according to the present invention or a pharmaceutically acceptable composition thereof, wherein the compound is the R of the compound W It forms a covalent bond with FGFR2 or its variant Cys491.

[0264] In another embodiment, the present invention provides a method for inhibiting the signaling activity of FGFR2 or its variants in a subject, the method comprising administering a therapeutically effective amount of the compound according to the present invention or a pharmaceutically acceptable composition thereof to a subject in need. In some embodiments, the present invention provides a method for inhibiting FGFR2 signaling activity in a subject, the method comprising administering a therapeutically effective amount of the compound according to the present invention or a pharmaceutically acceptable composition thereof to a subject in need.

[0265] In some embodiments, the present invention provides a method for treating a disorder mediated by FGFR2 or its variants in a patient who requires treatment for such disorder, the method comprising administering to the patient a compound according to the present invention or a pharmaceutically acceptable composition thereof, wherein the compound reversibly inhibits FGFR2 or its variants.

[0266] The compounds described herein may also inhibit FGFR2 function by incorporating them into agents that catalyze the disruption of FGFR2. For example, these compounds may be incorporated into proteolytic chimeric proteins (PROTACs). PROTACs are bifunctional molecules in which one portion is capable of engaging with an E3 ubiquitin ligase, and the other portion has the ability to bind to a target protein that is to be degraded by the cell's protein quality control mechanisms. The recruitment of the target protein to a specific E3 ligase results in tagging for its disruption (i.e., ubiquitination) and subsequent degradation by the proteasome. Any E3 ligase may be used. The portion of the PROTAC that engages with the E3 ligase is linked to the portion of the PROTAC that engages with the target protein via a linker consisting of a variable atomic chain. Thus, the recruitment of FGFR2 to the E3 ligase results in the disruption of the FGFR2 protein. Examples of this variable atomic chain include rings, heteroatoms, and / or repeating polymer units. This can be rigid or flexible. It can be bonded to the two parts mentioned above using techniques that are standard in the field of organic synthesis. Combination therapy

[0267] Depending on the specific disorder, condition, or disease to be treated, additional therapeutic agents that are normally administered to treat that condition may be administered in combination with the compounds and compositions of the present invention. When used herein, additional therapeutic agents that are normally administered to treat a particular disease or condition are known to be "appropriate for the disease or condition being treated."

[0268] Accordingly, in certain embodiments, the treatment method comprises the step of administering the compound or composition of the present invention in combination with one or more additional therapeutic agents. In certain other embodiments, the treatment method comprises the step of administering the compound or composition of the present invention as the sole therapeutic agent.

[0269] In some embodiments, one or more additional therapeutic agents are selected from antibodies, antibody-drug conjugates, kinase inhibitors, immunomodulators, and histone deacetylase inhibitors. In some embodiments, one or more additional therapeutic agents are selected from the following drugs or their pharmaceutically acceptable salts: BCR-ABL inhibitors: e.g., imatinib, inilotinib, nilotinib, dasatinib, bosutinib, ponatinib, bafetinib, danusertib, saracatinib, PF03814735; ALK inhibitors (see Dardaei et al, 2018, Nat Med.; 24(4):512-517): e.g., crizotinib, NVP-TAE684, ceritinib, alectinib, brigatinib, entrecinib, lorlatinib; BRAF inhibitors (see Prahallad et al, 2015, Cell See Rep. 12, 1978-1985): e.g., vemurafenib, dabrafenib; FGFR inhibitors: e.g., infigratinib, dovitinib, erdafitinib, BLU-554, AZD4547; FLT3 inhibitors: e.g., sunitinib, midostaurin, tanutinib, sorafenib, restaurtinib, quizartinib, and crenolanib; MEK inhibitors (Fedele et al, 2018, BioRxiv) See 307876; Torres-Ayuso et al, 2018, Cancer Discov. 8, 1210-1212; and Wong et al, 2016, Oncotarget. 2016 Oct 4; 7(40):65676-65695): e.g., trametinib, cobimetinib, binimetinib, selumetinib; ERK inhibitors: e.g., ulixertinib, MK-8353, LY-3214996; VEGF receptor inhibitors: e.g., bevacizumab, axitinib, aflibercept, brivanib, motesanib, pasireotide, sorafenib; tyrosine kinase ZE inhibitors: e.g., erlotinib, linifanib, sunitinib, pazopanib; Epidermal growth factor receptor (EGFR) inhibitors: gefitinib, osimertinib, cetuximab, panitumumab; HER2 receptor inhibitors: e.g., trastuzumab, neratinib, lapatinib; MET inhibitors: e.g., crizotinib, cabozantinib; CD20 antibodies: e.g., rituximab, toxinib Momab (tositumomab), ofatumumab; DNA synthesis inhibitors: e.g., capecitabine, gemcitabine, nelarabine, hydroxycarbamide; antitumor agents: e.g., oxaliplatin, cisplatin; HER dimerization inhibitors: e.g., pertuzumab; human granulocyte colony-stimulating factor (G-CSF) modulators: e.g., filgrastim; immunomodulators: e.g., afutuzumab, lenalidomide, thalidomide, pomalidomide; CD40 inhibitors: e.g., dacetuzumab; apoptosis-promoting receptor agonists (PARAs): e.g., dulanermin; heat shock protein (HSP) inhibitors: e.g., tanespimycin (17-allylamino-17-desmethoxygeldanamycin); hedgehog antagonists: e.g., bismodegib; proteasome inhibitors: e.g., bortezomib;PI3K inhibitors: e.g., pictilisib, dactolisib, buparlisib, taselisib, idelalisib, duvelisib, umbralisib; phospholipase A2 inhibitors: e.g., anagrelide; BCL-2 inhibitors: e.g., venetoclax; aromatase inhibitors: exemestane, letrozole, anastrozole, faslodex, tamoxifen; topoiso Melase I inhibitors: e.g., irinotecan, topotecan; topoisomerase II inhibitors: e.g., etoposide, teniposide; mTOR inhibitors: e.g., temsirolimus, ridafololimus, everolimus, sirolimus; osteoclast bone resorption inhibitors: e.g., zoledronic acid; CD33 antibody-drug conjugates: e.g., gemtuzumab ozogamicin; CD22 antibody-drug conjugates: e.g., inotuzumab ozogamicin; CD20 antibody-drug conjugates: e.g., ibritumomab tiuxetan; somatostatin analogs: e.g., octreotide; interleukins -11 (IL-11): e.g., oprelvekin; synthetic erythropoetin: e.g., darbepoetin alfa; nuclear factor κB (RANK) inhibitor receptor activator: e.g., denosumab; thrombopoietin-mimicking peptide: e.g., romiplostim; cell growth stimulant: e.g., palifermin; anti-insulin-like growth factor-1 receptor (IGF-1R) antibody: e.g., figtumumab; anti-CSl antibody: e.g., elotuzumab; CD52 antibody: e.g., alemtuzumab; CTLA-4 Inhibitors: e.g., tremelimumab, ipilimumab; PD1 inhibitors: e.g., nivolumab, pembrolizumab; immunoadhesins: e.g., pidilizumab AMP-224; PDL1 inhibitors: e.g., MSB0010718C; YW243.55.S70, MPDL3280A; MEDI-4736, MSB-0010718C, or MDX-1105; LAG-3 inhibitors: e.g., BMS-986016; GITR agonists: GITR fusion proteins and anti-GITR antibodies;Histone deacetylase inhibitors (HDIs): e.g., voninostat; anti-CTLA4 antibodies: e.g., tremelimumab, ipilimumab; alkylating agents: e.g., temozolomide, dactinomycin, melphalan, altoretamine, carmustine, bendamustine, busulfan, carboplatin, lomustine, cisplatin, chlorambucil, cyclophosphamide, dacarbazine, altoretamine, ifosfamide, procarbazine, mechloretamine, mustine and mechloretamine (mechloroethamine), streptozocin, thiotepa; biological reaction modifiers: e.g., Calmet-Guéran bacilli, denileukin difutitox; antitumor antibiotics: e.g., doxorubicin, bleomycin, da Unorubicin, daunorubicin liposome, mitoxantrone, epirubicin, idarubicin, mitomycin C; microtubule inhibitors: e.g., estramustine; cathepsin K inhibitors: e.g., odanacatib; epothyron analogs: e.g., ixabepilone; TpoR agonists: e.g., eltrombopag; antimitotic agents: e.g., docetaxel; corticosteroid inhibitors: e.g., aminoglutethimide; antiandrogens: For example, nilutamide; androgen receptor inhibitors: for example, enzalutamide, abiraterone acetate, orteronel, galeterone, and seviteronel, bicalutamide, flutamide; androgens: for example, fluoxymesterone; CDK1 inhibitors: for example, alvocidib, palbociclib, ribociclib, trilaciclib Abemaciclib; gonadotropin-releasing hormone (GnRH) receptor agonists: e.g., leuprolide or leuprolide acetate; taxane antitumor agents: e.g., cabazitaxel, larotaxel; 5-HTla receptor agonists: e.g., xaliproden; HPV vaccines: e.g., Cervarix® marketed by GlaxoSmithKline, Gardasil® marketed by Merck;Iron chelators: e.g., deferasirox; antimetabolites: e.g., claribine, 5-fluorouracil, 6-thioguanine, pemetrexed, cytarabine, cytarabine liposome, decitabine, hydroxyurea, fludarabine, phloxuridine, cladribine, methotrexate, pentostatin; bisphosphonates: e.g., pamidronate; demethylating agents: e.g., 5-azacitidine, decitabine; antitumor plant alkaloids: e.g., protein-bound paclitaxel; vinblastine, vincristine, vinorelbine, paclitaxel; retinoids: e.g., alitretinoin, tretinoin, isotretinoin, bexarotene; glucocorticosteroids: e.g., hydrocortisone, dexamethasone, prednisolone Zolone, prednisone, methylprednisolone; Cytokines: e.g., interleukin-2, interleukin-11 (oprevelkin), α-interferon alpha (IFN-α); Estrogen receptor downregulators: fulvestrant; Anti-estrogens: e.g., tamoxifen, toremifene; Selective estrogen receptor modifiers (SERMs): e.g., raloxifene; Luteinizing hormone-releasing hormone (LHRH) agonists: e.g., goserelin; Progesterone: e.g., megestrol; Cytotoxic agents: arsenic trioxide, asparaginase (L-asparaginase, also known as Erwinia L-asparaginase); Antiemetics: e.g., NK-1 receptor antagonists (e.g., casopitant); Cytoprotective agents: e.g., amiphostin, leucovorin;Furthermore, immune checkpoint inhibitors. The term "immune checkpoint" refers to a group of molecules on the cell surface of CD4 and CD8 T cells. Examples of immune checkpoint molecules include, but are not limited to, programmed cell death 1 (PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), B7H1, B7H4, OX-40, CD137, CD40, and LAG3. Immunotherapy agents that may act as useful immune checkpoint inhibitors in the methods of this disclosure include, but are not limited to, inhibitors of PD-L1, PD-L2, CTLA4, TIM3, LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, and / or TGFRβ.

[0270] In some embodiments, one or more additional therapeutic agents are selected from the following: anti-FGFR antibodies; cytotoxic agents; estrogen receptor targeting or other endocrine therapies, immune checkpoint inhibitors, CDK inhibitors, other receptor tyrosine kinase inhibitors, BRAF inhibitors, MEK inhibitors, PI3K inhibitors, SHP2 inhibitors, and SRC inhibitors (see M. Katoh, Nat. Rev. Clin. Oncol. 2019, 16:105-122; YK Chae, et al. Oncotarget 2017, 8:16052-16074; L. Formisano et al., Nat. Comm. 2019, 10:1373-1386; and references cited herein).

[0271] The structures of active compounds identified by code number, generic name, or trade name can be obtained from the current edition of the standard reference book "The Merck Index" or from databases (e.g., Patents International (e.g., IMS World Publications)).

[0272] The compounds of the present invention may also be used in combination with known therapeutic processes, such as the administration of hormones or radiation. In certain embodiments, the provided compounds are used as radiosensitizers, particularly for the treatment of tumors that are poorly sensitive to radiation therapy.

[0273] The compounds of the present invention can be administered alone or in combination with one or more other therapeutic compounds. Possible combination therapies may take the form of a specific combination, or the administration of the compounds of the present invention and one or more other therapeutic compounds alternately or independently, or a specific combination with one or more other therapeutic compounds. The compounds of the present invention can also be administered, or in addition thereto, particularly for the treatment of tumors, in combination with chemotherapy, radiotherapy, immunotherapy, phototherapy, surgical intervention, or a combination thereof. As described above, long-term treatment is possible, as well as adjunctive therapy, in the context of other treatment strategies. Other possible treatments include treatment to maintain the patient's condition after tumor regression, or further, for example, chemopreventive therapy in patients at risk.

[0274] These additional agents may be administered separately from the compound-containing composition of the present invention as part of a multi-dose regimen. Alternatively, these agents may be part of a single dosage form mixed together with the compound of the present invention in a single composition. When administered as part of a multi-dose regimen, the two active agents may be administered simultaneously, sequentially, or within a certain period of time from each other, typically within 5 hours from each other.

[0275] As used herein, the terms “combination,” “combined,” and related terms refer to the simultaneous or sequential administration of therapeutic agents according to the present invention. For example, the compounds of the present invention may be administered simultaneously or sequentially in another therapeutic agent in a separate unit dosage form, or together in a single unit dosage form. Accordingly, the present invention provides a single unit dosage form comprising the compounds of the present invention, an additional therapeutic agent, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

[0276] The amounts of both the compound of the present invention and the additional therapeutic agent (in a composition containing the additional therapeutic agent as described above), which can be combined with a carrier material to produce a single dosage form, vary depending on the host being treated and the specific administration method. Preferably, the composition of the present invention should be formulated so that the compound of the present invention can be administered in doses between 0.01 and 100 mg per kg of body weight per day.

[0277] In these compositions containing additional therapeutic agents, the additional therapeutic agent and the compound of this invention may act synergistically. Therefore, the amount of additional therapeutic agent in such compositions is less than the amount required in monotherapy using only that therapeutic agent. In such compositions, an additional therapeutic agent can be administered in doses between 0.01 and 1,000 μg per kg of body weight per day.

[0278] The amount of additional therapeutic agent present in the composition of this invention is less than or equal to the amount typically administered in a composition containing that therapeutic agent as the sole active agent. Preferably, the amount of additional therapeutic agent in the composition of this disclosure is in the range of about 50% to 100% of the amount typically present in a composition containing that agent as the sole therapeutic agent.

[0279] The compounds of the present invention, or their pharmaceutically acceptable compositions, can also be incorporated into compositions for coating implantable medical devices, such as prostheses, artificial valves, vascular grafts, stents, and catheters. For example, vascular stents are used to overcome restenosis (re-narrowing of the vascular wall after injury). However, patients using stents or other implantable devices are at risk of clot formation or platelet activation. These undesirable effects can be prevented or mitigated by pre-coating the device with a pharmaceutically acceptable composition containing a kinase inhibitor. An implantable device coated with the compounds of the present invention is another embodiment of the present invention.

[0280] Any of the compounds and / or compositions of this disclosure may be provided in a kit containing these compounds and / or compositions. Accordingly, in some embodiments, the compounds and / or compositions of this disclosure are provided in a kit.

[0281] This disclosure is further described by the following non-limiting embodiments. [Examples]

[0282] Examples are provided herein to facilitate a more complete understanding of the present disclosure. The following examples are useful in illustrating exemplary methods for producing and carrying out the subject matter of the present disclosure. However, the scope of the present disclosure should not be construed as being limited to the specific embodiments disclosed in these examples, and these examples are merely illustrative.

[0283] As shown in the following examples, in certain exemplary embodiments, the compounds are prepared according to the general procedure described below. While the general method illustrates the synthesis of certain compounds of the present invention, it will be understood that the general method described below, and other methods known to those skilled in the art, may be applied to other classes and subclasses and species of each of these compounds as described herein.

[0284] In the descriptions of the synthesis methods described below, unless otherwise stated, all reaction conditions (e.g., reaction solvent, pressure, temperature, duration, and workup procedures) should be understood to be selected from standard conditions for the reaction, unless otherwise indicated. It will be understood by those skilled in organic synthesis that, in the general scheme, functional groups present in various parts of the molecule should be compatible with the proposed reactants and reactions. Substituents that are incompatible with the reaction conditions will be obvious to those skilled in the art, and therefore alternative methods (e.g., the use of protecting groups or alternative reactions) will be shown. The starting materials for these examples are either commercially available or readily prepared from known materials by standard methods.

[0285] It is assumed that at least some of the compounds identified as “intermediates” in this specification are compounds of the present disclosure.

[0286] In some embodiments, the compound of formula I is prepared according to the general procedure illustrated in Scheme 1 below. Scheme 1 [ka]

[0287] In some embodiments, step 1 involves Int-1 and formula XR 7 This involves condensation with the compound, thereby R 7 The compounds of formula Int-2 are formed, where X is a leaving group, as defined in the embodiments herein.

[0288] In some embodiments, step 2 involves the iodination of the compound of formula Int-2. In some embodiments, the reagent used is N-iodosuccinimide.

[0289] In some embodiments, step 3 involves a compound of formula Int-3 and Cy functionalized with a suitable reactive group. 6 -L 6 -R W This involves coupling with synthon, thereby forming a compound of formula Int-4. In some embodiments, a suitable reactive group is a boronic acid ester. In some embodiments, a suitable reactive group is a pinacol boronic acid ester.

[0290] In some embodiments, step 4 involves a compound of formula Int-4 and R functionalized with a suitable reactive group. 5 This involves coupling with synthon, which includes the group, thereby forming the compound of formula I. In some embodiments, suitable reactive groups are boronic acids or boronic acid esters. Example 1 N-(4-(4-amino-5-(3-methoxy-4-(pyrimidine-2-yloxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl)phenyl)methacrylamide [ka] 5-Bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine [ka]

[0291] Step 1: In a round-bottom flask, 5-bromo-7H-pyrrolo[2,3-d]pyrimidine-4-amine (3 g, 14.0 mmol), Cs2CO3 (9.10 g, 28.0 mmol), DMF (50 mL), and a stirring bar were placed. This mixture was cooled to 0°C, and iodomethane (1.98 g, 14.0 mmol) was added. The solution was stirred at 0°C for 3 hours. The reaction mixture was diluted with H2O (300 mL), and the aqueous phase was extracted three times with EA (300 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting crude material was purified by silica gel chromatography (eluting at MeOH / DCM = 1 / 80). Concentration under reduced pressure yielded 5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine (2.20 g, 70%) as a yellow crystalline solid. 5-Bromo-6-iodo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine [ka]

[0292] Step 2: In a round-bottom flask, 5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine (3 g, 13.2 mmol), TFA (7.52 g, 66.0 mmol), DCM (50 mL), and a stirring bar were placed. This mixture was cooled to 0°C, and 1-iodopyrrolidine-2,5-dione (2.96 g, 13.2 mmol) was added, and the solution was stirred at room temperature for 2 hours. The reaction mixture was diluted with saturated Na2SO3 solution (100 mL). The pH of this solution was adjusted to 7-8 with saturated NaHCO3 solution. The solid was filtered, washed with H2O, and then washed with a small amount of DCM to obtain 5-bromo-6-iodo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine (3.70 g, 80%) as a white amorphous solid. N-(4-(4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl)phenyl)methacrylamide [ka]

[0293] Step 3: In a resealable reaction vial, 5-bromo-6-iodo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine (3.7 g, 10.51 mmol), N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methacrylamide (3.7 g, 12.61 mmol), Pd(PPh3)4 (1.21 g, 1.05 mmol), K3PO4 (6.68 g, 31.53 mmol), DMF (50 mL), H2O (3 mL), and a stirring rod were added. The vial was then evacuated and purged with nitrogen three times. The mixture was stirred at 50°C for 1 hour. The reaction mixture was concentrated under reduced pressure. The resulting crude product was purified by silica gel chromatography (elution at MeOH / DCM = 1 / 100 to 1 / 20). Concentration under reduced pressure yielded N-(4-(4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl)phenyl)methacrylamide (2.2 g, 54%) as an off-white amorphous solid. N-(4-(4-amino-5-(3-methoxy-4-(pyrimidine-2-yloxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl)phenyl)methacrylamide [ka]

[0294] Step 4: In a resealable reaction vial, N-(4-(4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl)phenyl)methacrylamide (120 mg, 0.31 mmol), 2-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyrimidine (122 mg, 0.373 mmol), Pd(DtBPF)Cl2 (20.1 mg, 0.031 mmol), CsF (240 mg, 0.930 mmol), DMF (4 mL), H2O (0.5 mL), and a stirring rod were added. The vial was then evacuated and purged with nitrogen three times. The mixture was stirred at 90°C for 2 hours. The reaction mixture was concentrated under reduced pressure. The obtained crude material was purified by TLC (eluting at MeOH / DCM = 1 / 15). Concentration under reduced pressure yielded N-(4-(4-amino-5-(3-methoxy-4-(pyrimidine-2-yloxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl)phenyl)methacrylamide (13.9 mg, 9%) as a white amorphous solid. Example 2 Alternative route for N-(4-(4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl)phenyl)methacrylamide [ka] 6-(4-aminophenyl)-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine [ka]

[0295] Step 1: In a round-bottom flask, tert-butyl-4-(4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl)phenylcarbamate (20 g, 47.8 mmol), DCM (240 mL), and a stirring bar were placed. TFA (60 mL) was added. This solution was stirred at room temperature for 4 hours. The reaction mixture was made basic with saturated Na2CO3 aqueous solution (40 mL), and the solid was filtered and concentrated under reduced pressure. This yielded 6-(4-aminophenyl)-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine (14 g, 92.1%) as an off-white amorphous solid. N-(4-(4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl)phenyl)methacrylamide [ka]

[0296] Step 2: In a resealable reaction vial, 6-(4-aminophenyl)-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine (10.0 g, 31.4 mmol), DMF / pyridine (4:1, 200 mL), and a stirring rod were placed, and the vial was evacuated and purged with nitrogen three times. The solution was then cooled to 0°C. Next, methacryloyl chloride (4.0 g, 37.7 mmol) was dissolved in DMF (10 mL) and added to the above solution, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with H2O (200 mL), and the aqueous phase was extracted three times with ethyl acetate (200 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting crude material was recrystallized in MeCN. Concentration under reduced pressure yielded N-(4-(4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl)phenyl)methacrylamide (8.8 g, 73%) as an off-white amorphous solid. Example 3 4-(4-amino-6-(4-methacrylamidephenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl)-N-(oxetane-2-ylmethyl)benzamide [ka] 4-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl)methyl benzoate [ka]

[0297] Step 1: In a resealable reaction vial, 5-iodo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine (20 g, 72.9 mmol), [4-(methoxycarbonyl)phenyl]boronic acid (15.7 g, 87.4 mmol), Pd(DtBPF)Cl2 (4.74 g, 7.29 mmol), CsF (33.1 g, 218 mmol), DMF (200 mL), H2O (25 mL), and a stirring rod were placed. The vial was then evacuated and purged with nitrogen three times. The mixture was stirred at 90°C for 1 hour. The reaction mixture was diluted with H2O (500 mL), and the aqueous phase was extracted three times with DCM (200 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. 10 mL of MeCN was added to this reaction mixture, and the mixture was filtered through a Celite® pad, which was then washed with MeCN. The filtrate was concentrated under reduced pressure, and the resulting solid was methyl 4-{4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl}benzoate (11.0 g, 38.9 mmol), obtained as a yellow amorphous solid. 4-(4-amino-6-iodo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl)methyl benzoate [ka]

[0298] Step 2: In a round-bottom flask, methyl 4-{4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl}benzoate (10.9 g, 38.6 mmol), DCM (200 mL), TFA (13.1 g, 115 mmol), and a stirring bar were placed. This mixture was cooled to 0°C, NIS (9.53 g, 42.4 mmol) was added, and the solution was stirred at room temperature for 1 hour. The reaction mixture was diluted with Na2SO3 solution, and the aqueous phase was extracted three times with DCM (300 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. DCM (20 mL) was added, and the reaction mixture was filtered through a Celite® pad, which was then washed with a small amount of DCM. The filtrate was concentrated under reduced pressure, and the resulting solid was methyl 4-{4-amino-6-iodo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl}benzoate (12.0 g, 29.3 mmol), obtained as an off-white amorphous solid. 4-(4-amino-6-(4-methacrylamidophenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl)methyl benzoate [ka]

[0299] Step 3: A resealable reaction vial was filled with methyl 4-{4-amino-6-iodo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl}benzoate (11.9 g, 29.1 mmol), 2-methyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propa-2-enamide (10.0 g, 34.9 mmol), Pd(dppf)Cl2 (2.12 g, 2.91 mmol), K3PO4 (18.5 g, 87.3 mmol), DMF (100 mL), H2O (12.5 mL), and a stirring rod. The vial was then evacuated and purged with nitrogen three times. The mixture was stirred at 90°C for 1 hour. The reaction mixture was diluted with H2O (500 mL), and the aqueous phase was extracted three times with DCM (300 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting crude material was purified by silica gel chromatography (eluting at MeOH / DCM = 1 / 40). Concentration under reduced pressure yielded 4-{4-amino-7-methyl-6-[4-(2-methylpropa-2-enamide)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-5-yl}methyl benzoate (7.70 g, 17.4 mmol) as a yellow amorphous solid. 4-(4-amino-6-(4-methacrylamidophenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl)benzoic acid [ka]

[0300] Step 4: In a round-bottom flask, 7.65 g, 17.3 mmol, 4-{4-amino-7-methyl-6-[4-(2-methylpropa-2-enamide)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-5-yl}methyl benzoate, 40 mL of MeOH, 40 mL of NaOH (2N), and a stirring rod were placed. This solution was stirred overnight at room temperature. The pH of the resulting mixture was adjusted to 6-7 with 2 M HCl. The reaction mixture was filtered through a Celite® pad, and the pad was washed with H2O. The filtrate was concentrated under reduced pressure, and the resulting solid was 4-{4-amino-7-methyl-6-[4-(2-methylpropa-2-enamide)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-5-yl}benzoic acid (6.50 g, 15.2 mmol), obtained as an off-white amorphous solid. 4-(4-amino-6-(4-methacrylamidephenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl)-N-(oxetane-2-ylmethyl)benzamide [ka]

[0301] Step 5: In a round-bottom flask, 4-{4-amino-7-methyl-6-[4-(2-methylpropa-2-enamide)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-5-yl}benzoic acid (60 mg, 0.14 mmol), 1-(oxetan-2-yl)methaneamine (13.4 mg, 0.15 mmol), HATU (58.7 mg, 0.15 mmol), DIEA (54.2 mg, 0.42 mmol), and a stirring bar were placed. Dimethylformamide (3 mL) was added, and the solution was stirred at 25°C for 2 hours. The resulting crude material was purified by HPLC (column: XBridge Prep phenyl OBD column, 19 × 150 mm, 5 μm, 13 nm). By freeze-drying, 4-{4-amino-7-methyl-6-[4-(2-methylpropa-2-enamide)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-5-yl}-N-[(oxetan-2-yl)methyl]benzamide (20.0 mg, 0.040 mmol) was obtained as an off-white amorphous solid.

[0302] Further compounds prepared according to the methods of Examples 1-3 are shown in Table 2 below. [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] [Table 2-7] [Table 2-8] [Table 2-9] [Table 2-10] [Table 2-11] [Table 2-12] [Table 2-13] [Table 2-14] [Table 2-15] [Table 2-16] Table 2-17 Table 2-18 Table 2-19 Table 2-20 Table 2-21 Table 2-22 Table 2-23 Table 2-24 Table 2-25 Table 2-26 Table 2-27 Table 2-28 Table 2-29 Table 2-30 Table 2-31 Table 2-32 Table 2-33 Table 2-34 Table 2-35 Table 2-36 Table 2-37 Table 2-38 Table 2-39 Table 2-40 Table 2-41 Table 2-42 Table 2-43 Table 2-44 Table 2-45 Table 2-46 Table 2-47 Table 2-48 Table 2-49 Table 2-50 Table 2-51 Table 2-52 Table 2-53 Table 2-54 Table 2-55 Table 2-56 Table 2-57 Table 2-58 Table 2-59 Table 2-60 Table 2-61 Table 2-62 Table 2-63 Table 2-64 Table 2-65 Table 2-66 Table 2-67 Table 2-68 Table 2-69 Table 2-70 Table 2-71 Table 2-72 Table 2-73 Table 2-74 Table 2-75 Table 2-76 Table 2-77 Table 2-78 Table 2-79 Table 2-80 Table 2-81 Table 2-82 Table 2-83 Table 2-84 Table 2-85 Table 2-86 Table 2-87 Table 2-88 Table 2-89 Table 2-90 Table 2-91 Table 2-92 Table 2-93 Table 2-94 Table 2-95 Table 2-96 Table 2-97 Table 2-98 Table 2-99 Table 2-100 Table 2-101 Table 2-102

Table 2-103

Table 2-130

[0303] Step 1: In a round-bottom flask, N-(4-{4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl}phenyl)propa-2-enamide (200 mg, 537 μmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine-1-carboxylate tert-butyl (199 mg, 644 μmol), Pd(dtbpf)Cl2 (34.9 mg, 53.7 μmol), K3PO4 (341 mg, 1.61 mmol), 5 mL of DMF, and a stirring bar were placed. This solution was stirred at 90°C for 2 hours. The reaction mixture was diluted with water (50 mL), and the aqueous phase was extracted three times with dichloromethane (20 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting crude material was purified by silica gel chromatography (2 g column; eluted with heptane / ethyl acetate; 3:1). Concentration under reduced pressure yielded 4-{4-amino-7-methyl-6-[4-(propa-2-enamide)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-5-yl}-1,2,3,6-tetrahydropyridine-1-carboxylate tert-butyl (121 mg, 48%) as a yellow oil. N-(4-(4-amino-7-methyl-5-(1,2,3,6-tetrahydropyridine-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-6-yl)phenyl)acrylamide [ka]

[0304] Step 2: In a round-bottom flask, 30 mg, 63.2 μmol, 0.2 mL of TFA, 0.8 mL of DCM, and a stirring bar were placed. The solution was stirred at room temperature for 1 hour. The reaction mixture was filtered and concentrated under reduced pressure. The resulting crude product was purified by HPLC (acetonitrile / water / 0.1% formic acid). By freeze-drying, N-{4-[4-amino-7-methyl-5-(1,2,3,6-tetrahydropyridine-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-6-yl]phenyl}propa-2-enamide (16.8 mg, 71%) was obtained as a white amorphous solid. N-(4-(4-amino-7-methyl-5-(1-(2,2,2-trifluoroacetyl)-1,2,3,6-tetrahydropyridine-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-6-yl)phenyl)acrylamide [ka]

[0305] Step 3: In a round-bottom flask, N-{4-[4-amino-7-methyl-5-(1,2,3,6-tetrahydropyridine-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-6-yl]phenyl}propa-2-enamide (40 mg, 106 μmol), TEA (32.1 mg, 318 μmol), DMAP (1.29 mg, 10.6 μmol), 5 mL of DCM, and a stirring bar were placed. TFAA was added dropwise at 0°C. The solution was stirred at room temperature for 1 hour. The reaction mixture was diluted with water (30 mL), and the aqueous phase was extracted three times with dichloromethane (20 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting crude product was purified by HPLC (acetonitrile / water / 0.1% formic acid). By freeze-drying, N-(4-{4-amino-7-methyl-5-[1-(2,2,2-trifluoroacetyl)-1,2,3,6-tetrahydropyridine-4-yl]-7H-pyrrolo[2,3-d]pyrimidine-6-yl}phenyl)propa-2-enamide (27.9 mg, 37%) was obtained as a white amorphous solid.

[0306] Further compounds prepared according to the method of Example 4 are shown in Table 3 below. [Table 3] Scheme 3 [ka] Example 5 N-(4-(4-amino-7-methyl-5-(1-(pyrroridine-1-carbonyl)piperidine-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-6-yl)phenyl)methacrylamide [ka] 4-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate tert-butyl [ka]

[0307] Step 1: A round-bottom flask was filled with 5-iodo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine (3.00 g, 10.9 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine-1-carboxylate tert-butyl (4.01 g, 13.0 mmol), Pd(dtbpf)Cl2 (710 mg, 1.09 mmol), K3PO4 (6.91 g, 32.6 mmol), and a stirring rod. DMF (45 mL) and H2O (3 mL) were added, and the solution was stirred at 90°C for 3 hours. This mixture was diluted with toluene (300 mL) and washed with water (3 × 100 mL), the organic phase was concentrated, and the crude product was purified by silica gel column using DCM:MeOH = 25:1 to obtain 4-{4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl}-1,2,3,6-tetrahydropyridine-1-carboxylate tert-butyl (2.97 g, 83%) as a brown oil. 4-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl)piperidine-1-carboxylate tert-butyl [ka]

[0308] Step 2: In a round-bottom flask, 1.70 g, 5.16 mmol, tert-butyl 4-{4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl}-1,2,3,6-tetrahydropyridine-1-carboxylate, 326 mg, 154 μmol, and a stirring rod were placed. 50 mL of MeOH was added, and the solution was stirred at 50°C under H2 for 48 hours. The mixture was filtered and washed five times with MeOH, and the filtrate was concentrated to obtain 900 mg, 53%, tert-butyl 4-{4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl}piperidine-1-carboxylate as a brown oil. 4-(4-amino-6-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl)piperidine-1-carboxylate tert-butyl [ka]

[0309] Step 3: In a round-bottom flask, 4-{4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl}piperidine-1-carboxylate tert-butyl (800 mg, 2.41 mmol), NBS (428 mg, 2.41 mmol), and a stirring bar were placed. ACN (20 mL) was added, and the solution was stirred at 25°C for 0.5 hours. The mixture was concentrated under reduced pressure to obtain the product, 4-{4-amino-6-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl}piperidine-1-carboxylate tert-butyl (500 mg, 51%), as a brown solid. This crude product was used in the next step without further purification. 6-bromo-7-methyl-5-(piperidine-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-4-amine [ka]

[0310] Step 4: In a round-bottom flask, tert-butyl 4-{4-amino-6-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl}piperidine-1-carboxylate (500 mg, 1.21 mmol), DCM (5 mL), and a stirring bar were placed. TFA (0.5 mL) was added, and the solution was stirred at 25°C for 2 hours. The mixture was concentrated under reduced pressure, diluted with DCM (30 mL), washed with saturated NaHCO3 aq. (3 × 15 mL), and the organic phase was concentrated to obtain the product 6-bromo-7-methyl-5-(piperidine-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-4-amine (310 mg, 83%) as a brown oil. (4-(4-amino-6-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl)piperidine-1-yl)(pyrroridine-1-yl)methanone [ka]

[0311] Step 5: In a round-bottom flask, 6-bromo-7-methyl-5-(piperidine-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-4-amine (280 mg, 902 μmol), DIEA (580 mg, 4.50 mmol), DCM (10 mL), and a stirring bar were placed. Triphosgene (106 mg, 360 μmol) was added, and the solution was stirred at room temperature for 1 hour. Then pyrrolidine (512 mg, 7.21 mmol) was added, and the mixture was stirred at room temperature for 1 hour. The solvent was removed, and the crude product was purified by C18 flush to obtain 6-bromo-7-methyl-5-[1-(pyrrolidine-1-carbonyl)piperidine-4-yl]-7H-pyrrolo[2,3-d]pyrimidine-4-amine (160 mg, 21%) as an off-white solid. N-(4-(4-amino-7-methyl-5-(1-(pyrroridine-1-carbonyl)piperidine-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-6-yl)phenyl)methacrylamide [ka]

[0312] Step 6: In a resealable reaction vial, 6-bromo-7-methyl-5-[1-(pyrroridine-1-carbonyl)piperidine-4-yl]-7H-pyrrolo[2,3-d]pyrimidine-4-amine (140 mg, 0.34 mmol), N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylamide (112 mg, 0.41 mmol), Pd(dppf)Cl2 (25.1 mg, 34.3 μmol), K3PO4 (216 mg, 1.02 mmol), and a stirring bar were placed, and the vial was evacuated and purged with nitrogen three times. DMF (1 mL) and H2O (0.1 mL) were added, and the mixture was stirred at 90°C for 3 hours. The resulting mixture was purified by passing it through a C18 column. The resulting crude material was purified by HPLC. By freeze-drying, N-(4-{4-amino-7-methyl-5-[1-(pyrroridine-1-carbonyl)piperidine-4-yl]-7H-pyrrolo[2,3-d]pyrimidine-6-yl}phenyl)-2-methylpropa-2-enamide (24.3 mg, 15%) was obtained as a white amorphous solid.

[0313] Further compounds prepared according to the method of Example 5 are shown in Table 4 below. [Table 4] Scheme 4 [ka] Example 6 N-(4-(4-amino-7-methyl-5-(1-methylpiperidine-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-6-yl)phenyl)acrylamide [ka] 4-(6-(4-acrylamidophenyl)-4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl)piperidine-1-carboxylate tert-butyl [ka]

[0314] Step 1: A round-bottom flask was filled with 4-(4-amino-6-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl)piperidine-1-carboxylate tert-butyl (700 mg, 1.7 mmol), N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylamide (559 mg, 2.0 mmol), Pd(dtbpf)Cl2 (124 mg, 0.17 mmol), K3PO4 (1.08 g, 5.1 mmol), and a stirring rod. DMF (10 mL) and H2O (1 mL) were added, and the solution was stirred at 90°C for 3 hours. This mixture was diluted with 100 mL of toluene and washed with 3 × 100 mL of water. The organic phase was concentrated, and the crude product was purified by silica gel column chromatography using DCM:MeOH = 25:1 to obtain 4-(6-(4-acrylamidophenyl)-4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl)piperidine-1-carboxylate tert-butyl (340 mg, 42%) as a yellow solid. [ka]

[0315] Step 2: In a round-bottom flask, 4-(6-(4-acrylamidophenyl)-4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl)piperidine-1-carboxylate tert-butyl (340 mg, 0.71 mmol), DCM (5 mL), and a stirring bar were placed. TFA (0.5 mL) was added, and the solution was stirred at 25°C for 2 hours. The mixture was concentrated under reduced pressure, diluted with DCM (30 mL), washed with saturated NaHCO3 aq. (3 × 15 mL), and the organic phase was concentrated to obtain the product 4-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl)piperidine-1-carboxylate tert-butyl (240 mg, 89%) as a brown oil. N-(4-(4-amino-7-methyl-5-(1-methylpiperidine-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-6yl)phenyl)acrylamide [ka]

[0316] Step 3: In a round-bottom flask, 4-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-yl)piperidine-1-carboxylate tert-butyl (120 mg, 0.32 mmol), NaBH(OAc)3 (81 mg, 0.38 mmol), (CH2O)n (20 mg, 0.64 mmol), and a stirring bar were placed. DCM (5 mL) and AcOH (0.5 mL) were added, and the solution was stirred overnight at room temperature. The reaction mixture was diluted with water (50 mL), and the aqueous phase was extracted three times with DCM (20 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting crude product was purified by HPLC. By freeze-drying, N-(4-{4-amino-7-methyl-5-[1-(pyrroridine-1-carbonyl)piperidine-4-yl]-7H-pyrrolo[2,3-d]pyrimidine-6-yl}phenyl)-2-methylpropa-2-enamide (8 mg, 6%) was obtained as a white amorphous solid.

[0317] Further compounds prepared according to the method of Example 6 are shown in Table 5 below. [Table 5] Scheme 5 [ka] Example 7 N-(4-(4-amino-7-methyl-5-(1-((methylcarbamoyl)glycyl)piperidine-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-6-yl)phenyl)acrylamide [ka]

[0318] In a resealable reaction vial, N-{4-[4-amino-7-methyl-5-(piperidine-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-6-yl]phenyl}propa-2-enamide (100 mg, 0.265 mmol), 2-[(methylcarbamoyl)amino]acetic acid (35.0 mg, 0.265 mmol), HATU (121 mg, 0.32 mmol), DIEA (68.5 mg, 0.53 mmol), and a stirring rod were placed. Dimethylformamide (5 mL) was added, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with water (10 mL), and the aqueous phase was extracted three times with dichloromethane (15 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting crude product was purified by HPLC (acetonitrile / water / 0.1% formic acid). By freeze-drying, N-{4-[4-amino-7-methyl-5-(1-{2-[(methylcarbamoyl)amino]acetyl}piperidine-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-6-yl]phenyl}propa-2-enamide (6.00 mg, 5%) was obtained as a white amorphous solid.

[0319] Further compounds prepared according to the method of Example 7 are shown in Table 6 below. [Table 6] Example 8 Scheme 6 [ka] 5-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine [ka]

[0320] Step 1: In a resealable reaction vial, 5-iodo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine (20 g, 72.9 mmol), (4-methoxyphenyl)boronic acid (13.3 g, 87.5 mmol), Pd(DtBPF)Cl2 (4.74 g, 7.29 mmol), CsF (33.1 g, 218 mmol), DMF (200 mL), H2O (25 mL), and a stirring rod were placed. The vial was then evacuated and purged with nitrogen three times. The mixture was stirred at 90°C for 1 hour. The reaction mixture was diluted with H2O (500 mL), and the aqueous phase was extracted three times with DCM (200 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The reaction mixture was mixed with MeCN (10 mL), filtered through a Celite® pad, and washed with MeCN. The filtrate was concentrated under reduced pressure, and the resulting solid was 5-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine (10.2 g, 55%), obtained as a yellow amorphous solid. 6-iodo-5-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine [ka]

[0321] Step 2: In a round-bottom flask, 5-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine (9.8 g, 38.5 mmol), DCM (200 mL), TFA (13.1 g, 115 mmol), and a stirring bar were placed. This mixture was cooled to 0°C, NIS (9.53 g, 42.4 mmol) was added, and the solution was stirred at room temperature for 1 hour. The reaction mixture was diluted with Na2SO3 solution, and the aqueous phase was extracted three times with DCM (300 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. DCM (20 mL) was added, and the reaction mixture was filtered through a Celite® pad, which was then washed with a small amount of DCM. The filtrate was concentrated under reduced pressure, and the resulting solid was 6-iodo-5-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine (10.9 g, 74%), obtained as an off-white amorphous solid. 4-(4-(4-amino-5-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine6-yl)-1H-pyrazole-1-yl)piperidine-1-carboxylate tert-butyl [ka]

[0322] Step 3: Place 6-iodo-5-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine (1 g, 2.63 mmol), 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-yl)piperidine-1-carboxylate tert-butyl (1.2 g, 3.16 mmol), Pd(dppf)Cl2 (190 mg, 0.26 mmol), K3PO4 (1.5 g, 6.9 mmol), DMF (20 mL), H2O (2 mL), and a stirring rod into a resealable reaction vial. Then, evacuate and purge with nitrogen three times. Stir the mixture at 90°C for 1 hour. The reaction mixture was diluted with H2O (100 mL), and the aqueous phase was extracted three times with DCM (100 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting crude material was purified by silica gel chromatography (eluting at MeOH / DCM = 1 / 40). Concentration under reduced pressure yielded 4-(4-(4-amino-5-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl)-1H-pyrazole-1-yl)piperidine-1-carboxylate tert-butyl (800 mg, 61%) as a yellow solid. 5-(4-methoxyphenyl)-7-methyl-6-(1(piperidine-4-yl)-1H-pyrazole-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-4-aminetrifluoroacetate [ka]

[0323] Step 4: In a round-bottom flask, 4-(4-(4-amino-5-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl)-1H-pyrazole-1-yl)piperidine-1-carboxylate tert-butyl (800 mg, 1.6 mmol), DCM (20 mL), and a stirring bar were placed. TFA (5 mL) was added. The reaction mixture was stirred at room temperature for 1 hour. The solvent was removed under reduced pressure to obtain 5-(4-methoxyphenyl)-7methyl-6-(1(piperidine-4-yl)-1H-pyrazole-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-4-aminetrifluoroacetate (795 mg, 100%) as a dark oil. 1-(4-(4-(4-amino-5-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl)-1H-pyrazole-1-yl)piperidine-1-yl)prop-2-en-1-one [ka]

[0324] Step 5: In a round-bottom flask, 120 mg, 0.24 mmol of 5-(4-methoxyphenyl)-7-methyl-6-(1-(piperidine-4-yl)-1H-pyrazole-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-4-aminetrifluoroacetate, 72.9 mg, 0.72 mmol of Et3N, 10 mL of DCM, and a stirring bar were placed. The mixture was cooled to -30°C, and propa-2-enoyl chloride (21.6 mg, 0.24 mmol) was added dropwise. The solution was then stirred at -30°C for 0.5 hours. The reaction mixture was quenched with MeOH and concentrated under reduced pressure. The resulting crude product was purified by prep-HPLC. By freeze-drying, 1-(4-(4-(4-amino-5-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl)-1H-pyrazole-1-yl)piperidine-1-yl)propa-2-en-1-one (33 mg, 30%) was obtained as a white amorphous solid.

[0325] Further compounds prepared according to the method of Example 8 are shown in Table 7 below. [Table 7-1] [Table 7-2] [Table 7-3] [Table 7-4] [Table 7-5] [Table 7-6] [Table 7-7] [Table 7-8] [Table 7-9] [Table 7-10] [Table 7-11] [Table 7-12] [Table 7-13] [Table 7-14] [Table 7-15] [Table 7-16] [Table 7-17] [Table 7-18] [Table 7-19] Example 9 Scheme 7 [ka] N-(4-(4-aminopyrrolo[2,1-f][1,2,4]triazine-6-yl)phenyl)methacrylamide [ka]

[0326] Step 1: In a resealable reaction vial, 6-bromovyrrolo[2,1-f][1,2,4]triazine-4-amine (500 mg, 2.34 mmol), 2-methyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propa-2-enamide (804 mg, 2.80 mmol), K3PO4 (1.48 g, 7.02 mmol), Pd(dppf)Cl2 (171 mg, 234 μmol), and a stirring rod were placed. The vial was then evacuated and purged with nitrogen three times. DMF / H2O (10 mL) was added, and the mixture was stirred at 90°C for 1 hour. The reaction mixture was diluted with water (20 mL), and the aqueous phase was extracted three times with dichloromethane (20 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting crude material was purified by prep-TLC (eluted with dichloromethane / methanol; 15:1). Concentration under reduced pressure yielded N-(4-{4-aminopyrrolo[2,1-f][1,2,4]triazine-6-yl}phenyl)-2-methylpropa-2-enamide (280 mg, 34%) as an off-white amorphous solid. N-(4-{4-amino-5,7-dibromopyrrolo[2,1-f][1,2,4]triazine-6-yl}phenyl)-2-methylpropa-2-enamide [ka]

[0327] Step 2: In a round-bottom flask, N-(4-{4-aminopyrrolo[2,1-f][1,2,4]triazine-6-yl}phenyl)-2-methylpropa-2-enamide (260 mg, 886 μmol) was added, dimethylformamide (5 mL) was added, then NBS (313 mg, 1.77 mmol) was added at 0°C, and the solution was stirred at 0°C for 1 hour. The reaction mixture was diluted with Na2SO3(aq) (10 mL), and the aqueous phase was extracted three times with dichloromethane (10 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting crude product was purified by prep-TLC (eluted with dichloromethane / methanol; 20:1). Concentration under reduced pressure yielded N-(4-{4-amino-5,7-dibromopyrrolo[2,1-f][1,2,4]triazine-6-yl}phenyl)-2-methylpropa-2-enamide (350 mg, 87%) as an orange amorphous solid. N-(4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazine-6-yl)phenyl)methacrylamide [ka]

[0328] Step 3: In a resealable reaction vial, N-(4-{4-amino-5,7-dibromopyrrolo[2,1-f][1,2,4]triazine-6-yl}phenyl)-2-methylprop-2-enamide (300 mg, 665 μmol) was added, tetrahydrofuran (6 mL) was added, and a stirring bar was added. The vial was then evacuated and purged with nitrogen three times. At -78°C, n-BuLi (0.8 mL, 2 mmol) was added, and the mixture was stirred at -78°C for 5 minutes. The reaction mixture was diluted with water (5 mL), and the aqueous phase was extracted three times with dichloromethane (5 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting crude material was purified by TLC (elution with dichloromethane / methanol; 15:1). Concentration under reduced pressure yielded N-(4-{4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazine-6-yl}phenyl)-2-methylpropa-2-enamide (100 mg, 40%) as an off-white amorphous solid. N-(4-(4-amino-5-(4-((6-methylpyridine-2-yl)oxy)phenyl)pyrrolo[2,1-f][1,2,4]triazine-6-yl)phenyl)methacrylamide [ka]

[0329] Step 4: In a resealable reaction vial, N-(4-{4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazine-6-yl}phenyl)-2-methylpropa-2-enamide (90.0 mg, 241 μmol) was added, and 2-methyl-6-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]pyridine (82.4 mg, 265 μmol), K3PO4 (153 mg, 722 μmol), Pd(dppf)Cl2 (17.6 mg, 24.1 μmol), and DMF / H2O (4 mL) were added. A stirring rod was then added, followed by exhausting and purging with nitrogen three times, and the mixture was stirred at 90°C for 1 hour. The reaction mixture was diluted with water (10 mL), and the aqueous phase was extracted three times with dichloromethane (10 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting crude product was purified by HPLC (column: XBridge Prep OBD C18 column, 30 × 150 mm 5 μm; mobile phase A: unspecified, mobile phase B: unspecified; flow rate: 60 mL / min; gradient: 35B~50B for 8 minutes; 220 nm; RT1: 7.54; RT2:; injection volume: ml; number of runs:;). Lyophilization yielded N-[4-(4-amino-5-{4-[(6-methylpyridine-2-yl)oxy]phenyl}pyrrolo[2,1-f][1,2,4]triazine-6-yl)phenyl]-2-methylpropa-2-enamide (7.62 mg, 6%) as an off-white amorphous solid.

[0330] Further compounds prepared according to the method of Example 9 are shown in Table 8 below. [Table 8-1] [Table 8-2] Example 10 Scheme 8. [ka] 4-(4-amino-7-(hydroxymethyl)-6-(4-methacrylamidephenyl)pyrrolo[2,1-f][1,2,4]triazine-5-yl)-N-(2,2,2-trifluoroethyl)benzamide [ka] 4-(4-amino-7-(hydroxymethyl)pyrrolo[2,1-f][1,2,4]triazine-5-yl)-N-(2,2,2-trifluoroethyl)benzamide [ka]

[0331] Step 1: In a resealable reaction vial, (4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazine-7-yl)methanol (600 mg, 2.49 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(2,2,2-trifluoroethyl)benzamide (983 mg, 2.99 mmol), Pd(dtbpf)Cl2 (162 mg, 249 μmol), CsF (1.14 g, 7.47 mmol), DMF:water = 16:1 (8 mL), and a stirring rod were added. The vial was then evacuated and purged with nitrogen three times. The solution was stirred at 90°C for 2 hours. The reaction mixture was quenched with water and extracted with DCM. The organic phase was separated, dried over Na2SO4, filtered, and concentrated under reduced pressure. The obtained crude material was purified by prep-TLC. It was concentrated under reduced pressure to obtain 4-(4-amino-7-(hydroxymethyl)pyrrolo[2,1-f][1,2,4]triazine-5-yl)-N-(2,2,2-trifluoroethyl)benzamide (400 mg, 44%) as a yellow oil. 4-(4-amino-7-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolo[2,1-f][1,2,4]triazine-5-yl)-N-(2,2,2-trifluoroethyl)benzamide [ka]

[0332] Step 2: In a resealable reaction vial, 4-(4-amino-7-(hydroxymethyl)pyrrolo[2,1-f][1,2,4]triazine-5-yl)-N-(2,2,2-trifluoroethyl)benzamide (380 mg, 1.04 mmol), imidazole (283 mg, 4.16 mmol), DMF (5 mL), and a stirring bar were placed. TBSCl (314 mg, 2.08 mmol) was added, and the solution was stirred at room temperature for 1 hour. The resulting mixture was purified by passing it through a C18 column. It was concentrated under reduced pressure to obtain 4-(4-amino-7-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolo[2,1-f][1,2,4]triazine-5-yl)-N-(2,2,2-trifluoroethyl)benzamide (420 mg, 84%) as a yellow amorphous solid. 4-(4-amino-6-bromo-7-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolo[2,1-f][1,2,4]triazine-5-yl)-N-(2,2,2-trifluoroethyl)benzamide [ka]

[0333] Step 3: In a round-bottom flask, 4-(4-amino-7-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolo[2,1-f][1,2,4]triazine-5-yl)-N-(2,2,2-trifluoroethyl)benzamide (400 mg, 0.84 mmol), dimethylformamide (5 mL), and a stirring bar were placed. NBS (225 mg, 1.00 mmol) was added, and the solution was stirred at room temperature for 1 hour. The reaction mixture was quenched with water and extracted with DCM. The organic phase was separated, dried over Na2SO4, filtered, and concentrated under reduced pressure. The resulting crude material was purified by silica gel chromatography. Concentration under reduced pressure yielded 4-(4-amino-6-bromo-7-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolo[2,1-f][1,2,4]triazine-5-yl)-N-(2,2,2-trifluoroethyl)benzamide (450 mg, 94%) as a yellow amorphous solid. 6-{5-[2-(tert-butyldimethylsilyl)ethynyl]-3-methylpyrazine-2-yl}-7-methyl-5-{4-[(4-methylpyrimidine-2-yl)oxy]phenyl}-7H-pyrrolo[2,3-d]pyrimidine-4-amine [ka]

[0334] Step 4: Place 4-(4-amino-6-bromo-7-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolo[2,1-f][1,2,4]triazine-5-yl)-N-(2,2,2-trifluoroethyl)benzamide (200 mg, 0.36 mmol), N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methacrylamide (124 mg, 0.43 mmol), Pd(dtbpf)Cl2 (23.4 mg, 36 μmol), CsF (164 mg, 1.08 mmol), DMF:water = 16:1 (4 mL), and a stirring rod into a resealable reaction vial. Then, evacuate and purge with nitrogen three times. Stir this solution under N2 at 90°C for 2 hours. The reaction mixture was quenched with water and extracted with DCM. The organic phase was collected, dried over Na2SO4, filtered, and concentrated under reduced pressure. The resulting crude product was purified by Prep-HPLC (column: XBridge Prep OBD C18 column, 19 × 250 mm, 5 μm; mobile phase A: water (10 MMOL / L NH4HCO3), mobile phase B: ACN; flow rate: 25 mL / min; gradient: 20B~50B for 8 minutes; 220 nm; RT1: 7.23). Lyophilization yielded 4-(4-amino-7-(hydroxymethyl)-6-(4-methacrylamidephenyl)pyrrolo[2,1-f][1,2,4]triazine-5-yl)-N-(2,2,2-trifluoroethyl)benzamide (30.4 mg, 16%) as an off-white amorphous solid.

[0335] Further compounds prepared according to the method of Example 10 are shown in Table 9 below. [Table 9-1] [Table 9-2] Example 11 Scheme 9 [ka] 4-(4-amino-6-(4-methacrylamidophenyl)-7H-cyclopenta[d]pyrimidine-5-yl)methyl benzoate [ka]

[0336] Step 1: In a round-bottom flask, N-(4-{4-amino-5-bromo-7H-cyclopenta[d]pyrimidine-6-yl}phenyl)-2-methylpropa-2-enamide (800 mg, 2.15 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl benzoate (731 mg, 2.79 mmol), Pd(dtbpf)Cl2 (139 mg, 215 μmol), CsF (980 mg, 6.45 mmol), DMF:H2O = 16:1 (8 mL), and a stirring rod were placed. This solution was stirred at 90°C for 2 hours under N2. The reaction mixture was diluted with water (50 mL) and extracted three times with ELISA (50 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The obtained crude material was purified by silica gel chromatography. It was concentrated under reduced pressure to obtain methyl 4-{4-amino-6-[4-(2-methylpropa-2-enamide)phenyl]-7H-cyclopenta[d]pyrimidine-5-yl}benzoate (600 mg, 56%) as an off-white amorphous solid. 4-(4-amino-6-(4-methacrylamidophenyl)-7H-cyclopenta[d]pyrimidine-5-yl)benzoic acid [ka]

[0337] Step 2: In a round-bottom flask, methyl 4-{4-amino-6-[4-(2-methylpropa-2-enamide)phenyl]-7H-cyclopenta[d]pyrimidine-5-yl}benzoate (580 mg, 1.35 mmol), THF:LiOH (2M) = 1:1 (6 mL), and a stirring rod were placed. This solution was stirred at room temperature for 3 hours. The pH of this solution was adjusted to 6-7 with aq. HCl. The product was precipitated by the addition of HCl and then dried. This yielded 4-{4-amino-6-[4-(2-methylpropa-2-enamide)phenyl]-7H-cyclopenta[d]pyrimidine-5-yl}benzoic acid (350 mg, 63%) as an off-white amorphous solid. 4-(4-amino-6-(4-methacrylamidephenyl)pyrrolo[2,1-f][1,2,4]triazine-5-yl)-N-(2-hydroxy-2-methylpropyl)benzamide [ka]

[0338] Step 3: In a resealable reaction vial, 4-{4-amino-6-[4-(2-methylpropa-2-enamide)phenyl]-7aH-cyclopenta[d]pyrimidine-5-yl}benzoic acid (60 mg, 145 μmol), 1-amino-2-methylpropan-2-ol (15.5 mg, 174 μmol), HATU (55.2 mg, 145 μmol), DIEA (37.4 mg, 290 μmol), dimethylformamide (10 mL), and a stirring rod were placed. The mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched with water and purified by HPLC (column: XBridge Prep C18 OBD column, 5um, 19×150mm; mobile phase A: water (10MMOL / L NH4HCO3), mobile phase B: ACN; flow rate: 25mL / min; gradient: 15B~50B for 7 minutes; 254 / 220nm; RT1: 7.58). Lyophilization yielded 4-{4-amino-6-[4-(2-methylpropa-2-enamide)phenyl]pyrrolo[2,1-f][1,2,4]triazine-5-yl}-N-(2-hydroxy-2-methylpropyl)benzamide (40.2 mg, 56.4%) as a white amorphous solid.

[0339] Further compounds prepared according to the method of Example 11 are shown in Table 10 below. [Table 10-1] [Table 10-2] [Table 10-3] Example 12 Scheme 10 [ka] N-(3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylamide [ka]

[0340] Step 1: In a round-bottom flask, 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (10 g, 42.8 mmol), propa-2-enoyl chloride (3.87 g, 42.8 mmol), pyridine (10.1 g, 128 mmol), dichloromethane (150 mL), and a stirring bar were placed. This solution was stirred at 0°C for 1 hour. The reaction mixture was quenched with water and extracted with DCM. The organic phase was dried over Na2SO4, filtered, and evaporated under reduced pressure. The resulting crude product was purified by silica gel chromatography. Concentrated under reduced pressure, N-(3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylamide (12 g, 98%) was obtained as a yellow oil. N-(4-(4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl)-3-methylphenyl)acrylamide [ka]

[0341] Step 2: In a round-bottom flask, N-[3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propa-2-enamide (1 g, 3.48 mmol), 5-bromo-6-iodo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine (1.22 g, 3.48 mmol), Pd(dppf)Cl2 (254 mg, 348 μmol), K3PO4 (2.20 g, 10.4 mmol), DMF / H2O (16:1) (15 mL), and a stirring bar were placed. This solution was stirred at 50°C for 2 hours. The reaction mixture was quenched with water and extracted with DCM. The organic phase was washed three times with brine, dried over Na2SO4, filtered, and evaporated under reduced pressure. The obtained crude material was purified by silica gel chromatography. It was concentrated under reduced pressure to obtain N-(4-(4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl)-3-methylphenyl)acrylamide (440 mg, 33%) as an off-white amorphous solid. (R)-N-(4-(4-amino-7-methyl-5-(4-(pyrroridine-1-carbonyl)cyclohexa-1-en-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-6-yl)-3-methylphenyl)acrylamide [ka]

[0342] Step 3: In a resealable reaction vial, N-(4-{4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl}-3-methylphenyl)propa-2-enamide (200 mg, 517 μmol), 1-[(1R)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohexa-3-en-1-carbonyl]pyrrolidine (156 mg, 517 μmol), Pd(pddf)Cl2 (37.8 mg, 517 μmol), Na2CO3 (164 mg, 1.55 mmol), DMF (10 mL), and a stirring rod were added. The vial was then evacuated and purged with nitrogen three times. The mixture was stirred at 90°C for 2 hours. The reaction mixture was quenched with water and extracted with DCM. The organic phase was washed three times with brine, dried over Na2SO4, filtered, and evaporated under reduced pressure. The resulting crude material was purified by prep-HPLC (column: YMC-Actus Triart C18, 30×250, 5um; mobile phase A: water (10MMOL / L NH4HCO3), mobile phase B: ACN; flow rate: 50 mL / min; gradient: 40B~62B for 8 minutes; 220 nm; RT1: 6.83). Lyophilization yielded (R)-N-(4-(4-amino-7-methyl-5-(4-(pyrrolidin-1-carbonyl)cyclohexa-1-en-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-6-yl)-3-methylphenyl)acrylamide (40 mg, 16%) as an off-white amorphous solid. (S)-N-(4-(4-amino-7-methyl-5-(4-(pyrroridine-1-carbonyl)cyclohexa-1-en-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-6-yl)-3-methylphenyl)acrylamide [ka]

[0343] Step 4: In a resealable reaction vial, N-(4-{4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl}-3-methylphenyl)propa-2-enamide (240 mg, 621 μmol), Pd(dppf)Cl2 (45.4 mg, 62.1 μmol), Na2CO3 (197 mg, 1.86 mmol), 1-[(1S)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohexa-3-en-1-carbonyl]pyrrolidine (189240 mg, 621 μmol), dimethylformamide / H2O (8 mL), and a stirring rod were added. The vial was then evacuated and purged with nitrogen three times. The mixture was stirred at 90°C for 2 hours. The reaction mixture was quenched with water and extracted with DCM. The organic phase was washed three times with brine, dried over Na2SO4, filtered, and evaporated under reduced pressure. The resulting crude material was purified by prep-HPLC (column: YMC-Actus Triart C18, 30×250, 5um; mobile phase A: water (10MMOL / L NH4HCO3), mobile phase B: ACN; flow rate: 50 mL / min; gradient: 40B~60B for 8 minutes; 220 nm; RT1: 7.67; RT2:; injection volume: ml; number of runs:;). By freeze-drying, (S)-N-(4-(4-amino-7-methyl-5-(4-(pyrroridine-1-carbonyl)cyclohexa-1-en-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-6-yl)-3-methylphenyl)acrylamide (39 mg, 14%) was obtained as an off-white amorphous solid.

[0344] Further compounds prepared according to the method of Example 12 are shown in Table 11 below. [Table 11-1] [Table 11-2] [Table 11-3] [Table 11-4] Table 11-5 Table 11-6 Table 11-7 Table 11-8 Table 11-9 Table 11-10 Table 11-11 Table 11-12 Table 11-13 Table 11-14 Table 11-15 Table 11-16 Table 11-17 Table 11-18 Table 11-19 Table 11-20 Table 11-21 Table 11-22 Table 11-23 Table 11-24 Table 11-25 Table 11-26 Table 11-27 Table 11-28 Table 11-29 Table 11-30 Table 11-31 Table 11-32 Table 11-33 Table 11-34 Table 11-35 Table 11-36 Table 11-37 [Table 11-38] [Table 11-39] [Table 11-40] [Table 11-41] [Table 11-42] Example 13 Scheme 11 [ka] N-(2-(4-bromophenyl)propan-2-yl)acrylamide [ka]

[0345] Step 1: Acryloyl chloride (0.63 g, 7.006 mmol) was added dropwise to a stirred solution / mixture of 2-(4-bromophenyl)propan-2-amine (1.50 g, 7.006 mmol) and TEA (2.13 g, 21.018 mmol) in DCM (30 mL) under a nitrogen atmosphere at 0°C. The mixture was stirred at 0°C for 1 hour. The resulting mixture was extracted with CH2Cl2. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain N-(2-(4-bromophenyl)propan-2-yl)acrylamide (500 mg, 27%) as a yellow solid. N-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-yl)acrylamide [ka]

[0346] Step 2: The solution / mixture of N-[2-(4-bromophenyl)propan-2-yl]propa-2-enamide (470.00 mg, 1.753 mmol), bis(pinacolato)diborone (667.63 mg, 2.629 mmol), AcOK (516.05 mg, 5.258 mmol), and Pd(dppf)Cl2 (128.25 mg, 0.175 mmol) in DMF (10 mL) was stirred at 80°C under a nitrogen atmosphere for 2 hours. The resulting mixture was extracted with Â. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / siRNA=4 / 1 elution to obtain N-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-yl)acrylamide (400 mg, 72%) as an off-white solid. N-(2-(4-(4-amino-7-methyl-5-(4-(4-methylpyrimidine-2-yloxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-6-yl)phenyl)propan-2-yl)acrylamide [ka]

[0347] Step 3: The solutions / mixtures of 6-iodo-7-methyl-5-[4-[(4-methylpyrimidine-2-yl)oxy]phenyl]pyrrolo[2,3-d]pyrimidine-4-amine (200.00 mg, 0.44 mmol), N-[2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propan-2-yl]propa-2-enamide (165.1 mg, 0.52 mmol), K3PO4 (277.9 mg, 1.31 mmol), and Pd(dppf)Cl2 (31.9 mg, 0.04 mmol) in DMF (4 mL) and H2O (1 mL) were stirred at 90°C under a nitrogen atmosphere for 1 hour. The resulting mixture was extracted with ELISA. The combined organic layer was washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by HPLC (column: XBridge Shield RP18 OBD column, 5um, 19×150mm; mobile phase A: water (10mM NH4HCO3), mobile phase B: ACN; flow rate: 25mL / min; gradient: 25B~43B for 7 minutes; 220 / 254nm; RT1: 6.25; RT2:; injection volume: ml; number of runs:;). Lyophilization yielded N-(2-(4-(4-amino-7-methyl-5-(4-(4-methylpyrimidine-2-yloxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-6-yl)phenyl)propan-2-yl)acrylamide (51 mg, 22.3%) as an off-white amorphous solid.

[0348] Further compounds prepared according to the method of Example 13 are shown in Table 12 below. [Table 12-1] [Table 12-2] [Table 12-3] [Table 12-4] [Table 12-5] Table 12-6 Table 12-7 Table 12-8 Table 12-9 Table 12-10 Table 12-11 Table 12-12 Table 12-13 Table 12-14 Table 12-15 Table 12-16 Table 12-17 Table 12-18 Table 12-19 Table 12-20 Table 12-21 [Table 12-22] [Table 12-23] Example 14 Scheme 12 [ka] 3-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl)pyrrolidine-1-carboxylate tert-butyl [ka]

[0349] Step 1: In a resealable reaction vial, tert-butyl 3-{4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl}-2,5-dihydro-1H-pyrrole-1-carboxylate (1.2 g, 3.07 mmol), Pd-C (120 mg, 1.2 mol), and a stirring rod were placed, and the vial was evacuated and purged with hydrogen three times. MeOH (20 mL) was added, and the mixture was stirred overnight at 50°C. The reaction mixture was filtered through a Celite® pad, the pad was washed with water, and the filtrate was concentrated under reduced pressure to obtain tert-butyl 3-{4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl}pyrrolidine-1-carboxylate (0.9 g, 91.8%) as an off-white solid. 3-(4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl)pyrrolidine-1-carboxylate tert-butyl [ka]

[0350] Step 2: In a round-bottom flask, 3-{4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl}pyrrolidine-1-carboxylate tert-butyl (300 mg, 945 μmol), NBS (168 mg, 945 μmol), and a stirring rod were placed. Dichloromethane (5 mL) was added, and the solution was stirred at room temperature for 30 minutes. The reaction mixture was diluted with water (10 mL), and the aqueous phase was extracted three times with dichloromethane (10 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain 3-{4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl}pyrrolidine-1-carboxylate tert-butyl (230 mg, 61.4%) as a bright yellow solid. 3-(4-amino-7-methyl-5-(4-(pyrimidine-2-yloxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-6-yl)pyrrolidine-1-carboxylate tert-butyl [ka]

[0351] Step 3: In a resealable reaction vial, tert-butyl 3-{4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl}pyrrolidine-1-carboxylate (200 mg, 504 μmol), 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]pyrimidine (165 mg, 554 μmol), Pd(dtbpf)Cl2 (32.8 mg, 50.4 μmol), K3PO4 (320 mg, 1.51 mmol), and a stirring rod were placed, and the vial was evacuated and purged with nitrogen three times. DMF / water (2 mL) was added, and the mixture was stirred at 90°C for 2 hours. The reaction mixture was diluted with water (10 mL), and the aqueous phase was extracted three times with dichloromethane (10 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting crude material was purified by silica gel chromatography (5 g column; eluted with dichloromethane / methanol / 0.1% triethylamine; ratio). Concentration under reduced pressure yielded 3-{4-amino-7-methyl-5-[4-(pyrimidine-2-yloxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-6-yl}pyrrolidine-1-carboxylate tert-butyl (100 mg, 40.7%) as a light brown solid. 7-Methyl-5-(4-(pyrimidine-2-yloxy)phenyl)-6-(pyrrolidine-3-yl)-7H-pyrrolo[2,3-d]pyrimidine-4-amine [ka]

[0352] Step 4: In a round-bottom flask, tert-butyl 3-{4-amino-7-methyl-5-[4-(pyrimidine-2-yloxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-6-yl}pyrrolidine-1-carboxylate (200 mg, 410 μmol) and a stirring bar were placed. TFA / DCM (1 / 4 mL) was added, and the solution was stirred at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure. It was then dissolved in saturated NaHCO3 and extracted three times with DCM. The combined organic layers were dried over anhydrous Na2SO4. After filtration and evaporation, 7-methyl-5-[4-(pyrimidine-2-yloxy)phenyl]-6-(pyrrolidine-3-yl)-7H-pyrrolo[2,3-d]pyrimidine-4-amine (150 mg, 94.4%) was obtained as an off-white solid. 1-(3-(4-amino-7-methyl-5-(4-(pyrimidine-2-yloxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-6-yl)pyrroridine-1-yl)propa-2-en-1-one [ka]

[0353] Step 5: In a round-bottom flask, 7-methyl-5-[4-(pyrimidine-2-yloxy)phenyl]-6-(pyrrolidine-3-yl)-7H-pyrrolo[2,3-d]pyrimidine-4-amine (50 mg, 129 μmol), TEA (39.0 mg, 387 μmol), dichloromethane (4 mL), and a stirring bar were placed. Propa-2-enoyl chloride (10.4 mg, 116 μmol) was added at -30°C, and the solution was stirred at -30°C for 30 minutes. The reaction mixture was filtered through a Celite® pad, washed with DCM, and the filtrate was concentrated under reduced pressure. The resulting crude material was purified by HPLC (acetonitrile / water / 0.1% formic acid). By freeze-drying, 1-(3-{4-amino-7-methyl-5-[4-(pyrimidine-2-yloxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-6-yl}pyrrolidine-1-yl)propa-2-en-1-one (5.92 mg, 11.6% l) was obtained as a white amorphous solid.

[0354] Further compounds prepared according to the method of Example 14 are shown in Table 13 below. [Table 13-1] [Table 13-2] [Table 13-3] [Table 13-4] [Table 13-5] [Table 13-6] [Table 13-7] [Table 13-8] [Table 13-9] [Table 13-10] [Table 13-11] [Table 13-12] [Table 13-13] [Table 13-14] [Table 13-15] [Table 13-16] Table 13-17 Table 13-18 Table 13-19 Table 13-20 Table 13-21 Table 13-22 Table 13-23 Table 13-24 Table 13-25 Table 13-26 Table 13-27 Table 13-28 Table 13-29 Table 13-30 Table 13-31 Table 13-32 Table 13-33 Table 13-34 Table 13-35 Table 13-36 Table 13-37 Table 13-38 Table 13-39 Table 13-40 Table 13-41 Table 13-42 Table 13-43 Table 13-44 Table 13-45 Table 13-46 Example 15

change

[0355] Step 1: In a round-bottom flask, 1.7 g, 10.18 mmol, 4-chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine, 30 mL of THF, and a stirring bar were placed. 7.63 mL, 15.26 mmol, 2 M LDA was added dropwise to the solution at -78°C and stirred at the same temperature for 1 hour. Then, 4.05 g, 20.35 mmol, tert-butyl (S)-2-methyl-4-oxopyrrolidine-1-carboxylate in 10 mL of THF was added at -78°C, and the mixture was warmed to room temperature for 1 hour. The mixture was quenched with 10 mL of Sat.NH4Cl and extracted three times with 40 mL of SiO2. The combined organic phases were washed with brine, dried over Na2SO4, and combined under reduced pressure. The crude product obtained was purified by silica gel chromatography (eluting at PE / siRNA = 2:1) to obtain (2S)-4-(4-chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl)-4-hydroxy-2-methylpyrrolidine-1-carboxylate tert-butyl (550 mg, 1.50 mmol, 15%) as an off-white solid. (2S)-4-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl)-4-hydroxy-2-methylpyrrolidine-1-carboxylate tert-butyl [ka]

[0356] Step 2: Place (2S)-4-(4-chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl)-4-hydroxy-2-methylpyrrolidine-1-carboxylate tert-butyl (550 mg, 1.50 mmol), NH3 / H2O (10 mL, 25%~30%), and 1,4-dioxane (10 mL) into a 50 mL unsealed tube, seal the tube, and stir the mixture solution at 100°C for 12 hours. The tube was cooled to room temperature, and the mixture was poured out. The solvent was concentrated, and the crude product was washed three times with DCM (100 mL) and concentrated to obtain (2S)-4-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl)-4-hydroxy-2-methylpyrrolidine-1-carboxylate tert-butyl (400 mg, 77%) as an off-white solid. (S)-7-methyl-6-(5-methyl-2,5-dihydro-1H-pyrrole-3-yl)-7H-pyrrolo[2,3-d]pyrimidine-4-amine [ka]

[0357] Step 3: In a round-bottom flask, (2S)-4-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl)-4-hydroxy-2-methylpyrrolidine-1-carboxylate tert-butyl (380 mg, 1.09 mmol), HCl (5 mL), and a stirring rod were placed. The mixture was stirred at 100°C for 2 hours. After cooling to room temperature, the resulting mixture was concentrated and diluted with water (10 mL) to adjust the pH to 7-8, and then extracted three times with DCM (20 mL). The organic phases were combined and concentrated under reduced pressure to obtain the crude product (S)-7-methyl-6-(5-methyl-2,5-dihydro-1H-pyrrole-3-yl)-7H-pyrrolo[2,3-d]pyrimidine-4-amine (330 mg) as a brown solid. 7-Methyl-6-((5S)-5-methylpyrrolidine-3-yl)-7H-pyrrolo[2,3-d]pyrimidine-4-amine [ka]

[0358] Step 4: (S)-7-methyl-6-(5-methyl-2,5-dihydro-1H-pyrrole-3-yl)-7H-pyrrolo[2,3-d]pyrimidine-4-amine (330 mg, crude), Pd / C (30 mg), MeOH (10 mL), and a stirring rod were placed in a resealable reaction vial. The mixture was evacuated and purged with nitrogen three times, then evacuated and purged with hydrogen five times. The mixture was stirred overnight at 50°C. The mixture was then filtered, the filter cake was washed five times with MeOH, and the organic phase was concentrated to obtain 7-methyl-6-((5S)-5-methylpyrrolidine-3-yl)-7H-pyrrolo[2,3-d]pyrimidine-4-amine (220 mg, 63% in two steps) as a brown solid. (2S)-4-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-yl)-2-methylpyrrolidine-1-carboxylate tert-butyl [ka]

[0359] Step 5: In a round-bottom flask, 7-methyl-6-((5S)-5-methylpyrrolidine-3-yl)-7H-pyrrolo[2,3-d]pyrimidine-4-amine (220 mg, 0...

Claims

1. Formula X: 【Chemical 501】 A compound of or a pharmaceutically acceptable salt thereof, in formula X: R 5B R B or hydrogen, where R 5B R is the R of n examples. 5D It has been replaced with; R W teeth, 【Chemical 502】 And; R 6 each instance of is independently R A or R B , wherein R 6 is substituted with q instances of R C ; or R 6 Two examples of R 6 One example and R L One example is that together with the atoms between these, they form a 4- to 7-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where the ring is R in r examples C It has been replaced with; R 7 R B Or H, where R 7 R of t examples 7A It has been replaced with; L 5 and L 6 Each of them is independent, covalently bonded, or C 1~4 A divalent saturated or unsaturated, straight or branched hydrocarbon chain, where one or two methylene units in the chain are independently -CH(R L )-,-C(R L ) 2 -, C 3~5 Cycloalkylenes, 3- to 5-membered heterocycloalkylenes, 5- to 6-membered heteroarylenes, -NH-, -N(R) L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-,-NHS(O) 2 -, -N(R L ) S(O) 2 -, -S(O) 2 NH-, -S(O) 2 N(R) L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O) 2 - is replaced as needed; R WA , R WB , and R WC Each of these independently consists of hydrogen, halogen, -CN, -C(O)R, -C(O)OR, and -C(O)NR. 2 , -C(O)N(R)OR, or a group, the group is C 1~6 Selected from three- to seven-membered saturated or partially unsaturated heterocyclic rings having one or two heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and five- to six-membered heteroaryl rings having one or four heteroatoms independently selected from nitrogen, oxygen, and sulfur; or R WA and R WB , R WB and R WC , R WA and R L One example of this is R WC and R L One example is that together with the atoms between them, they form a 4- to 7-membered saturated or partially unsaturated ring having 0 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R 5C , R 5D , R 7A , and R L Each example is independent, R A or R B And R for u examples C It has been replaced with; R A Each of these examples is independent: halogen, oxo, -CN, -NO 2 , -OR, -SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2 , -S(O)R, -S(O)NR 2 , -C(O)R, -C(O)OR, -C(O)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , -N(R)C(NR)NR 2 , -N(R)S(O) 2 NR 2 , or -N(R)S(O) 2 It is R; R B Each example is independently a phenyl; a 5- to 6-membered monocyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; C 1~6 Aliphatic; 8- to 10-membered bicyclic heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 3- to 7-membered saturated or partially unsaturated carbocyclic rings; 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic rings having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or 7- to 12-membered saturated or partially unsaturated bicyclic heterocyclic rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R C Each of these examples is independent: oxo, halogen, -CN, -NO 2 , -OR, -SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2 , -S(O)R, -S(O)NR 2 , -S(O) 2 F, -OS(O) 2 F, -C(O)R, -C(O)OR, -C(O)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , -N(R)C(NR)NR 2 , -N(R)S(O) 2 NR 2 , -N(R)S(O) 2 R is a group, and the group is C 1~6 Selected from three- to seven-membered saturated or partially unsaturated heterocyclic rings having one or two heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and five- to six-membered heteroaryl rings having one or four heteroatoms independently selected from nitrogen, oxygen, and sulfur; Each R is independently a hydrogen atom or a group, and the group is C 1~6 Selected from 3- to 7-membered saturated or partially unsaturated heterocyclic rings having one or two heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having one or four heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: Two R groups on the same nitrogen atom, together with the atom between them, form a 4- to 7-membered saturated, partially unsaturated, or heteroaryl ring having 0 to 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, in addition to the nitrogen; and Each of m, n, p, q, r, t, and u is independently 0, 1, 2, 3, or 4. A compound or a pharmaceutically acceptable salt thereof.

2. L 5 is O, the compound according to claim 1, or a pharmaceutically acceptable salt thereof.

3. R 5B R is a 5- to 6-membered monocyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, where R 5B R for n examples 5D It is replaced by; and / or: The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein n is 1.

4. R 5D C 1~6 The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is a 5- to 6-membered monocyclic heteroaryl ring having one to four heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, a 3- to 7-membered saturated or partially unsaturated carbon ring, or a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring having one to two heteroatoms independently selected from nitrogen, oxygen, and sulfur.

5. R 5C is halogen, -CN, -OR, -S(O) 2 NR 2 , -C(O)R, -C(O)OR, -C(O)NR 2 , -OC(O)R, or -N(R)C(O)R, the compound according to claim 1, or a pharmaceutically acceptable salt thereof.

6. R 7 C 1~6 The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is an aliphatic, 3- to 7-membered saturated or partially unsaturated carbon ring, or a 3- to 7-membered saturated or partially unsaturated monocyclic or heterocyclic ring having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur.

7. R WA is hydrogen or C 1~6 An aliphatic compound according to claim 1 or a pharmaceutically acceptable salt thereof.

8. R W but, 【Chemical 503】 The compound according to claim 1 or a pharmaceutically acceptable salt thereof.

9. L 6 The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein is -NH-.

10. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein m is 1.

11. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein p is 0.

12. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein t is 0. 【Request Item 13】 【Chemistry 942-1】 【Chemistry 942-2】 【Chemistry 942-3】 【Chemistry 942-4】 【Chemistry 942-5】 【Chemistry 942-6】 【Chemistry 942-7】 【Chemistry 942-8】 【Chemistry 942-9】 【Chemistry 942-10】 【Chemistry 942-11】 【Chemistry 942-12】 【Chemistry 942-13】 【Chemistry 942-14】 【Chemistry 942-15】 【Chemistry 942-16】 【Chemistry 942-17】 【Chemistry 942-18】 【Chemistry 942-19】 【Chemistry 942-20】 【Chemistry 942-21】 【Chemistry 942-22】 【Chemistry 942-23】 【Chemistry 942-24】 【Chemistry 942-25】 【Chemistry 942-26】 【Chemistry 942-27】 【Chemistry 942-28】 【Chemistry 942-29】 【Chemistry 942-30】 【Chemistry 942-31】 【Chemistry 942-32】 【Chemistry 942-33】 【Chemistry 942-34】 【Chemistry 942-35】 【Chemistry 942-36】 【Chemistry 942-37】 【Chemistry 942-38】 【Chemistry 942-39】 【Chemistry 942-40】 【Chemistry 942-41】 【Chemistry 942-42】 【Chemistry 942-43】 【Chemistry 942-44】 【Chemistry 942-45】 【Chemistry 942-46】 【Chemistry 942-47】 【Chemistry 942-48】 【Chemistry 942-49】 【Chemistry 942-50】 【Chemistry 942-51】 【Chemistry 942-52】 【Chemistry 942-53】 【Chemistry 942-54】 【Chemistry 942-55】 【Chemistry 942-56】 【Chemistry 942-57】 【Chemistry 942-58】 【Chemistry 942-59】 【Chemistry 942-60】 【Chemistry 942-61】 【Chemistry 942-62】 【Chemistry 942-63】 【Chemistry 942-64】 【Chemistry 942-65】 【Chemistry 942-66】 【Chemistry 942-67】 【Chemistry 942-68】 【Chemistry 942-69】 【Chemistry 942-70】 【Chemistry 942-71】 【Chemistry 942-72】 【Chemistry 942-73】 【Chemistry 942-74】 【Chemistry 942-75】 【Chemistry 942-76】 【Chemistry 942-77】 【Chemistry 942-78】 【Chemistry 942-79】 【Chemistry 942-80】 【Chemistry 942-81】 【Chemistry 942-82】 【Chemistry 942-83】 【Chemistry 942-84】 【Chemistry 942-85】 【Chemistry 942-86】 【Chemistry 942-87】 【Chemistry 942-88】 【Chemistry 942-89】 【Chemicals 942-90】 【Chemistry 942-91】 【Chemistry 942-92】 【Chemistry 942-93】 【Chemistry 942-94】 【Chemical Engineering 942-95】 【Chemistry 942-96】 【Chemistry 942-97】 【Chemistry 942-98】 【Chemistry 942-99】 【Chemical 942-100】 【Chemistry 942-101】 【Chemical Engineering 942-102】 【Chemistry 942-103】 【Chemical Engineering 942-104】 【Chemical Engineering 942-105】 【Chemistry 942-106】 【Chemistry 942-107】 【Chemistry 942-108】 【Chemistry 942-109】 【Chemical Engineering 942-110】 【Chemistry 942-111】 【Chemical Engineering 942-112】 【Chemistry 942-113】 【Chemistry 942-114】 【Chemical Engineering 942-115】 【Chemistry 942-116】 【Chemistry 942-117】 【Chemistry 942-118】 【Chemistry 942-119】 【Chemicals 942-120】 【Chemistry 942-121】 【Chemistry 942-122】 【Chemistry 942-123】 【Chemistry 942-124】 【Chemistry 942-125】 【Chemistry 942-126】 【Chemistry 942-127】 【Chemistry 942-128】 【Chemistry 942-129】 【Chemistry 942-130】 【Chemistry 942-131】 【Chemistry 942-132】 【Chemistry 942-133】 【Chemistry 942-134】 【Chemistry 942-135】 【Chemistry 942-136】 【Chemistry 942-137】 【Chemistry 942-138】 A compound or a pharmaceutically acceptable salt thereof, selected from the above.

14. A pharmaceutical composition comprising a compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

15. A composition comprising a compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 14, for inhibiting FGFR2 signaling activity in a subject in which it is necessary to inhibit FGFR2 signaling activity.

16. A composition comprising a compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 14, for treating FGFR2-mediated disorders in subjects requiring treatment of FGFR2-mediated disorders.

17. A composition comprising a compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 14, for treating a disorder in a subject for which treatment of the disorder is necessary, wherein the disorder is bile duct cancer, liver cancer, breast cancer, prostate cancer, lung cancer, thyroid cancer, gastric cancer, ovarian cancer, rectal cancer, endometrial cancer, or urothelial cancer.

18. The composition according to claim 17, wherein the disorder is bile duct cancer.

19. The composition according to claim 18, wherein the bile duct cancer is intrahepatic bile duct cancer.

20. The composition according to claim 17, wherein the disorder is liver cancer.

21. The composition according to claim 20, wherein the liver cancer is hepatocellular carcinoma.

22. The composition according to claim 17, wherein the disorder is lung cancer.

23. The composition according to claim 22, wherein the lung cancer is squamous cell carcinoma of the lung or non-small cell lung cancer.

Citation Information

Patent Citations

  • 4-Amino-6-(3-(3-bromophenyl)phenyl)-5-cyano-7-(β-L-furanoxose)pyrrolo[2,3-d]pyrimidine, its derivatives, and their use in the preparation of antitumor drugs.

    CN102286048A

  • Use of pyrazolopyrazine as an adenosine antagonist

    JP2003515537A

  • Furo- and thienopyrimidine derivatives as angiogenesis inhibitors

    JP2005508904A

  • Azaindole kinase inhibitor

    JP2005538990A

  • Pyrazolopyridine and methods of making and using same

    JP2006502165A